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AIMS OF THIS DISSERTATION 
The aim of this dissertation was to gain insight into crucial steps involved in 
polymeric gene delivery and to construct novel vectors with advantageous 
properties.  
A major goal was to clarify crucial steps in the subcellular trafficking of 
polyethylenimine/nucleic acid complexes. Several publications have dealt with 
this issue, however, conclusive data describing mechanisms of cellular uptake 
and especially modalities of endosomal or lysosomal release are limited. To 
achieve this, it was necessary to monitor complex uptake and to identify the 
major subcellular compartment(s) of accumulation. Furthermore, we were 
interested in visualizing complex release from vesicular structures in order to 
estimate the extent to which this event happens and acquire insights into the 
mechanism. These issues were investigated by living cell confocal laser 
scanning microscopy and inhibitor experiments. 
A major shortcoming of polymeric gene delivery is the low specificity of 
polymer/nucleic acid complexes. Consequently, our aim was to develop a gene 
delivery system with a high specificity for target cells combined with a very low 
unspecific transfection of non target cells. We chose an ovarian carcinoma 
model for these studies and used an antibody directed against an epitope 
expressed by most ovarian carcinoma cells. We constructed a vector system by 
coupling the antigen binding fragment (Fab´) of this antibody to pegylated 
polyethylenimine. Our hypothesis was that the positive charge of the poly-
ethylenimine could be efficiently shielded by the linear PEG chains thus leading 
to a decrease in unspecific binding to non target cells, as well as increased 
specificity of the vector.   
Currently, only rudimentary knowledge of the stability of polyethylene-
imine/DNA and pegylated polyethlenimine/DNA complexes in the bloodstream 
is available. To address this issue, we performed pharmacokinetic studies in 
mice, in which polymer and DNA were labelled with two different radioactive 
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tracers. Comparison of polymer and DNA profiles allowed us to form 
conclusions about complex stability. Furthermore, in order to get an insight into 
the mechanisms of complex destabilization, we performed in vitro stability 
investigations, in which we tried to simulate certain aspects of an in vivo 
environment. 
A further issue addressed in this thesis was the development of a new vector 
system with favourable properties, such as a high transfection efficiency, high 
stability and a low toxicity. To achieve this, novel shielding strategies were 
developed, which exhibited an onion-like structure when complexed with DNA. 
The inner core of the system consisted of polyethylenimine and DNA 
surrounded by a hydrophobic shell and an outer hydrophilic corona. Further, a 
triblock polymer was developed consisting of polyethylenimine, 
polycaprolactone and polyethylenglycol. In order to enhance the solubility of 
this compound, cyclodextrin was threaded over the linear polyethylenglycol and 
polycaprolactone chains. Our hypothesis was that, due to the hydrophobic chains 
surrounding the central core of the vector, complexes should become more 
stable, as a result of the decreased penetration of e.g. plasmaproteins into the 
core. The in vivo properties of these novel vectors were investigated and 
pharmacokinetic studies in mice were performed.           

           
PROSPECTS FOR CATIONIC POLY-
MERS IN GENE AND OLIGONUCLEO- 
TIDE THERAPY AGAINST CANCER            
Published in Advanced Drug Delivery Reviews 54 (2002) 715-758   
Chapter 1  18
 
SUMMARY  
Gene and antisense/ribozyme therapy possess a tremendous potential for the 
successful treatment of genetically based diseases, such as cancer. Several 
cancer gene therapy strategies have already been realized in vitro, as well as in 
vivo. A few have even reached the stage of clinical trials, most of them phase I, 
whereas some antisense strategies have advanced to phase II and III studies. 
Despite this progress, a major problem in exploiting the full potential of cancer 
gene therapy is the lack of a safe and efficient delivery system for nucleic acids. 
As viral vectors possess toxicity and immunogenicity, non viral strategies are 
becoming more and more attractive. They demonstrate adequate safety profiles, 
however their rather low transfection efficiency remains a major drawback. This 
review will introduce the most important cationic polymers used as non viral 
vectors for gene and oligonucleotide delivery and will summarize strategies for 
the targeting of these agents to cancer tissues. Since the low efficiency of this 
group of vectors can be attributed to specific systemic and subcellular obstacles, 
these hurdles, as well as strategies to circumvent them, will be discussed. Local 
delivery approaches of vector/DNA complexes will be summarized and an 
overview of the principles of anticancer gene and antisense/ribozyme therapy as 
well as an outline of ongoing clinical trials will be presented.   
1. INTRODUCTION 
Since progress in the therapy of cardiovascular diseases is improving rapidly, 
cancer is on the way to become leading cause of death in industrialized 
countries. Due to its invasive, aggressive growth profile as well as the complex 
mechanisms involved in cancer development and propagation, an efficient, 
specific therapy is not yet available. If a tumor is discovered at a defined, well 
localized stage, surgery, chemo- and/or radiation therapy may represent 
promising curative strategies. However, at latter stages, especially when 
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metastases have already spread to remote sites of the body, such approaches are 
less successful. In this case, chemotherapy is the most frequently applied 
treatment. However, it exhibits general limitations, such as a poor specificity of 
most chemotherapeutic drugs resulting in suppression of the bone marrow and 
other fast dividing tissues as well as potential genesis of secondary cancer. 
Another drawback of chemotherapy is the development of resistant phenotypes, 
which no longer respond to chemotherapy thus making the treatment inefficient. 
Therefore, an urgent need is evident for new anticancer strategies exhibiting 
high specificity, low toxicity and lack of resistant phenotypes. Conventional 
drugs to specifically block molecular pathways responsible for uncontrolled 
cancer growth [1], angiogenesis [2] or metastases genesis [3] are currently under 
investigation, however success is still limited.  
The human genome project has substantially increased our knowledge about 
molecular mechanisms of cancer during the last decade, thus opening up new 
possibilities for cancer gene therapy. In contrast to classic cancer treatments, this 
approach in theory represents a much more efficient and specific therapy, due to 
its ability to directly influence the defected genes responsible for cancer. Several 
strategies have been considered for manipulation of gene expression either on 
the transcriptional or on the translational level and have been performed 
successfully in vitro and in vivo. A deficient gene can either be replaced or the 
effect of an unwanted gene can be blocked by introduction of a counteracting 
one. Suicide gene therapy offers the perspective to kill cancer cells selectively 
by using prodrug-converting enzymes and tumor specific promoters. 
Furthermore antisense and ribozyme strategies offer the potential to selectively 
downregulate the expression of specific genes mainly on the translational level 
predominantly by sequence specific interaction with messenger RNAs.  
Despite the enormous potential of gene therapy, there are still numerous 
difficulties to be overcome before efficient clinical application is attempted. 
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Although remarkable advances have been made in identifying target structures 
for cancer gene therapy and synthesis or biotechnological production of nucleic 
acids has become feasible in larger quantities, progress is mainly hampered by 
the lack of a safe and efficient delivery system. 
Generally, two different approaches have been utilized for the delivery of 
nucleic acids in gene therapy, namely that of viral vectors and non viral delivery 
systems mainly using cationic polymers or lipids. Viral vectors including 
retroviruses, adenoviruses and adeno-associated viruses impress by their high 
efficiency in introducing their genetic material into host cells. Researchers 
thought that it would be feasible to domesticate viruses and to take advantage of 
them for therapeutic needs. However, in the last few years a reappraisal has 
occurred due to serious safety risks. Viral vectors show excellent transfection 
efficiencies. However, they develop a high immunogenicity after repeated 
administration since the mammalian immune system has developed strategies to 
eliminate viral invaders as well. Other problems associated with viral vectors are 
their potential oncogenicity due to insertional mutagenesis and the limited size 
of DNA that can be carried. Furthermore the inclusion of a targeting moiety in 
order to transfect specific cell types or tissues is problematic. Despite these 
problems, still more than two thirds of clinical gene therapy trials use viral 
vectors. Because of these concerns non viral vectors are emerging as a viable 
alternative. Non viral systems, especially polymers, show significantly lower 
safety risks and can be tailored to specific therapeutic needs. They are capable of 
carrying large DNA molecules and can be produced in large quantities easily 
and inexpensively. The major disadvantage of these non viral vectors is their 
low transfection efficiency. Great efforts have been undertaken to improve the 
efficiency, however we are still far away from a system that could be considered 
as satisfactory. In the past much work went into the improvement of  
transfection efficiency under in vitro conditions with little attention of vectors 
for in vivo use. However most applications especially in the context of cancer 
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gene therapy require an in vivo application. A thorough investigation of the 
behavior of vector/nucleic acid complexes in vivo and key obstacles to their 
effectiveness is essential for further rational advances.   
The first section of this review provides an overview of the most frequently used 
cationic polymers in non viral gene and oligonucleotide delivery. Since the 
inefficiency of these vectors in (cancer) gene therapy can be attributed to 
specific hurdles on a systemic, as well as subcellular level, strategies to 
surmount these will be discussed. The second section provides an overview of 
gene therapy and antisense/ribozyme strategies, as well as clinical trials using 
these approaches.  
Looking for efficient and safe vector systems for cancer gene therapy raises the 
question: What is easier, taming viruses or making synthetic vectors more 
intelligent and efficient? A paradigm shift is currently underway, as it is 
questionable if viral vectors will ever be considered safe. Therefore the 
development of non viral systems, which may be safer and more versatile, is 
warranted. The goal must be to create systems that act as targeted synthetic 
viruses displaying high specificity for cancer tissue, high transfection 
efficiencies and controllable safety risks. Vectors that are currently used in non 
viral gene therapy are far from optimal, however studying their biological and 
physicochemical properties will provide valuable knowledge for the future 
design of more sophisticated systems. Regarding the advantages of non viral 
vectors compared to viruses it is obvious that they have a great perspective in 
(cancer) gene therapy, although more research is needed for optimisation of 
these systems. A combination of non viral vectors with viral moieties like 
fusogenic peptides or protein transduction domains may represent additional 
promising approaches.      
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2. NON VIRAL VECTORS 
Cationic polymers and cationic lipids are by far the most widely used vectors in 
non viral gene and oligonucleotide delivery. Other strategies including particle 
bombardment, ultrasound transfection [4] or the application of naked DNA have 
been realized as well, however their applicability is restricted to specific 
circumstances. This review focuses on cationic polymers. For a recent review 
about gene delivery using cationic lipids we refer to reference [5].  
Polymers display striking advantages as vectors for gene delivery. They can be 
specifically tailored for the proposed application by choosing appropriate 
molecular weights, coupling of cell or tissue specific targeting moieties and/or 
performing other modifications that confer upon them specific physiological or 
physicochemical properties. After identifying a suitable polymer structure a 
scale up to the production of large quantities is rather easy as well. A weakness 
of gene therapy with cationic polymers is our limited knowledge regarding the 
formation of electrostatic complexes with DNA and their biological effects. For 
example when forming complexes with polyethylenimine (PEI) the addition of 
polymer to DNA, rather than the opposite results in higher transfection 
efficiency [6]. Many other factors play crucial roles in this context, e.g. 
concentration of the polymer and DNA solutions, ionic strength of the solvents 
[7] and speed of mixing. Thus, gene therapy with cationic polymers is still 
rudimentarily understood and ongoing investigations will provide avenues to 
more sophisticated approaches. Figure 1 gives an overview over frequently used 
cationic polymers for non viral nucleic acid delivery.  
2.1. Polyethylenimine (PEI) 
PEI polymers have become the gold standard of non viral gene delivery. 
Polymers with different molecular weights and degrees of branching have been 
synthesized and evaluated in vitro as well as in vivo. Highly branched polymers 
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such as the 25 kDa PEI (Aldrich) and the 800 kDa PEI (Fluka) are most 
frequently used as well as polymers with lower degrees of branching [8]. PEI 
polymers are able to effectively complex even large DNA molecules [9,10], 
leading to homogeneous spherical particles with a size of around 100 nm or less 
that are capable of transfecting cells efficiently in vitro as well as in vivo. They 
offer a significantly more efficient protection against nuclease degradation than 
other polycations, e.g. poly(L-lysine) possibly due to their higher charge density 
and more efficient complexation. The huge amount of positive charges, 
however, results in a rather high toxicity of PEI polymers which is one of the 
major limiting factors especially for its in vivo use. The high density of primary, 
secondary and tertiary amino groups exhibiting protonation only on every 3rd or 
4th nitrogen at pH 7 confers significant buffering capacity to the polymers over a 
wide pH range. This property, known as ´proton sponge property´ [11] is likely 
one of the crucial factors for the high transfection efficiencies obtained with 
these polymers. Despite this recognized association, knowledge about 
relationships between polymer structure and important biological properties 
such as toxicity or transfection efficiency is rather limited. Polymers with high 
molecular weight, e.g. the highly branched 25 kDa or 800 kDa PEI exhibit high 
transfection efficiencies, however toxicity is rather high as well [8]. Polymers 
with low molecular weight, e.g. with a molecular weight of 800 Da, display low 
toxicity yet transfection efficiency is very low as well [own unpublished data]. 
An approach to combine the advantages of high and low molecular weight PEI 
has been realized recently by crosslinking small PEIs via biodegradable 
disulfide bonds. A greatly enhanced transfection efficiency of crosslinked small 
PEIs could be observed with only a moderate increase in toxicity [12].  
Not only the size, also the degree of branching plays an important role for 
biological properties of complexes with nucleic acids. Linear PEIs [13] have 
been synthesized and investigated [14] and it could be demonstrated that linear 
PEI 22 kDa, e.g. ExGenTM 500 (Euromedex, France), displays excellent 
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transfection efficiency with a rather low toxicity [13-15]. Linear PEI has 
recently been reported to mediate a cell cycle independent nuclear entry of 
plasmid DNA [16] This finding is of particular importance in the therapy of 
slowly dividing tissues.  
2.2. Poly(L-lysine) 
Poly(L-lysine) was one of the first polymers used in non viral gene delivery and 
a large variety of polymers with different molecular weights have been utilized 
in physicochemical and biological experiments [17]. Due to its peptide structure 
poly(L-lysine) is biodegradable, a property that makes it especially suitable for 
in vivo use, however the polymer exhibits modest to high toxicity. If prepared 
with poly(L-lysine) of suitable molecular weights and at suitable N/P ratios, 
complexes with plasmid DNA display a size of around 100 nm [17] and are 
taken up into cells as efficiently as PEI complexes (own unpublished data), 
however transfection efficiencies remain several orders of magnitude lower. A 
potential reason for this is the lack of amino groups with a pKa between 5 and 7, 
thus allowing no endosomolysis and low levels of transgene expression [18]. 
The inclusion of targeting moieties or co-application of endosomolytic agents 
like chloroquine [19] or fusogenic peptides [20] may improve reporter gene 
expression.   
2.3. Imidazole containing polymers 
Polymers containing the heterocycle imidazole have shown promising 
transfection capabilities. In several approaches modification of -amino groups 
of poly(L-lysine) using histidine or other imidazole containing structures 
showed a significant enhancement of reporter gene expression compared to 
poly(L-lysine) [21-23]. The imidazole heterocycle displays a pKa around 6 thus 
possessing a buffering capacity in the endolysosomal pH range, and possibly 
mediating vesicular escape by a ´proton sponge´ mechanism. Supports for this 
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assumption is the fact that endosomal acidification is required for the efficiency 
of these polymers in gene transfer [23]. A sophisticated approach is the 
optimization of the balance between free -amino groups of L-lysine moieties 
that enable effective complex formation with DNA and the amount of imidazole 
heterocycles responsible for endolysosomal escape of the complexes. With this 
approach a polymer has been developed that mediates a transfection efficiency 
equal to PEI and demonstrates little toxicity due to its optimized charge density 
[24]. The incorporation of imidazole moieties represents a promising option for 
the improvement of endolysosomal escape and enhancement of the efficiency of 
polymers without increasing toxicity.  
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Cationic polymers most frequently used for nucleic acid delivery  
2.4. Chitosans 
Chitosans are biodegradable linear aminopolysaccharides with randomly 
distributed beta1-4 linked N-acetyl-D-glucosamine and D-glucosamine, derived 
from the common biopolymer chitin. They have been utilized as a food additive 
for some time and display a significantly better biocompatibility than PEI, thus 
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they represent interesting candidates as gene transfer agents. Depending on the 
molecular weight and the degree of deacetylation, chitosans are capable of 
forming small (<100 nm), rather stable, toroidal complexes with plasmid DNA 
[25,26] and provide protection for the complexed DNA against DNase 
degradation that is comparable to PEI [26]. Structure-property relationships 
show that the percentage of positively charged monomer units must be greater 
than 65 % in order to obtain stable complexes capable of transfecting cells in 
vitro [26]. Small (1.2 kDa) and very large chitosan polymers lead to minimal 
levels of reporter gene expression [27]. However, in the molecular weight range 
between 30-170 kDa chitosan polymers provide levels of gene expression that 
are comparable to PEI [26]. When a pH-sensitive endosomolytic peptide is 
incorporated into chitosan/plasmid complexes, significantly increased levels of 
reporter gene expression can be observed [25] indicating that endolysosomal 
escape may be a major limiting factor in gene delivery with chitosans, probably 
due to the poor buffering capacity of this polymer around pH 5.5.   
Remarkably the kinetics of gene expression seem to be different for chitosans 
compared to PEI. While gene expression using PEI reaches maximum levels at 
24-72 h post incubation depending on the kind of plasmid and cell line, it 
reaches its highest levels for chitosans significantly later [26,28]. The reason for 
these different kinetics is unclear. While for PEI the polymer itself displays 
buffering capacity, resulting in rapid escape, it is possible that in the case of 
chitosans degradation of the polymer is crucial. Lysosomal enzymes may 
degrade the polymer into small molecules, thus leading to increased osmolarity 
and eventually to subsequent release by rupture of lysosomes [26]. This however 
is speculation.  
Intratracheal instillation of chitosan and PEI (25 kDa) polyplexes revealed 
similar distribution patterns, however levels of gene expression were 
approximately 10fold lower for chitosan [26].  
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2.5. Dendrimers 
Dendrimers are spherical, highly branched polymers prepared either by 
divergent (starting from a central core molecule) or convergent (starting with 
what will become the periphery of the molecule building inwards) synthesis 
strategies. The degree of branching is expressed in the generation of the 
dendrimer. Most commonly used dendrimers for non viral nucleic acid delivery 
are synthesized via the divergent strategy [29] and represent 6th generation 
StarburstTM polyamidoamine (PAMAM) dendrimers either in intact (PolyfectR) 
or fractured (SuperfectR) form. Intact dendrimers bear two new polymer arms at 
each point of branching, whereas in fractured polymers either one or two arms 
originate or the polymer is terminated at this point. Similar to PEI the structures 
of these polymers show high densities of amines in the periphery of the 
molecule. These outer amines enable efficient condensation of nucleic acids, 
leaving the inner amine functions available for neutralization during 
endolysosomal acidification, thus enabling more efficient endosomal escape. 
Concerning 6th generation PAMAM dendrimers the fractured dendrimers show 
significantly enhanced (>50-fold) levels of reporter gene expression compared 
to the intact polymer. The reason for this finding is unclear yet, however an 
increased flexibility of the polymer with a better ability to complex DNA might 
play a crucial role [29].   
2.6. Comparison of transfection agents 
Generally the in vitro transfection efficiency of a polymer or lipid formulation 
depends on a large variety of factors including dose, N/P ratio, confluency of 
cells, composition of incubation medium, mode of complex formation and time 
of incubation. Therefore, optimal formulation techniques would be established 
by considering each of these factors and their influence on complex properties, 
cellular uptake, toxicity and transfection efficiency.  
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Only a few studies comparing efficiency and toxicity of several transfection 
reagents under similar experimental conditions have been performed. Table 1 
shows results of a study using several commercially available transfection 
agents (Data from [30]) at optimized N/P ratios on Cos-7 cells. It is obvious that 
lipid formulations overall showed a higher toxicity than polymers tested, 
although doses were only slightly more than half than when using polymers. 
Among the latter linear PEI ExGenTM 500 and the dendrimer formulation 
SuperfectTM show superior transfection efficiency compared to PEI 25 kDa 
(Aldrich) with moderate toxicities. Among lipids only LipofectAMINETM 
exhibits high transfection efficiency (higher than any of the tested polymers). 
Since not all factors mentioned above have been optimized for each formulation 
in this study, changes in experimental conditions may lead to significantly 
different results.  
Transfection system DNA dose Luciferase expression cellular protein
 
( g/well) % of ExGenTM 500 % of control 
POLYMERS 
ExGenTM 500  0,75 100 79 
(linear PEI 22 Kda) 
PEI (25 Kda), Aldrich 0,75 39 85 
SuperfectTM 0,75 134 84 
(dendrimer formulation) 
LIPID FORMULATIONS
LipofectinTM 0,4 40 63 
LipofectAMINETM 0,4 176 61 
CellfectinTM 0,4 8 67 
Table 1  
Comparison of reporter gene expression and toxicity of different cationic polymers and 
lipids at optimized N/P ratios on Cos-7 cells  (Data from [30]).     
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3. HURDLES IN NUCLEIC ACID DELIVERY 
Ideally, a vector/nucleic acid complex should be delivered exclusively to target 
tissue where it may be subsequently taken up and further processed on the 
cellular level. To accomplish this, however, the complexes must first overcome 
numerous obstacles, such as misrouted deposition or complex destabilization 
with subsequent degradation in the bloodstream. On the cellular level great 
amounts of complexes are buried in the endolysosomal compartment or 
degraded in the cytoplasm. In the end, only a very small fraction of the applied 
dose has been observed to exhibit the desired effect, whereas the remaining 
portion of the dose is either inactivated or shows gene expression elsewhere.   
3.1. Hurdles on the systemic level 
3.1.1. The endothelial barrier 
One major problem for systemic gene therapy is the delivery of agents beyond 
the endothelial barrier. Extravasation of complexes is highly dependent on their 
size and the permeability of the endothelia at specific sites. In most tissues the 
structure of the endothelia is tight. Only organs and tissues with an irregular 
fenestration, such as the liver, spleen, bone marrow and certain tumors (see 
below), have endothelia with large meshes, which allow extravasation of 
molecules ranging up to 0.1 – 1 m. Thus, in most tissues the access of 
polyplexes to parenchymal cells is denied, a fact that hampers the efficacy of 
gene therapy dramatically.  
3.1.2. Problems resulting from cationic surface charge 
Unmodified polyplexes exhibit numerous problems when applied systemically. 
The major problem associated with this type of vectors is their cationic surface 
charge, which leads to numerous unspecific interactions with e.g. cellular blood 
components, vessel endothelia and plasma proteins such as albumin, fibronectin, 
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immunoglobulines, complement factors or fibrinogen [31]. These interactions 
lead to very short plasma half lives for complexes with a high cationic surface 
charge [32].  
Due to their size and the high number of cationic charges, polyplexes can 
activate the complement system [33] in a manner that suggests a correlation 
between the density of accessible positive surface charges and the extent of 
complement activation. Activation occurs via attachment of complement 
components, i.e. factor C3, to the complex surface and eventually leads to 
complex removal by the reticular endothelial system (RES). Large cationic 
polymers, such as long chain poly(L-lysine), PEI 25 kDa or high generation 
dendrimers, have enormous potential in activating the complement system, 
while small polyamines, i.e. oligo(L-lysine), exhibit this effect to a much lesser 
extent [33]. Complex formation of such polymers with DNA reduces the overall 
charge and as a consequence also reduces complement activation significantly. 
A decrease in the nitrogen to phosphate ratio leads to lower extents of activation 
and electrostatic neutral complexes only exhibit very low levels of complement 
activation.  
Interactions with plasma proteins are omnipresent in vivo and, therefore, play a 
major role in determining circulation time and cellular uptake. The major 
component, albumin, is primarily responsible for the rapid clearance of 
complexes from the bloodstream [34]. It has been demonstrated that interaction 
of albumin with polyplexes leads to the formation of ternary complexes with a 
reversed surface charge [34,35], resulting in the formation of large aggregates 
[32,35]. These associates are removed rapidly from the bloodstream, presumably 
via phagocytic capture by scavenger receptors of phagocytic liver cells or via 
accumulation in fine capillary beds.  
The administration of highly charged complexes leads to aggregate formation 
with cellular blood components, especially with erythrocytes. A subsequent 
obstruction of blood vessels accompanied by undesired consequences, such as 
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pulmonary embolism [31] may be the result. The complex-mediated aggregation 
of erythrocytes also influences the biodistribution and gene expression patterns 
of polyplexes in vivo, resulting in enhanced accumulation in the lung, due to a 
certain sieve effect of the pulmonary capillaries.   
3.1.3. Biodistribution and gene expression after i.v. application  
The biodistribution of unmodified polyplexes using different cationic polymers 
is quite similar. Organ distribution of the complexes immediately after injection 
shows a high accumulation in the lung, approximately 80-90 % of the injected 
dose, possibly resulting from aggregate formation with blood cells or plasma 
proteins and subsequent filtration in fine lung capillaries [35]. Due to the low 
stability of such aggregates, complexes are often released into the circulation 
again, leading to a secondary redistribution with high concentrations found in 
Kupffer cells of the liver. The endothelial tissue of other organs and tissues, e.g. 
spleen, kidney and especially endothelia close to the site of injection, 
accumulate significant levels of complexes, as well [36]. After 30 minutes post 
injection, usually less than 5 % of the injected dose is detectable [31] and the 
majority of the complexes remaining in circulation are attached to cellular blood 
components. A typical biodistribution pattern after i.v. administration of poly(L-
lysine)/DNA complexes is shown in Figure 2.  
Gene expression patterns after i.v. administration are rather similar to those of 
organ distribution, whereas phagocytic capture by the RES does not lead to high 
levels of reporter gene expression. The highest levels of gene expression are 
found in the lung, not only due to enhanced deposition, but also due to a more 
efficient gene expression in this organ [37]. Although the lung capillaries 
possess a tight endothelia, reporter gene expression after i.v. application has 
been measured not only in endothelial, but also in interstitial cells [38,39].  
Some studies have even discovered a rapid crossing of the endothelial barrier by 
polyplexes [39], although the mechanism of this transport has yet to be 
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elucidated.  It has been suggested that at sites where the vasculature is fragile, as 
in the alveoli, small complexes may be able to pass the endothelial barrier, due 
to vascular leakage. This theory is favored by experimental findings, which 
showed that only PEI/DNA complexes with a size of around 60 nm are able to 
exhibit this effect [40]. Other mechanisms, such as transport via a form of 
transcytosis or the existence of transport systems for polyamines, have also been 
postulated. Support for the latter theory has been shown in studies demonstrating 
that polyamines, such as putrescine, spermine or spermidine, are taken up into 
arterial endothelial cells via specific polyamine carrier systems [41,42]. Overall 
the lung represents an attractive organ for non viral gene delivery for the 
treatment of e.g. cystic fibrosis or lung cancer.  
Figure 2 
Typical organ distribution 30 min after i.v. administration of  cationic polymer/DNA 
complexes. Empty columns show distribution of unmodified complexes, filled columns of 
pHPMA-modified complexes (Figure from [48]).  
3.1.4. Steric stabilization of complexes 
The pattern of organ distribution showing initial deposition in the lung and 
subsequent rapid uptake predominantly into Kupffer cells of the liver is of 
limited value for therapeutic application. Hence, strategies must be developed to 
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change this biodistribution pattern and to prolong circulation, hereby enabling 
the targeting of specific tissues. 
Steric stabilization involves the attachment of hydrophilic polymers to 
complexes, thus shielding positive surface charges and creating a steric barrier 
against aggregation with e.g. albumin, complement factors or cellular 
components in the bloodstream. The modification of such complexes may 
reduce the potential of nonspecific interactions, such as opsonization or 
deposition due to cationic surface charges. Several strategies have been tested 
for their ability to shield the cationic surface charge of polyplexes.
 
Polyethylenglycol: Two different general strategies using PEG for steric 
stabilization of polyplexes have been developed. The first strategy is based on 
the formation of copolymers from cationic polymers and PEG [36,43-45], 
whereas the second approach relies on the initial formation of polymer/DNA 
complexes with subsequent attachment of PEG to free amino groups [31]. It 
could be demonstrated that small particles with a size of approximately 100 nm 
and surface charges close to neutrality could be obtained under appropriate 
conditions with both strategies [31,36,44]. The in vivo application of both 
construct types displayed a slightly prolonged circulation time compared to 
unmodified complexes. However, the circulation half-lives were still rather short 
compared to e.g. stealth liposome formulations. A decrease in gene expression 
in the lung and a lower initial toxicity was observed in both cases, when 
compared to unmodified complexes, most likely due to decreased interactions 
with blood constituents and, therefore, a lower rate of deposition in lung 
capillaries via filtration. Significant gene expression was also detected close to 
the site of injection for both approaches, suggesting a still significant rate of 
nonspecific electrostatic interactions. Overall however both PEG coating 
approaches were of limited use. 
Transferrin not only represents a possible targeting moiety for tumor cells 
and brain endothelia (see below), but has also been demonstrated to effectively 
Chapter 1  34
 
shield the surface charges of polyplexes [46]. When incorporated at appropriate 
densities it leads to a significant decrease of non-specific interactions with 
erythrocytes. In vivo studies using charge neutral transferrin-PEI/DNA 
complexes displayed the accumulation of DNA primarily in the liver and tumor 
tissues, whereas liver uptake mainly occurred into Kupffer cells, resulting in 
DNA degradation without significant gene expression. In tumor tissue, on the 
other hand, a remarkable 100-500 fold higher reporter gene expression was 
detected compared to other major organs, including the lung [46], thus making 
this strategy an interesting approach for further research. 
Poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA): HPMA polymers 
have displayed versatile properties as polymeric carriers for a large variety of 
drugs with an excellent biocompatibility [47]. Hence, this group of hydrophilic 
polymers represents an interesting candidate for surface charge shielding of 
polyplexes. The formation of electrostatic complexes consisting of poly(L-
lysine) and plasmid DNA with the subsequent attachment of semitelechelic 
pHPMA to uncomplexed -aminogroups led to decreased interactions with 
albumin and reduced association with macrophages in vitro [48]. In vivo 
experiments, however, did not display a prolonged circulation time in this study 
and liver uptake was even higher than for uncoated complexes (Figure 2). The 
detailed reason for these poor in vivo results remain as of yet unclear. 
Innovative shielding strategies: Shielding by simple attachment of PEG or 
pHPMA has not shown satisfying results. Therefore more sophisticated 
strategies have been developed, in order to obtain vectors that show sufficient 
extracellular stability in combination with triggered intracellular release of the 
complexed DNA. Crosslinking of primary amines of poly(L-lysine)/DNA 
complexes via disulfide bonds has shown promising results [49]. In circulation 
those complexes are stable thus offering efficient stabilization of the DNA, 
however when taken up into cells disulfide bonds are reductively cleaved and 
DNA is released. Such crosslinked complexes showed 10 fold increased plasma 
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circulation after i.v. administration compared to unmodified complexes with 
similar levels of reporter gene expression in vitro.  
Another approach uses plasmid DNA complexed with a reducible linear 
polycation and subsequent steric and lateral stabilization by multivalent HPMA 
copolymers [50]. In circulation these complexes provide efficient protection of 
DNA against degradation and furthermore shielding of the positive surface 
charge leads to a decrease of unspecific interactions. Transfer to a reducing 
environment (cellular uptake) again results in degradation, in this case of the 
polycation, leading to lower molecular weight compounds and hereby DNA 
release (see Figure 3). The exploitation of bioreversible bonds represents a very 
promising strategy.  
 
Figure 3  
Example for a polyplex modification with trigerred intracellular DNA release. 
RPC=reductively cleavable linear polycations (data from [50]).   
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3.1.5. Local application 
If a particular tissue or organ needs to be targeted in non viral gene or  
oligonucleotide therapy, local application may in many cases represent a more 
promising approach, since several barriers of systemic application can be 
avoided. This approach has been utilized for a variety of cases, including tumors 
[51-54], kidney [55], lung [56], brain [57-60], heart [61,62], skin [63], muscle 
[64], and arterial blood vessels [65,66]. Here we will discuss some important 
applications employing non viral vectors. 
Lung: Due to its direct accessibility, local gene therapy to the lung by 
direct airway application is an attractive approach. However, access is impeded 
by several obstacles. The first obstacle of gene delivery to and across the 
epithelial cells of the lung is a mucus layer secreted by goblet cells, which 
creates a mechanical barrier against access to the plasma membrane of the 
epithelial cells. Furthermore, the epithelium itself hinders the uptake of 
particulate structures, due to its dense structure with actin strengthened apical 
surfaces and characteristic tight junctions between cells inhibiting intercellular 
transport. Additionally, countless alveolar macrophages constantly patrol the 
lung removing particles from the deeper airway via phagocytosis.  
The method of application greatly influences the extent of gene expression in the 
lung [67,68]. For example, the instillation of poly- or lipoplexes in the 
respiratory airways was shown to lead to significant gene expression levels that 
could be significantly enhanced by the coadministration of penetration 
enhancers.  However, the use of penetration enhancers increased toxicity [69]. A 
further problem encountered using instillation strategies is the insufficient 
spreading of vector solutions on the lung surface and the channeling of airway 
administered solutions [70]. These factors led to unequal distribution and 
inhomogeneous gene expression patterns showing maximum levels in epithelial 
cells lining the bronchioles and in distal airways [70,71]. The even distribution 
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of preparations may be improved by the use of artificial surfactants, resulting in 
increased levels of gene expression [72]. 
A more convenient way of application for local gene therapy to the lung is 
aerosol delivery, a method that has been used for lipo-, as well as polyplexes 
[67,73,74]. In contrast to instillation, this method of application enables a more 
uniform distribution of transgene expression along the airways. In a study 
targeting lung metastases, a p53 tumor suppressor gene complexed with PEI was 
able to significantly inhibit growth of tumors, as well as to prolong survival time 
of laboratory animals [75].
 
Tumor: To reach cancer cells in a tumor, a blood-borne polyplex must 
enter the tumor supplying blood vessels, extravasate into the interstitium and 
finally migrate through the tumor tissue [76].  
Two general means of application are most frequently used to treat tumor tissue: 
The first method is a direct injection of complexes into arterial blood vessels 
that supply the tumor. As previously mentioned, tumors often show irregular 
endothelial fenestration, which makes it possible to reach the interstitial tissue 
via afferent blood vessels. Furthermore, complexes may even accumulate at this 
site, due to the enhanced permeation and retention (EPR) effect and/or 
electrostatic interactions [77,78], thus, enabling passive tumor targeting. 
However the problem using this technique is the poor distribution of polyplexes 
throughout tumor tissue and thus a limited transfection efficiency towards the 
mass of the tumor. 
Another method of application is the direct injection of the complexes into the 
tumor.  In this case, however, the low extent of complex diffusion throughout 
the tissue limits its applicability. When a direct injection into tumor tissue is 
performed, complex size, charge and concentration are of utmost importance for 
mobility within the tissue and, ultimately, the overall efficiency of the 
complexes. Even the speed of injection seems to play a crucial role for 
efficiency of intratumoral (i.t.) gene delivery [52]. A more detailed 
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characterization of complex properties with regard to their diffusibility in tumor 
tissue would be helpful for optimization of this approach.  
A method to enhance transfection efficiencies after i.t. injection has been 
demonstrated in mammary tumors. In this study in vivo electroporation lead to a 
significant increase of reporter gene expression [54]. Although this technique is 
limited to certain applications it represents an interesting method to enhance 
treatment efficiency.  
Intraperitoneal application of complexes has been performed successfully in 
several studies in animals exhibiting intraperitoneal disseminated tumors [51] 
whereas a certain specificity of gene expression could be achieved in tumors, 
due to their high mitotic activity. In this case complexes consisting of linear PEI 
and DNA displayed a higher efficiency than several lipoplex formulations 
without showing significant levels of toxicity [51].  
Brain: The brain endothelium is composed of non fenestrated cells 
surrounded by tight junctions that block the exchange of proteins, hydrophilic 
molecules, and ionic diffusion. Furthermore, transcellular movement via non-
specific fluid phase endocytosis does not occur in these cells and only small 
lipophilic molecules are capable of surmounting this barrier. However, there are 
several receptor mediated transport systems for specific molecules, such as 
transferrin. A successful approach of exploiting this transferrin receptor to cross 
the blood brain barrier after i.v. application has been described recently [79]. 
Local approaches for non viral gene therapy to the brain have also been 
developed. The injection of complexes into the internal carotid artery supplying 
the brain displayed significant gene expression in experimental brain tumors and 
other tissues. Approaches using direct intraventricular application or injection of 
polyplexes into specific structures of the brain have also been performed 
[58,60]. In all these cases significant, and in several cases long lasting, levels of 
gene expression could be observed, however, distribution was highly dependent 
on mobility and stability of complexes [57].  
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An inventive, non invasive approach for gene delivery to the brain stem was 
developed based on the observation that neurons are capable of taking up 
exogenous particles from the muscles they innervate. Thus, the injection of 
PEI/plasmid complexes into the tongue led to retrograde axonal transport to 
hypoglossal motoneurons of the brain stem and significant levels of gene 
expression in this area [59]. More detailed studies about the applicability of this 
technique are necessary to estimate their potential.  
3.2. Hurdles on the cellular level 
Reaching the cell membrane of a targeted cell is only half the way to efficient 
gene/antisense/ribozyme therapy. The nucleic acid has to be carried across 
several cellular hurdles in order to reach its desired site of action and to display 
the desired therapeutic effect.  
3.2.1. Across the cellular membrane 
The first obstacle to be surmounted in gene delivery is traversing the cellular 
membrane. Composed of a lipid bilayer and containing various integral proteins, 
it acts as a gatekeeper, selectively screening all foreign matter entering the cell. 
It has been shown that polyplexes are able to pass the cellular membrane via 
endocytosis [18,80], as long as they exhibit suitable surface properties and are of 
the appropriate size range. Endocytotic uptake, however, does have its 
disadvantages. Not only may complexes be exposed to enzymatic degradation in 
the lysosomes, but they also may be entrapped and never released.  
Strategies to circumvent such difficulties have become the object of intense 
investigations. A new and most promising approach includes the use of viral 
protein transduction domains, such as the HIV-TAT protein from HIV-1 virus. 
These proteins are capable of mediating the entry of large biomolecules directly 
into the cytoplasm without the use of endocytotic mechanisms. Some even 
promote transport across the nuclear envelope.   
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Uptake of polyplexes: Uptake into the cells may occur in various ways, 
including adsorptive or fluid phase endocytosis, receptor mediated endocytosis, 
macropinocytosis or phagocytosis.  
The predominant, if not the only route of entry for polyplexes, is fluid phase or 
adsorptive endocytosis [80,81] following the clathrin coated pit mechanism [81]. 
Due to their content of glycoproteins, proteoglycans and glycerolphosphates 
[82] cell surfaces are negatively charged. Thus, adsorptive endocytosis is a 
plausible mechanism of entry for vectors with positive surface charges. The 
importance of proteoglycans for efficient uptake has been demonstrated 
experimentally [83], since removal of these compounds leads to a significant 
decrease in cellular uptake. Confocal microscopy studies have demonstrated that 
complexes adhere to the cell membrane in clumps and migrate to specific areas, 
most likely coated pits [81], within 30 minutes. Such findings support the theory 
of an adsorptive endocytotic mechanism. Additionally, uncomplexed 
polyethylenimine has been shown to deposit on the cell surface and 
subsequently enter the cell via endocytosis. [84].  
In contrast studies using L929 fibroblasts demonstrated that no aggregation on 
the cell membrane could be observed and a rapid uptake occurred within 10 
minutes, thus favoring a fluid phase mechanism of entry [80]. An explanation 
for this apparent discrepancy may be that, depending upon the cell line, 
adsorptive and fluid-phase endocytosis superpose. Therefore, factors such as the 
composition of the cell membrane or surface charge of complexes may influence 
the balance in favor of either one or the other route. 
Polyplexes coupled to targeting moieties are taken up by receptor mediated 
endocytosis (see below). At the early endosome level the receptor is recycled 
back to the cell membrane, while the receptor ligand attached to the vector is 
processed to late endosomes and lysosomes [85]. Targeted complexes featuring 
targeting moieties with a positive surface charge may also enter cells via 
adsorptive endocytosis and, in this case, both routes of entry may be observed. 
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3.2.2. Improving  unspecific cellular uptake 
Cationization of complexes: One way to achieve improved uptake into cells is 
by increasing the surface charge of complexes [86]. This modification results in 
a higher affinity to negatively charged membrane constituents and subsequently 
to a higher rate of uptake. At the same time, an increase in positive surface 
charges also results in an increased toxicity both on the cellular and systemic 
level. The in vivo applicability of such complexes becomes increasingly 
problematic, since a higher surface charge leads to increased nonspecific 
interactions resulting in a rapid removal from the blood stream as well as 
unwanted events such as lung embolism due to aggregate formation with 
erythrocytes. Therefore, the therapeutic use of this strategy is limited to local 
administrations and for improving transfection efficiencies in vitro. 
Protein transduction domains: An alternative route into the cell may be achieved 
with the help of so-called protein transduction domains (PTDs). Although the 
number of publications dealing with nucleic acid delivery in conjunction with 
PTDs is currently limited, this group of compounds will be discussed here to 
some extent, as they may hold the potency to open up a whole new branch in 
gene/ODN delivery. Since their discovery more than a decade ago [87,88] it has 
been demonstrated that PTDs mediate an endocytosis independent cellular 
uptake [89] of proteins, as well as other large molecules. Physiological 
membranes do not seem to hinder the PTDs, due to the fact that they are able to 
accumulate in cells in a concentration dependent manner. The overwhelming 
advantage of this type of cell entry is the circumvention of the harmful 
endolysosomal compartment with its acidic environment resulting in DNA/RNA 
degradation, as well as an inefficient release. All cell types used to date are 
susceptible to transduction which means that even cell lines with low 
transfection efficiencies via the classical route should be transfectable via PTDs 
and the percentage of transfected cells should increase. In vivo studies with 
PTDs have shown very encouraging results. The intraperitoneal injection of a 
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120-kilodalton beta-galactosidase protein coupled to the HIV-1 TAT protein led 
to a significant delivery in virtually all tissues [90] including the brain. 
Several sequences have been identified to possess transducing efficiency: The 
TAT protein derived from the HIV-1 virus [88], the drosophila antennapedia 
transcription factor ANTP [91] and the herpes simplex virus type-1 VP22 
transcription factor [89] are three examples possessing the highest efficiencies. 
Minimal sequences mediating a transducing efficiency are shown in Table 2. It 
should be noted that the 11 amino acid sequence derived from the TAT protein 
also bears a potential nuclear localization sequence, making it even more 
attractive for gene delivery purposes.  
A characteristic feature of PTD sequences is the presence of a high number of 
basic amino acids, such as arginine and lysine (see Table 2), which may be 
necessary for interactions with negatively charged constituents of cell 
membranes. Indeed, it can be demonstrated experimentally that membrane 
bound heparan sulfate proteoglycans are required for an efficient internalization 
of TAT [92]. Interestingly, the maximal size of the cargo molecule gaining entry 
to the cell varies depending upon the PTD: While TAT and VP22 are capable of 
mediating the cellular entry of peptides consisting of more than 1000 amino 
acids [90] and even 4 µm iron nanoparticles [93], ANTP mediated delivery is 
limited to peptides with less than 100 amino acids [94]. Mechanistic knowledge 
as to how PTDs mediate cell entry is currently limited, however we do know 
that no classical routes, such as receptor- or transporter-mediated mechanisms, 
as well as adsorptive endocytosis are involved [89,95-97]. Furthermore uptake is 
ATP independent and cannot be inhibited by cooling to 4°C. 
It is unclear if all PTDs mediate cell entry via the same mechanism. However 
direct interactions with the cell membrane seem to occur in all cases. A 
disruption of the membrane bilayer can also be ruled out, as no studies have 
reported leaking of cell content during transport. 
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Sequences of frequently used protein transduction domains 
HIV-1 TAT YGRKKRRQRRR (bold:a potential nuclear localization sequence) 
HSV VP22 DAATATRGRSAASRPTERPRAPARSASRPRRPVE 
ANTP RQIKIWFQNRRMKWKK 
  
Table 2 
Sequences of most frequently used protein transduction domains  
The major physiological task of all three peptides is the interaction with nucleic 
acids during transcription. Their transducing property is not necessary to fulfill 
this function, thus the evolutionary purpose remains as of yet unclear. This, 
however, could also mean that PTDs may have not undergone a selection 
process for their transducing potential during evolution and, therefore, it might 
be possible to improve this property by modifying the sequences. This has been 
done recently with success [98]. 
Making use of PTDs: A major difficulty of PTD utilization in DNA/RNA 
delivery is the positive charge of the peptides, which leads to electrostatic 
interactions. As a result, the peptide is not in its maximally active conformation 
and, thus, a reduced transducing efficiency is observed. An additional problem is 
the lack of specificity, so that combinations of PTD and targeting moieties will 
be required. 
The formation of ternary complexes using TAT peptide together with PEI and 
plasmid DNA has led to approximately a 10fold increase in reporter gene 
expression, as compared to regular PEI/plasmid complexes and an increased 
nuclear accumulation could be observed [99].  
Furthermore it has been demonstrated that liposomes with a size of 200 nm can 
be delivered directly into the cytosol without causing major damage of the 
vesicles by attaching TAT peptides to their surface [100]. ntisense 
oligonucleotides have been coupled to the ANTP peptide as well resulting in an 
efficient and specific downregulation of the target gene product using 
concentrations much lower than with regular ODNs [101].   
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3.2.3. Strategies to improve uptake into specific cell types  
Especially for in vivo therapy it is necessary to address gene delivery vehicles to 
specific cell types in order to avoid unwanted effects in non target cells. 
Targeting can be achieved actively by incorporating structures, which facilitate 
the exclusive uptake of the vector in certain tissues or cell types. Furthermore, in 
some cases, it can be achieved passively by taking advantage of particular 
physiological conditions of the target tissue such as irregular endothelial 
fenestration in tumors in conjunction with certain complex properties. A third 
method of achieving gene expression in specific tissues is the use of cell type 
specific promoters or enhancers, which can be activated by induction factors 
(e.g. hormones, growth factors, cytokines etc.) via responsive elements. This 
strategy has been pursued with success in several targets and represents a very 
helpful tool for increasing cell specific efficiency [102-106]. 
Active targeting: To achieve an efficient active targeting in vivo the vector must 
fulfill two requirements: On the one hand, unspecific interactions must be 
reduced by shielding positive surface charges of the complexes and by using 
rather low nitrogen to phosphate ratios. On the other hand, a targeting moiety, 
enabling uptake into a specific cell type, needs to be incorporated (see table 3).  
Target structure Targeting moiety cell/tumor type Reference 
folate receptor folate various [107] 
integrines RGD peptides tumor endothelia [108] 
transferrin receptor transferrin rapidly dividing tissues [109] 
asialoglycoprotein  lactose hepathocytes [110] 
receptor galactose hepathocytes [111] 
 
mannose dendritic cells/(hepathocytes) [111] 
asialoglycoprotein hepathocytes [112] 
LDL receptor LDL various [113] 
FGF receptor FGF various [114] 
EGF receptor EGF various [115] 
Table 3 
Active targeting strategies realized with polyplexes. For targeting with antibodies see 
Table 4 
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Integrins: Integrins are heterodimeric membrane receptors that are involved in 
interactions between cells and the extracellular matrix. Furthermore several 
bacterial, viral and eukaryotic pathogens use it as a receptor to efficiently bind to 
and enter the cell. Peptides containing the highly conserved arginine-glycine-
aspartic acid (RGD) motif, such as fibronectin [116], kistrin [117], and several 
viral capsid proteins [118] have been identified as candidates for specific 
interactions with integrins. Since integrins are highly overexpressed in tumor 
endothelia they represent an interesting approach for the improvement of nucleic 
acid delivery to tumor tissue. Several strategies have been realized to make use 
of this target, such as varying the carrier polymer. The size of the RGD 
containing peptide has been shown to influence integrin binding and the use of 
cyclic RGD containing oligopeptides has resulted in superior receptor affinities 
[119].  RGD peptides attached to polyplexes [108,120,121] and combinations of 
polyplex and liposomal approaches [122] have been shown to associate with 
cells much readily than those without a targeting moiety, resulting in an 
increased reporter gene expression of up to 200fold.  
Transferrin: The transferrin receptor was one of the first targeting structures 
used in non-viral gene delivery. It is physiologically necessary for the uptake of 
transferrin-iron complexes into all actively proliferating cells and highly 
overexpressed in rapidly dividing tissues such as tumors. Cerebral endothelial 
cells and hepatocytes possess significant levels of transferrin receptors, a fact 
that makes transferrin an attractive target for systemic gene therapy. Transferrin 
has been incorporated into polyplexes [123-126] via covalent or electrostatic 
attachment with and without PEG-spacers, resulting in a significant increase in 
reporter gene expression when compared to complexes without a targeting 
moiety. Several formulations have also been evaluated in vivo via regional [124] 
administration, whereby a significant increase in transfection activity in tumors 
was measured.  
Chapter 1  46
 
As described above the inclusion of high amounts of transferrin into polyplexes 
leads to both, effective shielding of surface charge and tumor targeting [46]. 
Interestingly, it has been demonstrated by an in vitro study with lipoplexes that 
apo-transferrin is as efficient as transferrin in enhancing reporter gene 
expression. Furthermore, inhibition studies using an excess of free ligand 
displayed no decrease in effectiveness [127]. These results are contradictory to 
previous results and suggest that attachment of transferrin might also improve 
gene therapy e.g. by facilitating endolysosomal escape. More detailed studies 
are underway.   
Folate: The folate receptor represents an attractive structure to target cancer 
cells. This issue of Advanced Drug Delivery Reviews contains a detailed review 
about cancer targeting with folate [128]. 
Glucosylated vehicles: The so-called asialoglycoprotein receptor (ASGPr) is 
expressed abundantly in hepatocytes and selectively binds to galactose-
terminated glycoproteins. Various saccharide ligands have shown affinity to the 
ASGPr, including mono- or oligosaccharides, such as lactose, galactose, 
mannose, fucose, as well as larger carbohydrates like asialo-oromucoid. The 
receptor is well characterized and ligand binding leads to receptor mediated 
endocytosis. The high level of receptor expression on hepatocytes in addition to 
the rather simple coupling chemistry of the sugars, has stimulated research on 
gene delivery vehicles incorporating ASGPr targeting moieties. The low 
immunogenicity of these conjugates compared to antibody- or peptide- 
conjugates makes them attractive for in vivo use.  
Several approaches have been developed to couple the above mentioned sugars 
to polyplexes and to evaluate their efficiency in the selective transfection of 
hepatocytes. Successful in vitro targeting has been reported in various cases 
using charge-neutral complexes containing poly(L-lysine) and 
polyethylenimine. A 10-1000fold increase of gene expression can be achieved in 
targeted cells when compared to complexes without a targeting moiety [129-33]. 
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The attachment of sugars not only leads to a targeting effect, if incorporated at 
sufficient amounts it also increases the physical stability of complexes and 
enables the formation of small associates with neutral zeta potential, thus 
making them suitable for in vivo use. Efficient in vivo targeting of hepatocytes 
has been described in several studies using asialoglycoprotein-, asialo-
oromucoid-, mannose-, fucose- or galactose-conjugates [111,112,134-136]. 
Incorporation of a sugar moiety has increased uptake into liver cells 
significantly, however, the ratio of uptake into parenchymal or non-parenchymal 
(endothelial and Kupffer cells) liver cells differs depending on the type of sugar 
attached. Since hepatic disorders, such as cirrhosis or liver cancer, affect 
predominantly parenchymal cells this cell type should be the predominant target. 
Galactosylated polyplexes have shown a higher affinity to parenchymal cells 
than non parenchymal cells, while mannosylation or fucosylation leads to a 
lower ratio of distribution between both cell types [111,137].  A possible 
explanation for this preference is the fact that the asialoglycoprotein receptor, 
which is present on parenchymal cells, recognizes all three sugars, while the non 
parenchymal cells such as Kupffer cells, also exhibit mannose and fucose 
receptors, that take up additional conjugate concentrations [137]. A galactose-
receptor has been identified on Kupffer cells, however, uptake efficiency is 
much lower when compared to the asialoglycoprotein receptor on hepatocytes. 
Promising hepatocyte targeting results in vivo have been achieved by 
intravenous injection of a vector consisting of poly(L-ornithine) modified with 
galactose and a fusogenic peptide. The use of this vector led to highly enhanced 
uptake into parenchymal liver cells and 95 % of total reporter gene expression 
was observed in the liver [138]. Hepatic uptake could be inhibited by prior 
administration of BSA conjugates with galactose or mannose, a fact that 
provides evidence for a predominantly receptor mediated uptake [111,138].   
Mannose conjugates are most frequently used as for enhancing the uptake into 
dendritic cells  [139]. 
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Conjugation of antibodies: Due to the high specificity of binding to their target 
structures antibodies or antibody fragments represent very promising candidates 
for targeted gene and oligonucleotide delivery. Several types of antibodies or 
their fragments have been conjugated to polyplexes via different conjugation 
strategies in order to achieve a targeting of specific cell types (see table 4)   
Target Antibody Polymer Reference 
lung endothelia anti platelet endothelial cell adhesion PEI [140] 
 
molecule (anti PECAM) 
leukemia T-cells anti-JL1  poly(L-lysine) [141] 
neuroblastoma anti-RET receptor-  poly(L-lysine) [142] 
tyrosine kinase 
neuroblastoma anti chCE7 poly(L-lysine) [143] 
squamous carcinoma anti erythrocyte growth poly(L-lysine) [144] 
factor  
epithelial cells antibody fragments against  poly(L-lysine) [145] 
polymeric immunglobulin receptor 
peripheral blood anti-CD3 antibody PEI [146] 
mononuclear cells 
T lymphocytes T101  poly(L-lysine) [147] 
Table 4 
Examples for antibodies used as targeting moieties in polyplex gene delivery  
All immunologically targeted conjugates summarized in Table 4 have shown a 
significant increase in transfection efficiencies, as compared to complexes 
without targeting moiety. Enhancement of gene expression is usually greater 
than obtained by most other targeting moieties. However, a potential 
disadvantage of the in vivo application of antibody conjugates is the possibility 
of immunogenicity after repeated administration and their huge size, which 
might affect complex size and stability. 
Low density lipoprotein (LDL) receptor: Effective targeting of cells displaying 
the LDL receptor on their surface like hepathocytes or artery wall cells can be 
achieved by using complexes carrying LDL on their surface. A sophisticated 
strategy in this context is the so-called terplex system. It consists of stearyl-
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poly(L-lysine), low density lipoprotein (LDL) and DNA wherein the ratio 
between the charged stearyl-poly(L-lysine) and the hydrophobic moiety of LDL 
is optimised for obtaining particles that are suitable in size and charge for an 
efficient cellular uptake. This system is capable of mediating a receptor 
dependent uptake into artery wall cells in vitro [113] as well as the efficient and 
long lasting transfection of myocardial cells in vivo [62].   
Growth factors: Growth factor receptors, such as the epidermal growth factor 
(EGF) or fibroblast growth factor (FGF) receptors are attractive targets in cancer 
gene therapy, since they are highly overexpressed in a large variety of cancer 
tissues, including lung, head, neck, bladder, liver and breast cancers (EGF-
receptor) [148]. These receptors bind to their target specifically and with high 
affinity, whereby upon binding the receptors dimerize and are internalized 
together with their bound target. Recently, EGF has been covalently coupled to 
PEI [115]. This modification led to a 300fold increase of reporter gene 
expression, when compared to the unmodified polymer. Similar observations 
were made when EGF-poly(L-lysine) [149], EGF-PEI [150] or FGF–poly(L-
lysine) [151] conjugates where employed.  
Passive targeting: Complexes or macromolecules may accumulate passively in 
solid tumors, due to an increased permeability of tumor endothelia and lack of 
normal lymphatic drainage in connection with hypervasculature of the tissue 
[77]. This effect is known as the enhanced permeability and retention (EPR) 
effect and leads to the capture of complexes in the tumor interstitium. It has 
been exploited successfully to passively target polymers [152] or liposomes 
[153] to tumors without incorporating a more specific targeting moiety. The 
extent of accumulation depends on size and charge of the compound. It has been 
demonstrated that cationic lipoplexes or cationic dextran derivatives accumulate 
in regions of high angiogenic proliferation, most likely due to electrostatic 
interactions [78] and this effect may be applicable to polyplexes, as well. 
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Figure 4 
Scheme of subcellular trafficking of polyplexes  
3.2.4. Escape from the endosome 
Independent of the mechanism of endocytotic uptake, polyplexes invariably 
follow the scheme of the endolysosomal pathway, leading from the early to late 
endosomes, and ultimately ending in the lysosomal compartment. The lysosomal 
vesicles fuse and assemble in the perinuclear region [80]. Here the majority of 
complexes remains without significant changes in distribution patterns [18]. In 
order to be effective, a small fraction of complexes or at least their nucleic acid 
component must escape from this route since the lysosomal environment, with 
its aggressive nucleases and acidic pH of approximately 5, eventually destroys 
the potential efficacy of the entrapped complexes. Release has to take place 
rapidly, otherwise degradation occurs. Since endosomal escape is one of the 
major bottlenecks in non viral nucleic acid delivery, researchers are seeking to 
improve nucleic acid delivery at this level. They have attempted to mimic viral 
strategies by using peptides with pH triggered fusogenic activity, which are 
capable of destabilizing lysosomal vesicles.  Another method uses specific 
polymer properties, which enable the polyplexes to exit from 
ensosomes/lysosomes more efficiently. 
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Mechanism of endosomal escape: Vesicular escape of polyplexes most likely 
occurs via a pH dependent process. It is obvious that the efficiency of the 
polymers used for non viral nucleic acid delivery is narrowly connected to their 
buffering capacity in the lysosomal pH range of 5-7. Polymers that exhibit high 
transfection efficiencies, such as polyethylenimine [8], Starburst DendrimersTM 
[29], or imidazole-containing polymers [21-24,154] exhibit this property. The 
fact that the latter enhance gene expression is a rather strong evidence for the 
importance of buffering capacity, since their structure is unrelated to PEI or 
dendrimers. In contrast, cationic polymers with strong basic residues, e.g. 
poly(L-lysine) or polymers without titrable groups, such as quaternary amines, 
exhibit very low transfection efficiencies [18].  This may very well be due to the 
lack of protonable groups between pH 5-7. A plausible explanation for the 
mechanism of polyplex release, the so called ´proton sponge hypothesis´ has 
been developed [11]. According to this hypothesis the buffering capacity of the 
polymer leads to increased influx of protons and chloride ions during 
endolysosomal acidification, which results in an increased osmotic pressure in 
the vesicle. As a consequence, the passive diffusion of water into the vesicle 
increases, thus leading to swelling and eventually rupture or leakage of the 
vesicle. The expansion of the polymer structure, due to repulsion of positive 
charges may contribute to the vesicle destabilization. An indication for the 
validity of this hypothesis is shown by the fact that reporter gene expression is 
reduced dramatically when lysosomal acidification is abolished by the selective 
inhibitor bafilomycin A1. This has been demonstrated for PEI  [18,155] and 
imidazole-containing polymers [23]. Recently more experimental evidence was 
obtained for a pH dependent release of PEI-polyplexes possibly due to vesicle 
bursting. Living cell confocal laser scanning microscopy showed that release of 
PEI/ribozyme complexes occurs as a sudden event and that this process could be 
abolished by inhibiting endolysosomal acidification [18]. Another finding 
supporting the ´proton sponge hypothesis´ is that complexes with improved 
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packaging and thus a higher density of amine groups possesses a greater 
buffering potential, which results in higher transfection efficiencies [156]. 
It has been demonstrated that high generation PAMAM dendrimers and PEI 
possess a high membrane destabilizing potential compared to low generation 
dendrimers or poly(L-lysine) [157,158]. This may be a result of electrostatic 
interactions between the negatively charged membrane constituents and cationic 
polymers, a process that may cause disturbances in the curvature of the vesicles 
and finally lead to leakage [157] or bursting. In the case of dendrimers, these 
destabilizing effects seem to be more prominent for high rather than for low 
generation polymers, possibly resulting from the more rigid structure of the 
former. The results of these studies were obtained using anionic vesicles 
incubated with the cationic polymers, a system in which the described 
interactions occurred on the outside of the vesicles and not from within, as is 
found in vivo. This mechanism seems to play a role in gene delivery as well, 
since there seems to be a correlation between efficient membrane disruption in 
vitro and reporter gene expression. 
Strategies to enhance endolysosomal escape/ to prevent lysosomal degradation: 
Great efforts have been undertaken to abolish the endosomal bottleneck. The 
most important strategy is adapted from viruses, which have evolved 
sophisticated methods to escape the harsh environment of this compartment and 
deliver their genetic information safely into the nucleus.  
One approach is the use of short amino acid sequences derived from the N-
terminus of Haemophilus Influenza Haemagglutinin-2.  These amino acid 
sequences are responsible for enabling endolysosomal escape during the 
acidification process. Several sequences with approximately 20 amino acids 
have been identified and used successfully.  It has been discovered that all 
sequences follow a similar scheme [20]. For example, the INF7 peptide with the 
sequence GLFGAIAGFIENGWEGMIDGGGC exhibits a hydrophobic side 
chain, such as leucine, isoleucine or tryptophan (underlined) at nearly every 
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fourth amino acid. The rest of the sequence consists of variable amino acids, 
although it is important that no helix breaking amino acids are present and 
several glutamic acids are included. The ?-carboxyl groups of these glutamic 
acids play the key role in the activation of the fusogenic activity of the peptide.  
At neutral pH the ?-carboxyl groups are deprotonated, thus, leading to 
electrostatic repulsion and thereby conferring the sequence a random coil 
structure without fusogenic activity. When the pH drops, however, the carboxyl 
groups are protonated and the charge repulsions diminish. This process leads to 
a transition from the random coil to an a-helical structure, which displays the 
above mentioned hydrophobic residues on one side, thus making the helix 
amphipathic. The hydrophobic side of the helix may be able to insert itself into 
the vesicular membrane and disturb the membrane geometry, eventually leading 
to release of the vesicle contents. Furthermore, inserted helices may aggregate 
and form pores, which result in vesicle leakage. 
Experimental evidence has been gathered implying that this is not the only 
mechanism of transfection enhancement, at least for the INF7 peptide. It was 
discovered that this peptide also effects transfection at later stages, e.g. that it 
promotes dissociation of DNA from polyplexes in the nucleus [159] or acts as a 
nuclear localization sequence.  
Several synthetic peptides displaying pH dependent fusogenic properties have 
been synthesized successfully following similar structure principles [160,161]. 
The synthetic peptide GALA WEAALAEALAEALAEHLAEALAEALEALAA 
has been demonstrated to bind to phospholipid membranes at acidic pH 
[160,161] and to form aggregates within the membrane. These aggregates form 
membrane pores, although they are too small to enable plasmid DNA to escape 
from vesicles [162,163]. Therefore, other mechanisms must contribute to the 
transfection enhancement of GALA. Simoes suggested that in the case of 
lipoplexes the conformational change of the peptide could promote 
deaggregation of complexes, hereby releasing larger amounts of cationic lipids. 
Chapter 1  54
 
These could lead to a flip flop of anionic lipids from the cytoplasmic leaflet of 
the membrane into the region of pores formed by GALA peptides and 
subsequently to extensive membrane destabilization [164].    
Another example of a synthetic fusogenic peptide following the above described 
rationale is KALA WEAKLAKALAKALAKHLAKALAKALKACEA [165]. 
This peptide also mediates acid dependent increased vesicular escape and 
achieves transfection enhancement [166-68].  
Disadvantages of using protein structures like fusogenic peptides are low 
stability of the peptides, high costs for peptide synthesis and an immunogenic 
potential of these structures. They also do not enhance transfection efficiencies 
of polymers that already display rather high levels of reporter gene expression.   
Treatment with the lysosomotropic agent chloroquine has been used to enhance 
transfection efficiencies of cationic polymers without proton sponge properties, 
e.g. poly(L-lysine) in vitro. Chloroquine is thought to protect internalized 
material from degradation by preventing pH decrease [169,170] or acting as an 
endosomolytic agent [19,171]. The dimension of enhancement, however, is even 
lower than for fusogenic peptides and shows great variations between cell lines. 
The overall transfection efficiencies remain comparably low. Due to toxicity 
problems with chloroquine in vivo, the applicability of this compound is limited 
to the enhancement of transfection in vitro. 
A method developed to disrupt the membranes of endosomes and lysosomes 
precisely in a desired location, such as in tumor tissue, is the so-called 
photochemical transfection. In this technique photosensitizing compounds 
selectively accumulate in endosomal or lysosomal membranes, which upon 
illumination disrupt the vesicle. This method, in conjunction with regular 
poly(L-lysine) mediated transfection, led to a 20fold higher reporter gene 
expression, as well as a significant increase in the number of transfected cells 
[172].  
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3.2.5. Through the cytoplasm to the nucleus 
After release from endosomes/lysosomes the DNA/RNA component of 
polyplexes has to cross the cytoplasm in order to reach its site of action. The 
mobility of large molecules, such as plasmid DNA, is extremely low in the 
cytoplasm, making them an easy target for cytoplasmic nucleases. While 
ribozymes and antisense oligonucleotides may already be active in the cytosol, 
plasmid DNA has to be transported into the nucleus, in order to exhibit the 
desired gene expression. Thus, the major challenge is to modify the nucleic acid 
or complex in such a way as to protect it from degradation, however enable 
release from carrier and facilitate transportation into the nucleus.     
Stability and mobility of DNA in the cytoplasm: The cytoplasm is a critical 
place with respect to stability of DNA and RNA, due to the presence of 
nucleases that reduce their half life dramatically. Naked plasmid DNA, for 
example, exhibits a half-life as short as 50-90 minutes, which is likely due to 
degradation by cytoplasmic nucleases [173,174]. The importance of this fact 
becomes even more obvious when one recognizes that the majority of plasmid 
DNA enters the nucleus during cell division and, therefore, must remain stable 
until the next disassembly of the nuclear envelope. Accordingly, the role of the 
cell cycle length in this process must also be stressed. It is recognized that 
rapidly dividing cell lines show more efficient gene expression than slowly 
dividing ones, which is attributed to the short intervals of nuclear disassembly.  
Another factor that plays an important role in nucleic acid transit through the 
cytoplasm is the rate of mobility, which depends on size and spherical structure 
of the molecule. Low mobility means a longer trafficking time to the nucleus 
and thus a prolonged exposure to aggressive nucleases. While the diffusion rate 
for a small 100 bp DNA fragment is only ~5 times slower than in water, it is 
reduced dramatically with increasing size. Large DNA molecules, such as 
plasmids exhibit an extremely low mobility [175]. Several factors are 
responsible for the decrease in cytosolic diffusion rate. The higher viscosity of 
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the cytosol and sievelike effects of the cytoskeleton, forming meshes of ~10 nm 
that sterically hinder diffusion of large molecules contribute to this effect. 
Interactions of the negatively charged DNA with cytosolic constituents may also 
play an important role [176]. Microinjection studies have shown that the 
majority of the injected plasmid remains at its site of injection. Injections farther 
from the nucleus (60-90 µm) lead to a significant decrease in gene expression, as 
compared to injections performed in close proximity to the nucleus [176]. 
Therefore the site, where plasmid DNA is released into the cytosol is of great 
importance for efficient nuclear delivery.  
Effect of delivery agent in the cytoplasm: The above mentioned microinjection 
studies of naked DNA may not accurately display the situation for plasmid DNA 
or oligonucleotides during non viral nucleic acid delivery, since the mode of 
cytosolic transit for these molecules is not currently known. They may be 
complexed to some extent either with the transfection agent or with other cell 
constituents such as membrane lipids [81], and thus in a compacted state. This 
compaction could lead to an increased cytosolic mobility, as compared to naked 
DNA, or could offer an increased stability against cytoplasmic nucleases. 
Evidence for these assumptions has been gathered experimentally by cytosolic 
microinjection of polyplexes [177]. The microinjection of PEI/plasmid 
complexes resulted in a 10fold higher level of gene expression, as compared to 
naked DNA. This effect was independent of the polymer-nitrogen to DNA-
phosphate ratio, suggesting that the compaction mediated by the polymer may 
be of greater importance than the positive net charge of the complexes. In other 
words, the enhanced gene expression may be a consequence of increased 
cytoplasmic mobility, due to the smaller size of compacted DNA. 
Alternatively the cationic polymer could alter the structure of the cytoskeleton 
by widening the ´meshes´ and, thus, enhancing the permeability for large 
molecules. In vitro studies reported interactions between cationic polymers and 
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f-actin fibres leading to the formation of bundles and thus disturbing their 
natural assembly [178].  
A further reason for the higher level of gene expression could be the protection 
of DNA from cytoplasmic nuclease degradation afforded by the complex 
formation with cationic polymers demonstrated in vitro. Several studies have 
evaluated the stability of naked and complexed DNA/RNA in the presence of 
DNases or RNases, whereas excellent stabilization was observed using cationic 
polymers such as PEI even using very high enzyme concentrations [179,180].   
3.2.6. Into the nucleus 
The final barrier in non viral gene delivery is the nucleus. Access to this 
compartment enables the expression of the delivered gene and the desired 
therapeutic effect. The nuclear compartment is surrounded by a formidable, but 
not impenetratable barrier, the nuclear envelope, which consists of a double 
membrane interrupted by large integral protein structures, the so called nuclear 
pore complexes (NPC). Two paths lead into the nucleus: During mitosis the 
nuclear membrane disassembles and, thus, even large molecules, such as 
plasmids are able to gain access. In contrast, during interphases, the only way to 
enter the nucleus is through the NPC. This entry may occur via one of two 
different routes: While small molecules or ions are able to diffuse passively 
through the NPC, larger molecules, such as proteins or RNA, require something 
similar to an identification tag that is recognized by receptors and, thus, enables 
translocation into and out of the nucleus. These “tags” are termed nuclear 
localization sequences (NLS) if they mediate transport into the nucleus and 
nuclear export signals (NES) if they enable exit from the nucleus.  
DNA, however, does not move into the nuclear compartment under 
physiological conditions and, therefore, does not interact with NPCs [181]. 
Hence, the rate of DNA entry into the nucleus is very low and highly 
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sophisticated strategies are required to increase entry to levels necessary for 
efficient gene therapy.  
For therapeutic purposes nuclear translocation through the NPC seems to be 
only important for slowly dividing tumors. Fast dividing tissues have a sufficient 
frequency of cell divisions, thus nuclear entry occurs during disassembly of the 
nuclear membrane. 
The nuclear pore complex (NPC): NPCs are large, nuclear membrane protein 
structures of ~120 million Daltons in vertebrates [182]. They contain 50-100 
functionally distinct proteins [183], the so-called nucleoporins, which are 
involved in transport processes or form the structure of the NPC. During mitosis 
in vertebrates these proteins are fragmented into approximately 12 
subcomplexes, which then are reassembled at the end of the telophase to form 
the structure of the pore complex again [183].
Transport through the NPC: Molecules which are trafficked through the NPC 
can be classified into molecules with or without affinity to components of the 
NPC. The entry of molecules with no affinity occurs via passive diffusion and 
seems to be controlled only by size and steric properties [184,185]. The upper 
size limit for this form of nuclear entry is approximately 50 kDa [186], 
corresponding to a molecule diameter of approx. 10 nm. The velocity of this 
process is, as in every diffusion process, inversely proportional to the size of the 
molecule.  
On the other hand, a variety of molecules larger than 50 kDa are able to enter 
the nucleus via a different route. This process, however, requires not only 
energy, but also specific interactions with components of the NPC. Generally, a 
series of association/dissociation processes is thought to mediate nuclear entry 
of the substrate [182]. Feldherr et al. determined the upper size limit for this 
form of entry using gold particles of various sizes coupled to nucleoplasmin (see 
below) [187], and discovered that it is approximately 26 nm, which corresponds 
to a molecular mass of ~ 8 million Dalton. This size limit varies not only 
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between species, but also within the same cell line depending on the confluency 
or energy status of the cells [187]. The diameter of the substrate seems to be the 
most important property for passage across the NPC, as no limitation for the 
length of a substrate was found.  
Nuclear localization sequences (NLS): Protein sequences that mediate nuclear 
import are so called nuclear localization sequences (NLS). A NLS is a short 
amino acid sequence that enables the active transport of proteins or viral DNA 
into the nucleus. Although more than 100 NLS have been identified [188], 
several aspects regarding their function remain yet to be investigated. One of the 
most intriguing questions still unanswered is: To what extent do homologies 
exist among NLS? NLS do not conform to a specific consensus sequence, very 
likely because they interact with different receptors. However, they can be 
classified into monopartite and bipartite motifs [189]. In these sequences, the 
positively charged amino acids, lysine and arginine, are typical [190]. Usually, 
the monopartite motif consists of several positively charged amino acids, 
accompanied by a helix breaking residue, for example, the 92 kDa SV40 large 
T-antigen NLS, PKKKRKV [191]. For this example it has been demonstrated 
that phosphorylation and dephosphorylation of the SV40 large T-antigen protein 
upstream from this sequence is involved in the regulation of affinity to proteins 
interacting with the NPC machinery [192]. Bipartite NLS usually consist of two 
sets of positively charged residues with a small upstream cluster of two arginine 
or lysine residues separated by a 9-12 amino acid point mutation tolerant linker 
from a downstream cluster similar to a monopartite NLS [193]. Examples for 
bipartite NLS are the nucleoplasmin NLS, KRPAATKKAGQAKKKK
 
[194] or 
the nucleolin NLS, KRKKEMANKSAPEAKKKK [195]. It should be noted that 
not all experimentally identified NLS fit into the above mentioned scheme and 
also many cytosolic, non-nuclear proteins show sequences similar to the above 
mentioned properties. Interestingly, if a protein contains both a NLS and a DNA 
binding site these regions overlap in ~90 % of the cases, indicating that during 
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evolution the principle of DNA binding via electrostatic interactions was used 
for targeting DNA binding proteins to the nuclear compartment.   
Examples for NLS functions differing from the classical ones described above 
are the arginine-rich sequences, Tat and Rev, from the human 
immunodeficiency virus type 1 (HIV-1). These sequences do not only act as 
protein transduction domains, mediating access to the cell in an endocytosis-
independent way, but also enhance nuclear uptake [196].  
It has been thought that poly(L-lysine) acts as a NLS, due to the large density of 
positive charges similar to those found in mono- and bipartite NLS [197]. This 
assumption, however, has been refuted. By using polylysine carrying peptides it 
could be demonstrated that no significant affinity to NLS-binding subunits of 
the nuclear import machinery exists and no rapid accumulation in the nucleus 
occurred [197].  
Specific DNA sequences have also been observed that mediate increased nuclear 
import. Plasmids containing a region of the SV-40 early promoter and enhancer 
have been shown to cross the nuclear envelope much more efficiently than those 
without this specific sequence [198]. Studies investigating the mechanism of 
nuclear uptake have pointed out that NLS harbouring cytosolic transcription 
factors selectively bind to specific DNA sequences on the plasmid thus forming 
a DNA/peptide complex that is able to enter the nucleus [199]. The 
incorporation of such a viral nucleotide sequences in order to enhance nuclear 
uptake is a conceivable strategy to improve nuclear uptake of plasmid DNA. 
Modifying the binding site of these sequences for transcription factors that 
particularly occur in specific cell types enables the selective targeting to the 
nucleus in these cells [199].
Nuclear entry of DNA: In contrast to protein or viral DNA entry into the 
nucleus, little is currently known about the mechanism of DNA entry. What we 
do know is that, although the transport of DNA from the cytosol into the nucleus 
does not occur under physiological conditions, the NPC does not seem to be an 
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impenetratable barrier to passive diffusion. Unfortunately, the passive entry of 
DNA becomes less efficient with increasing size. Small nucleic acid molecules 
with a size of less than 300 bp have little difficulty entering the nucleus via free 
diffusion [200]. For larger DNA molecules >300 bp the rate of transfer through 
the intact nuclear envelope decreases with the size of the molecule.  
The mode of nuclear entry of plasmid DNA in non dividing cells occurs 
independently of NLS-bearing proteins, as it cannot be inhibited by cooling 
down to 4 °C or ATP depletion, which inhibit both active protein uptake [181]. 
Evidence suggests that two different mechanisms of nuclear entry are likely for 
plasmid DNA. On one hand a rather inefficient passive diffusion through the 
aqueous pores of the NPC is postulated, whereas, on the other hand, entry may 
occur at the time of nuclear membrane disassembly during cell division. The 
former path has been demonstrated by several groups via microinjection studies. 
Pollard [177] found that no more than 0.1 % of the plasmid copies microinjected 
into the cytoplasm reached the nucleus. This result was improved by 10fold 
when plasmid DNA was complexed to PEI. Mirzayans [201], in contrast could 
not detect any transient gene expression after cytosolic microinjection. An 
explanation for this inefficient nuclear entry could be the low velocity of the 
translocation process in conjunction with the short half life [173] and low 
mobility [175] of the plasmid DNA in the cytosol. 
Evidence for the latter route is supported by the fact that gene expression is 
generally much higher in rapidly dividing, than in slowly dividing cell lines. If 
cells are arrested in the G1 phase and, thus, unable to perform mitosis, reporter 
gene expression is up to 500 times lower than in cells that undergo mitosis 
starting from the S or G2 phase [202].  
Nuclear localization sequences have been used in various ways to improve the 
uptake of plasmid DNA into the nucleus.  
Non-covalent attachment of NLS: Electrostatic complexes between negatively 
charged DNA and positively charged SV40 large T-antigen NLS have been 
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utilized. Cytoplasmic microinjection of complexes into zebrafish embryos have 
shown a significant increase in nuclear uptake in comparison to naked DNA 
[203-205], which increased with higher NLS:plasmid ratios. Complexes with a 
nuclear import deficient reverse sequence and plasmid DNA did not show 
nuclear accumulation or increased gene expression under the same experimental 
conditions. These findings indicate that if plasmid DNA and NLS reach the NPC 
simultaneously, electrostatic interactions can promote the nuclear uptake of 
DNA.   
Another approach using non-covalent interactions between DNA and NLS 
bearing proteins is their complexation to histones. These relatively small 
proteins are synthesized in the cytosol and imported into the nucleus via the 
NLS/NPC machinery. The use of a recombinant histone containing the 
carboxyterminal domain of the human histone, H1, complexed to plasmid DNA 
and a lipid formulation resulted in a 20fold higher luciferase expression than 
plasmid-lipofectin complexes alone [206,207].  
The Tat sequence has also been used in electrostatic complexes with PEI. In this 
study an enhanced nuclear uptake was observed microscopically and a more 
than 10fold increase in reporter gene expression was detected [99].   
Strategies exploiting complementary base pairing between DNA strands to non 
covalently attach a NLS to a specific site of a DNA molecule have been realized 
as well. For example Neves et al. [208] attached a NLS specifically to plasmid 
DNA by forming a triple helix with an oligonucleotide-NLS peptide conjugate 
complementary to a specific sequence on the plasmid. These complexes were 
able to interact specifically with proteins involved in nuclear uptake. 
Microinjection of the complexes into cells, however, did not lead to nuclear 
accumulation, as no diffusion from the site of injection could be observed.  
Another elegant example of a complementary approach is the use of a peptide 
nucleic acid (PNA) sequence conjugated to a NLS. PNA contains the same 
bases as DNA, however, the desoxyribose-phosphate backbone is replaced by a 
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peptide structure that can be functionalized with a NLS. PNA can form double 
or triple strands with complementary DNA. The use of PNA-NLS conjugates 
have lead to an increased nuclear uptake of oligonucleotides and enhanced 
transfection efficacy of plasmid DNA, which could be even further improved by 
the use of PEI as delivery agent [209].   
Recently it has been reported that linear 22 kDa PEI is able to mediate efficient 
and cell cycle independent nuclear uptake of plasmid DNA [16]. The detailed 
mechanism how transport through the NPC occurs, however, remains 
unelucidated and needs further investigation. 
Covalent coupling of NLS: A different way to take advantage of NLS is to 
synthesize covalent conjugates with DNA. This strategy has been realized by 
several groups using various coupling methods and different evaluation 
techniques [200, 210-12]. Zanta et al. [210] synthesized a capped 
CMVLuciferase-NLS gene containing a single SV-40 large T-antigen NLS per 
DNA molecule. They found a 1000fold enhancement of the transfection 
efficiency for this conjugate when compared to unmodified DNA. This effect 
was reduced to normal levels after the replacement of a single lysine residue 
with a threonin in the NLS, suggesting that the enhancement of transfection was 
the result of an increased nuclear uptake. Ludtke et al. [200] synthesized NLS-
DNA conjugates with various sizes of DNA. They observed that the coupling of 
NLS to DNA significantly enhanced DNA uptake into the nucleus, whereas the 
efficiency of uptake was dependent upon the size of the DNA.  
Although the non covalent strategy for binding NLS to DNA has been tested in 
vivo with some success [213] the use of a covalently linked NLS seems to be 
more promising, due to the much higher stability of these conjugates.   
Chapter 1  64
 
4. GENE THERAPY STRATEGIES TOWARDS 
CANCER 
Progress of molecular biology has provided a remarkable increase in our 
knowledge about cancer and its molecular mechanisms. The introduction of 
genes and nucleic acids into mammalian cells has become feasible during this 
information explosion. These advances have enabled cancer gene therapy to step 
from a diffuse vision into laboratory routine and even into clinical trials. 
Specific forms of cancer are especially suitable for gene therapy since cancer 
development has its origin in genetic mechanisms. At least one mutation from a 
protooncogene to an oncogene in conjunction with an aberration of a tumor 
suppressor gene leads to cancer genesis and proliferation. In contrast to other 
strategies, a therapy on this level is capable of providing high efficiency and 
specificity. Several strategies have been pursued to exploit the potential of this 
new field. Antisense- and ribozyme therapy provide the possibility of 
specifically downregulating the expression of particular genes predominantly by 
interactions with mRNA. In gene therapy new DNA material is introduced into 
the nucleus of the target cell. Different strategies such as knockout gene therapy, 
gene replacement, suicide gene therapy and immunomodulatory strategies have 
been performed successfully. The principles of these approaches will be 
introduced briefly, however non viral strategies most often use reporter genes 
which have no cancer relevance. Furthermore the vast majority of the studies 
have been accomplished with viruses.   
4.1. Antisense oligonucleotides and ribozymes 
Antisense oligonucleotides and ribozymes possess the potential to downregulate 
the expression of particular genes in a highly specific manner. In contrast to 
knockout gene therapy where a gene coding for an antisense RNA 
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oligonucleotide or ribozyme is introduced into the target cell, this method 
employs synthetic oligonucleotides. 
 
Antisense approaches: Antisense strategies make use of a highly specific 
binding of an oligonucleotide (in most cases DNA) to its complementary 
sequence on a target mRNA and hence the subsequent inactivation of the target. 
To achieve sufficient specificity, the sequence must consist of at least 12 
nucleotides, however, most antisense oligonucleotides contain 16-24 
nucleotides. 
The mechanisms of antisense action are complex and not fully understood, 
however, a major one appears to be RNA cleavage after hybridization of the 
DNA antisense oligonucleotide with its target mRNA. This reaction is catalyzed 
by the ubiquitous enzyme Ribonuclease H (RNase H). RNase H is an 
endoribonuclease that specifically degrades the RNA strand in a RNA-DNA 
hybrid and has its evolutionary roots in the defense of mammalian cells against 
retroviruses. The RNase H mechanism is by far the most important due to the 
fact that the antisense oligonucleotide is not destroyed or permanently occupied 
and therefore only catalytic amounts are necessary. Several other mechanisms 
such as transcriptional arrest, inhibition of splicing and inhibition of 
posttranslational modifications are involved as well (see Figure 7), however, 
they require stoichiometric amounts of oligonucleotide and are probably less 
important.  
Since regular phosphodiester oligonucleotides are inactivated by serum 
nucleases rather rapidly, chemical modifications especially on the 
phosphodeoxyribosyl-backbone were investigated to achieve higher stability. 
Phosphorothioate oligonucleotides (SODN) with one of the oxygen atoms in the 
phosphate group replaced with sulfur have a significantly increased resistance to 
nuclease inactivation, however, their binding affinity to the target mRNA and 
their affinity to RNase H is slightly reduced. In total however the higher 
resistance leads to an enhanced efficiency and therefore SODN have become the 
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standard type of oligonucleotide for antisense therapy and several SODN 
targeting cancer are in clinical trials [214]. A problem associated with this type 
of oligonucleotides is their susceptibility towards unspecific effects due to their 
interactions with biomacromolecules such as proteins. Therefore a careful 
evaluation of experimental data should be performed in order to attribute 
therapeutic effects exclusively to an antisense mechanism.  
Another example for a stabilizing modification on oligonucleotides is the 
introduction of a methoxyethoxy group at the 2' position of the ribose ring [215], 
which leads to significant stabilization and displays synergistic effects with 
phosphorothioate modifications. For a deeper insight into antisense mechanisms 
and chemistry we refer the reader to an extensive review for details [216].  
Figure 5 
Major sites of action of antisense oligonucleotides  
Ribozymes: Ribozymes are RNA molecules endowed with catalytic activity and 
capable of cleaving mRNA molecules in a sequence specific, catalytic manner. 
They contain sequences for selective ligation with target mRNAs which confers 
upon them high specificity. They also contain sequences that perform cleavage 
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reactions with the target mRNA. By modifying the substrate recognizing 
sequences, ribozymes can be specifically tailored for the suppression of 
particular genes. A large variety of gene products have been targeted 
successfully using this strategy (see Table 5 for cancer specific targets). 
Two types of ribozymes, the hammerhead and hairpin ribozymes have been 
extensively studied due to their small size and high cleavage efficiency. 
One problem using these structures is their low stability against ubiquitous 
RNases. Therefore strategies have been developed that enable efficient 
protection of ribozymes without loss of catalytic activity. Modifications of the 
chemical structure of the phosphoribosyl backbone have been performed, 
including the use of 2´-O-methyl nucleotides instead of 2´-hydroxyls throughout 
the sequence. The addition of an inverted deoxyabasic sugar residue on the 3´ 
end or the introduction of phosphorothioate nucleotides on the 5´ end of the 
ribozyme have also been performed [217]. The sum of these modifications leads 
to a decreased recognition by nucleases and an increased biological activity. 
Complexation with cationic polymers or application of DNA/RNA chimeras 
have shown promising results for stabilization as well (own unpublished data). 
A major advantage of this strategy is the high efficiency of stabilization 
provided by these agents and the possibility of attaching targeting moieties to 
polymers in order to target specific cells. 
A problem when using hammerhead ribozymes is their dependence on 
magnesium ion concentration for catalytic activity. Physiological concentrations 
of this ion are 5-10fold lower than in optimized cell culture conditions [218]. 
Therefore correlation from in vitro to in vivo activity is problematic. 
For reviews about hammerhead and hairpin ribozymes see references [219,220]. 
To date the major site of action for either antisense oligonucleotides or 
ribozymes on the subcellular level has not been determined and it remains 
unclear if actual delivery into the nucleus is required for effectivity.  
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Target genes for antisense/ribozyme strategies: Several antisense and ribozyme 
strategies have been pursued with some success in cancer therapy in vitro as 
well as in vivo. One approach is to make cancer cells more sensitive to 
chemotherapy by blocking the expression of genes that are involved in 
multidrug resistance. A target that has been investigated intensively in this 
context is the Multidrug resistance gene (MDR1) and its product P-glycoprotein 
that removes a large variety of chemotherapeutic agents from the cell. Treatment 
with anti-MDR1 oligonucleotides or ribozymes led to a significant reduction of 
MDR1 expression (see Table 5) and subsequently to a higher sensitivity of the 
treated cells against a variety of cytostatic substances. 
For further examples see Table 5.  
Target Gene Biological effect of ODN/ribozyme (a)ntisense / (r)ibozyme Reference 
MDR1 reverse multidrugresistance a,r [215,222] 
BCL2 apoptosis a,r [223,224] 
MDM2 inhibition of proliferation  a [225] 
c-ERBB-2  inhibition of proliferation  a,r [226,227] 
c-Myc apoptosis a,r [228,229] 
Ras inhibition of proliferation and a [230,231] 
 
CAM expression 
Raf inhibition of proliferation and a [231] 
CAM expression 
AKT1 apoptosis a [232] 
EGFR inhibition of cell prolifration a,r [233,234] 
FGF  antiangiogenesis a [235] 
angiogenin antiangiogenesis a [236] 
telomerase cell death a,r [237,238] 
survivin cell death a [239] 
Table 5  
Examples for cancer related targets in antisense and ribozyme therapy  
Antisense treatment towards these targets has been investigated intensively in 
vitro and in clinical trials at several stages. Early clinical trials show only 
modest efficiency in some patients. At present, antisense therapy in combination 
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with classic chemotherapy seems to be the more favorable regimen [221]. More 
research is necessary to optimize such combinations and antisense therapy itself.   
Target  Effector structure Reference 
  
(a)ntisense/(r)ibozyme
k-ras r [240,241] 
Epidermal growth factor (EGF) r [242] 
bcl-2 r [243] 
Alpha1-antitrypsin r [244,245] 
HER2/neu r [246] 
mutant p53 r [247] 
BCRABL r [248] 
Interleukin-8 a [249] 
Cyclin D1 a [250] 
VEGF  a [251] 
c-myc a [252] 
Basic fibroblast growth factor  a [253] 
High mobility group I proteins a [254] 
hNr-CAM a [255] 
Urokinase-type plasminogen  a [256] 
activator receptor 
Table 6  
Cancer related targets used for knockout gene therapy  
4.2. Knockout gene therapy 
Knockout gene therapy aims to inactivate or attenuate the expression of 
oncogenes and hereby to inhibit uncontrolled cell proliferation, angiogenesis, 
drug resistance or metastasis formation. This can be achieved by the 
introduction of a gene coding for an antisense RNA which hybridizes with the 
target mRNA of the desired oncogene. Since duplexed mRNA cannot be 
translated, it is degraded quickly and the expression of the targeted oncogene is 
inhibited specifically. Furthermore genes can be introduced coding for ribozyme 
molecules that reduce the expression of an aberrant gene by specific cleavage of 
its mRNA. Since decoding of the human genome has provided knowledge about 
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a large variety of oncogene sequences, this approach can be utilized in a variety 
of clinical situations and has been realized mainly using viral vectors (Table 6).
A second strategy to ´knock out´ the effect of a cancer gene is the introduction 
of a modified oncogene that acts in a dominant manner towards the cancer 
causing gene and thereby attenuates or even inhibits its expression. This method 
is less versatile due to difficulties in finding genes with counteracting properties 
and its application is limited to very specific targets.   
4.3. Gene replacement/gene augmentation  
This strategy tends to replace either a missing or a mutated/defective gene, in 
most cases tumor suppressor or other apoptosis-inducing genes. The difficulty 
with this approach is that this type of gene therapy replaces only one gene and is 
thus less effective if the cancer is oligo- or multigenic in origin. There are 
numerous diseases that are based on monogenic defects for example cystic 
fibrosis, hemophilia IX or familial hypercholesterolemia. In these situations 
gene replacement may be suitable. Cancer, however, is usually caused by 
multiple gene defects, so that either more than one gene has to be introduced or 
a combination with other forms of therapy must be performed. In fact the 
combination with chemo/radiotherapy showed synergistic effects and represents 
a valuable augmentation of classical cancer therapy [257]. 
P53 in cancer gene therapy: P53 is the best investigated tumor suppressor and 
mutations within the p53 gene are involved in a large portion of human tumors. 
It acts as a transcriptional factor and is involved in the regulation of apoptosis, 
cell growth arrest and senescence. Its malfunction is a common mechanism for 
tumorigenesis leading to cell immortalization, multidrug resistance and 
uncontrolled cell division. One approach in selective treatment of p53 
aberrations is to reactivate its expression with low molecular weight drugs like 
actinomycin D or leptomycin B [258]. This has been done with success in 
several cell lines, however, it requires a residual level of p53 expression and is 
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therefore not suitable in all situations. Furthermore, toxicological problems 
make this approach applicable only for local administration and is therefore 
limited to easily accessible tumors. 
Gene replacement represents a direct approach towards the restoration of wild 
type p53 function. It has been demonstrated in vitro that introduction of wild 
type p53 gene into human carcinoma cells induces apoptosis of cancer cells 
[259] and may induce remission of drug resistance connected with mutant p53 
variants [260]. Most forms of lung cancer are p53 deficient, therefore this 
approach has been investigated in detail for this target. Delivery of wild type 
p53 to the lung either by systemic or local application via inhalation of 
aerosolized polyplexes led to a significant suppression of tumor growth in both 
cases and a prolonged survival time of laboratory animals [56,261].  
Delivery to breast cancer cells in vivo using immunolipoplexes including anti-
transferrin receptor antibody as targeting moiety has been reported recently 
[262]. This treatment led to a high level of p53 gene expression in the targeted 
cells and a combination treatment with docetaxel resulted in significantly 
improved efficacy of the drug with prolonged survival of laboratory animals. 
For a review concerning non-viral p53 delivery see reference [263].  
4.4. Suicide gene therapy 
A special form of gene augmentation therapy is the introduction of prodrug-
converting enzyme genes, better known as suicide genes. A suicide gene 
encodes for an enzyme usually of viral or prokaryotic origin that performs the 
conversion of a non-toxic prodrug into an active toxin that causes cell death. The 
gene for this enzyme is either under the control of a tumor specific promoter, 
thus limiting the cytotoxic effect to specific tissues or injection directly into 
target tissue is performed in order to limit nonspecific toxicity. Table 7 gives an 
overview of frequently used suicide genes and their substrates. This strategy 
recently was effective in an in vivo model using PEI as non viral vector in 
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hepatocellular carcinoma [264]. Transfection with herpes simplex thymidine 
kinase (HSV1-tk) gene and subsequent ganciclovir treatment, one of the most 
common suicide gene systems, was used in this study. HSV1-tk converts the 
rather non-toxic drug ganciclovir into its triphosphate that interferes with DNA 
synthesis and leads to death of transfected cells. This treatment leads to a 
suppression of tumor growth and a significantly prolonged survival time of 
laboratory animals. Many suicide gene therapy approaches mainly with viral 
vectors as well as some liposomal formulations have been performed and 
resulted in tumor and metastasis remission in vivo [265,266]. Furthermore the 
HSV1-tk/ganciclovir and cytosine deaminase/5-Fluorocytosine system are 
currently being evaluated in clinical trials [267-69]. A major disadvantage of 
this strategy is that gene expression must occur specifically in tumor tissue in 
order to spare healthy cells. Therefore highly tumor specific promoters need to 
be developed in order to minimize toxic effects. Targeting moieties specific for 
cancer cells may also help to limit impact of non target cells. For a review about 
prodrug activation enzymes in cancer gene therapy see reference [270].  
Enzyme Prodrug Active drug Reference 
Thymidine kinase (HSVtk) ganciclovir ganciclovir triphosphate [271] 
Cytosine deaminase 5-fluorocytosine 5-fluorouracil [272] 
Purine nucleoside phosphorylase 6-methylpurine-2´deoxyribonucleoside 6-methylpurine [273] 
Guanosine-xanthine Phosphoribosyl 6-Thioguanine 6-thioguanine triphosphate [274] 
transferrase  
 
Varizella zoster virus thymidine  araM araM-MTP [275] 
Kinase 
E. coli nitroreductase CB 1954  (5-(aziridin-1-yl)- (5-(aziridin-1-yl)-4-hydroxyl [276] 
2,4-dinitrobenzamide) amino-2-nitrobenzamide) 
Table 7 
Enzyme/Substrate systems used in suicide gene therapy     
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4.5. Cancer vaccination using gene therapy approaches 
Vaccination approaches have been performed successfully for a large variety of 
cancers and they represent promising strategies for future advances especially 
due to their rather low toxicity and their ability to reach multifocal targets 
throughout the body [277,278]. In fact most of the clinical trials of cancer gene 
therapy employ such immunological strategies, using the transfer of genes for 
cytokines, costimulatory factors or tumor associated antigens into a variety of 
cellular targets. 
Malignant cells do show antigenic differences to normal cells, however their 
immunogenicity is not recognized by the host´s immune system. The goal of 
immunological strategies is either to boost the immune system in a way that 
enables it to identify and efficiently eliminate tumor cells or to enhance the 
immunogenicity of tumor cells so they can no longer remain undiscovered.  
One strategy relies on augmentation of the conspicuousness of tumor cells to the 
immune system by explantation of cancer cells from a patient´s body and 
transfection ex vivo with a cytokine gene such as interferon-?, tumor necrosis 
factor-a and interleukin 12 or genes of costimulatory factors such as B7 (CD80) 
or intercellular adhesion molecule-1 (CD54) [279,280]. Cells are then 
transplanted back into the patient where the expression of cytokines and 
costimulatory factors in proximity to tumor antigens presented on MHC class I 
proteins on the surface of tumor cells draws attention of the host´s immune 
system to the tumor.  
An alternative approach towards cancer vaccination is a modification in the way 
a tumor associated antigen is presented to the host´s immune system. If antigens 
are only weakly expressed via MHC class I proteins on tumor cells they are not 
recognized under normal conditions and the tumor remains unmolested. If, 
however, they are presented with professional antigen presenting cells (APC) of 
the immune system, especially dendritic cells in association with costimulatory 
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factors, an immune reaction is initiated. This strategy is most effective when 
combined with the introduction of cytokine genes. 
One approach to achieve the presentation of tumor antigens on dendritic cells is 
based on the insertion of the DNA sequence encoding the desired antigen into a 
plasmid vector, capable of expressing exogenous proteins in mammalian cells. 
These plasmids are then introduced into skeletal muscle cells or subcutaneous 
tissue via gene gun or injection of naked DNA with the intention that these cells 
will express the protein and export it into the surrounding tissue interstitium. 
The antigen is captured by antigen presenting cells, especially dendritic cells 
(DC) and presented after intracellular processing on major histocompatibility 
complex (MHC) class I and II, thus leading to cellular and humoral immune 
response against the presented antigen. 
A second strategy aims to directly introduce the vector containing the tumor 
antigen sequence into DC via a targeted vector resulting in similar effects as 
described above [139,281]. Introduction of the tumor antigen can be performed 
ex vivo as well, with subsequent reimplantation into the patients [282].  
4.6. Bystander effect 
One problem concerning knockout and suicide gene therapy is the fact that in 
theory the whole cell population of a tumor has to be transfected in order to 
achieve tumor eradication. Otherwise non-transfected cells survive and 
proliferate, thus leading to survival of the cancer. A helpful phenomenon in this 
context is the so called bystander effect, which means that the introduced gene 
can affect cells in which the gene is not expressed itself. The mechanisms of 
action is not fully understood, however, cell-cell exchange of soluble factors 
through gap junctions may be involved. Using suicide gene therapy strategies 
with herpes simplex virus thymidine kinase/ganciclovir treatment for example, a 
transfer of toxic metabolites of ganciclovir from transfected to non-transfected 
cells through cell-cell contacts can be observed, thus augmenting efficiency of 
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the treatment [283]. A mechanism involved in bystander effects in distant cells 
and/or anatomically separated tumors is the activation of innate and adaptive 
immunological antitumor responses against cancer cells [284] This effect is 
probably mediated by significant increase of CD4 positive, CD8 positive and 
natural killer cells. 
A more detailed knowledge about mechanisms of action and methods to 
augment the bystander effect will be very valuable to future cancer gene therapy 
regimens.  
4.7. Clinical trials 
Cancer gene therapy: Cancer treatment is by far the most important proposed 
application of gene and antisense therapy and many clinical trials are underway 
(Figure 6). Approximately 50 percent of all cancer gene therapy trials use 
various forms of immunemodulatory strategies via systemic or local 
administration. Another significant contribution (15%) to the studies is 
represented by suicide gene therapy strategies. Further approaches like insertion 
of multidrug resistance genes in stem cells or tumor suppressor gene therapy 
represent approximately five percent. The vast majority of gene therapy clinical 
trials are in phase I and only a very few have progressed to phase II studies. The 
majority of the studies have demonstrated that gene therapy is generally feasible 
using both, viral as well as non viral strategies, however at present cancer gene 
therapy has not fulfilled the high expectations initially predicted. No one has 
been cured through the use of gene therapy and the therapeutic efficiency 
monitored in clinical trials is disappointing. 
More than two thirds of gene therapy clinical trials use viral vectors, only 13 % 
employ lipid vectors and ~ 10 % use naked DNA (Figure 7). Cationic polymers 
have only been used in animal models and have not advanced into clinical trials 
due to the various problems described in this review. Some of the clinical trials 
using lipid vectors are summarized in Table 8. The majority of these studies 
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employ immunological strategies against cancer and another significant portion 
aims the transcriptional repression of HER-2/neu gene by introduction of the 
adenovirus type 5 E1A gene via local application. Her-2/neu is a growth factor 
receptor overexpressed in multiple human cancers, especially breast and ovarian 
cancer. Several studies demonstrated E1A gene expression in target tissue, 
accompanied by HER-2/neu downregulation, increased apoptosis, and reduced 
proliferation. 
Antisense therapy: Antisense therapy is clinically far ahead of actual gene 
therapy and remarkably the FDA has already approved one drug. This drug is 
named Fomivirsen (VitraveneR), a 21mer phosphorothioate oligonucleotide that 
is being used against infections of the eye caused by human cytomegalovirus 
(HCMV). It inhibits the expression of proteins necessary for virus replication 
through an antisense mechanism and needs to be administered via intravitreal 
(eye) injections.  
Target Vector  Phase Reference 
Metastatic melanoma DMRIE/DOPE II [285] 
Breast and ovarian cancer DC-Chol I [286] 
Brest and head and neck cancer tgDCC I [287] 
Peripheral neuroektodermal cationic lipid preliminary clinical [288] 
malignancy (ex vivo) trial 
 
Cutaneous metastases DC-Chol/DOPE I [289] 
Hepathic metastases of DMRIE/DOPE I [290] 
colorectal carcinoma 
Melanoma DMRIE/DOPE I [291] 
Table 8  
Examples for clinical trials with cationic lipids (Abbreviations: DMRIE=1,2-
dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide, DOPE=dioleoyl 
phosphatidylethanolamine, DC-Chol=3-beta(N-(N',N'-dimethylaminoethane)carbamoyl) 
Cholesterol, tgDCC=3 beta[N-(n',n'-dimethylaminoethane)-carbamoyl] cholesterol/ 
dioleoylphosphatidyl-ethanolamine). 
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Figure 6 
Percentage of diseases treated in clinical trials using cancer gene therapy 
(data from http://www.wiley.co.uk/genetherapy/clinical/).  
Figure 7 
Overview about vectors used in clinical trials (data from 
http://www.wiley.co.uk/genetherapy/clinical/).  
With regard to cancer therapy a variety of phase I studies are underway. An 
antisense oligonucleotide for the treatment of melanoma and B-cell lymphoma 
targeting bcl-2 and an antisense inhibitor of protein kinase C alpha in solid 
tumors are being investigated in phase III trials [214]. Phase II clinical trials are 
in progress against raf-kinase, Hras, R2-protein and DNA methyltransferase (see 
table 9 and [214]).   
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Name Company Application Disease Target Stage 
ISIS 3521 ISIS/Lilly parenteral non-small cell lung cancer PKC-a phase III 
 
and others 
G3139  Genta subcutaneous melanoma bcl-2 phase III 
ISIS 2503 ISIS parenteral cancer, pancreatic  H-ras phase II 
and others 
ISIS 5132 ISIS parenteral cancer, ovarian raf phase II 
and others 
GTI-2040 Lorus parenteral advanced or metastatic  R2-protein of ribo-  Phase II 
renal cell carcinoma nucleotid reductase 
GEM 231 Hybridon parenteral various cancers PKA Phase II 
Table 9  
Antisense ODN against cancer in higher stages of clinical trials  
Numerous other antisense approaches against cancer related targets are in 
clinical trials and the interest in antisense strategies is expected to increase as it 
displays several advantages. It is easier to synthesize large amounts of pure 
antisense oligonucleotides as compared to plasmids as the antisense sequences 
used are much shorter. Furthermore, the antisense mechanism is applicable to a 
wide range of conditions and antisense oligonucleotides are physiologically well 
tolerated.  
5. CONCLUSIONS  
Progress in molecular biology has provided the opportunity for the introduction 
or replacement of missing, as well as malfunctioning genes. Using these tools, 
cancer cells may be selectively destroyed via suicide strategies or the expression 
of undesired genes may be blocked by antisense or ribozyme strategies. 
Immunological approaches have displayed promising therapeutic effects, as 
well. The best clinical results, however, have been achieved by local 
administration or the use of antisense oligonucleotides, as is indicated by the 
high number of clinical trials currently taking place. These new techniques, 
however, lack efficient and specifically targeted delivery systems for nucleic 
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acids and raise toxicity concerns. No one system meets all needs; instead 
different therapeutic circumstances will require different vectors. Remarkable 
efforts have been made to optimize gene delivery systems in vitro; in vivo 
application, however, requires different vector features. Properties of non viral 
vectors determined in vitro are insufficient for predicting their behavior in vivo 
and the development of a set of in vitro assays that allow prediction of in vivo 
behavior of the vectors would be a valuable tool for further advances. Additional 
research, which elucidates the factors influencing opsonization and other 
mechanisms leading to RES uptake and other forms of elimination in vivo, is 
necessary.  
A useful strategy to reduce unspecific interactions of polyplexes after systemic 
administration is the steric stabilization of complexes via the attachment of 
hydrophilic polymers. The poor in vivo results displayed by the first generation 
of these complexes using simple attachment of PEG or pHPMA occurred 
probably due to ineffective shielding. Strategies developed by Oupicky et al. 
[49,50] using bioreversible crosslinking of surface modifying structures or DNA 
compacting polymers lead to higher stability in circulation and efficient 
intracellular release. Research employing other bioreversible complex 
modifications and the use of more efficient shielding strategies represent 
interesting approaches to improve in vivo vectors.  
Another major problem occurring in vivo is gene expression in sites other than 
the target tissue. A number of targeting moieties for cancer tissues have been 
identified and these structures were effective in vitro and, in some cases, even 
after systemic application. Incorporation of tissue specific promoters, in order to 
limit gene expression exclusively to the target tissue, will provide synergistic 
effects with active targeting strategies and should be addressed in particular 
therapeutic circumstances.  
Local gene therapy approaches, at this time, hold more promise than systemic 
application, because the danger of misrouted deposition and unwanted gene 
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expression in non target tissues can be partly avoided. Local strategies using 
immunological approaches have shown most promising results, due to strong 
bystander effects.   
Delivery at the subcellular level remains inefficient as well. While endocytotic 
uptake of polyplexes occurs rather efficiently, the release from endosome is still 
one of the primary reasons for the low efficiency of non-viral gene and 
oligonucleotide therapy. For polyplexes, there is some evidence that the majority 
of the nucleic acid is entrapped in such vesicles [80]. Although some success has 
been obtained with fusogenic peptides or other endosomolytic agents, such as 
chloroquine, the applicability of these structures in vivo is limited. Subcellular 
trafficking at this stage probably bears great potential for further advances in 
non viral vectors. However, it should be noted that the release mechanism, as far 
as it is known to date, leads to the release of endosomal or lysosomal content 
into the cytosol. This event represents a perturbation of subcellular 
compartmentalization and, therefore, stress for the cell. The stage of the pathway 
at which the release occurs is of great importance since hydrolytic enzymes and 
other lysosomal content may cause major damage in the cell finally leading to 
apoptosis or necrosis [292]. Further improvements at the stage of vesicular 
escape will result in increased reporter gene expression, however, it may lead to 
a higher toxicity of the method, as well. More research about the release 
mechanism, especially for polyplexes is required for a better understanding of 
this problem. 
Transfer of DNA, once released into the cytosol, to the nucleus and across the 
nuclear envelope is very inefficient. It is still unclear how plasmid DNA reaches 
the nucleus, if via free diffusion or via a specific cellular transport system, e.g. 
dynein. The complexing agent plays an important role [177] for nuclear 
delivery, by either helping to reach the nuclear envelope through the cytoplasm 
or facilitating nuclear entry. Nuclear uptake is inefficient and highly connected 
to the mitotic activity of the cells. This may help to target fast growing tumors, 
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however, there are applications that require uptake in slower dividing cells. Here 
some improvements have been achieved using nuclear localization sequences, 
however, increase in reporter gene expression is still moderate and there is 
probably more potential for optimization.  
To summarize, cancer gene therapy still represents a highly promising research 
area that bears a great potential for future cancer therapy, however, to achieve 
this goal numerous hurdles have to be surmounted.   
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SUMMARY 
Purpose: Critical steps regarding the subcellular processing of 
polyethylenimine/nucleic acid complexes, especially endosomal/lysosomal 
escape, were visualized using living cell confocal laser scanning microscopy 
(CSLM) to obtain an insight into their mechanism. 
Methods: Living cell confocal microscopy was used to examine the intracellular 
fate of polyethylenimine/ribozyme and poly(L-lysine)/ribozyme complexes over 
time, in the presence of and without bafilomycin A1, a selective inhibitor of 
endosomal/lysosomal acidification. The compartment of complex accumulation 
was identified by confocal microscopy with a fluorescent acidotropic dye. To 
confirm microscopic data, luciferase reporter gene expression was determined 
under similar experimental conditions. 
Results: Polyethylenimine/ribozyme complexes accumulate in acidic vesicles, 
most probably lysosomes. Release of complexes occurs in a sudden event, very 
likely due to bursting of these organelles. After release, polyethylenimine and 
ribozyme spread throughout the cell, during which slight differences in 
distribution between cytosol and nucleus are visible. No lysosomal escape was 
observed with poly(L-lysine)/ribozyme complexes, or when polyethylene-
imine/ribozyme complexes were applied together with bafilomycin A1. 
Polyethylenimine/plasmid complexes exhibited a high luciferase expression, 
which was reduced approximately 200-fold when lysosomal acidification was 
suppressed with bafilomycin A1. 
Conclusions: Our data provide, for the first time, direct experimental evidence 
for the escape of  polyethylenimine/nucleic acid complexes from the 
endosomal/lysosomal compartment. CLSM, in conjunction with living cell 
microscopy, is a promising tool for studying the subcellular fate of polyplexes in 
nucleic acid/gene delivery. 
Supplementary material for this publication can be accessed under: 
http://www.uni-marburg.de/iptb/institut/akkissel/motherpage.htm 
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INTRODUCTION 
Polyethylenimine [PEI] is one of the most commonly used nonviral vectors 
based on polycations for DNA/RNA delivery both in vitro and in vivo [1]. In 
spite of numerous  publications dealing with the mechanisms of uptake and 
subcellular processing of PEI/plasmid complexes, current understanding of the 
release mechanism from the endosomal/lysosomal compartment is still limited 
[1,2,3]. New insights could facilitate the design of new polymers for nonviral 
gene delivery systems. It has been demonstrated by several groups that PEI 
polyplexes are taken up via endocytosis [4,5], however, theories regarding 
intracellular processing of these complexes remain controversial. Using confocal 
microscopy studies Godbey et al. [3] found that PEI/plasmid complexes access 
cells in culture via endocytosis. According to Godbey et al. [2] these endocytotic 
vesicles do not seem to fuse with lysosomes, but rather proceed directly to the 
perinuclear region where PEI and DNA are released and taken up into the 
nucleus [2,3]. Further Lecocq et al. [4] examined uptake and subcellular 
distribution of radioactively labelled PEI/plasmid complexes in vivo using 
differential and isopycnic centrifugation methods. They observed that PEI was 
localized in plasma membrane fractions 5 minutes after administration and in 
lysosomal fractions after 4 hours. According to this study PEI persists in the 
lysosomal compartment without significant release for days. Another unclear, 
yet very important question, is how PEI/nucleic acid complexes escape from the 
endosomal/lysosomal compartment. Behr [6] proposed the so-called ´proton-
sponge hypothesis´ explaining the lysosomal release of PEI polyplexes by their 
buffering capacity. During acidification of endosomes/lysosomes this property 
leads to increased influx of protons, chloride ions, and water, thus eventually 
causing rupture of the vesicles due to the high osmotic pressure. Although this 
hypothesis was developed some years ago, no convincing experimental 
verification has been provided by anyone so far. 
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Another intensively discussed issue is the mode of entry that DNA/RNA and 
PEI, once released from lysosomes, use to gain access into the nucleus. There 
has been some preliminary work done in this field, however much still remains 
to be discovered [7]. 
In contrast to previous reports we attempted to gain insight into these subcellular 
distribution processes using living cell confocal laser scanning microscopy. This 
method is unique, as it allows a direct observation of PEI/nucleic acid 
complexes in the intact subcellular environment over a long time period. More 
specifically, it may prove to be a valuable tool in elucidating the release 
mechanism of PEI polyplexes from the endosomal/lysosomal compartment.  
PEI/ribozyme complexes were used in the presence of and without bafilomycin 
A1, a selective inhibitor of the vacuolar-type H(+)-ATPase, which prevents 
acidification of endosomes/lysosomes. We compared the findings of these 
CLSM experiments to those obtained with poly(L-lysine)/ribozyme complexes 
under identical conditions. To confirm our observations we also performed 
transfection experiments with a luciferase plasmid under similar experimental 
conditions. Our aim was to gain a mechanistic insight in subcellular processing 
of dually labelled PEI/ribozyme complexes by observing fluorescence 
distribution over time.  
MATERIALS AND METHODS 
Chemicals 
Polyethylenimine (Mw 25,000), poly(L-lysine) (Mw 34,300), chloroquine and 
bafilomycin A1 were purchased from Sigma-Aldrich.  
Labelling of PEI and poly(L-lysine) with Oregon Green 488  
Polymer (20 mg) was dissolved in 2 mL 0.1 M sodium bicarbonate solution with 
pH 9. Oregon Green carboxylic acid succinimidyl ester (1 mg, Molecular 
Probes) was dissolved in 200 L dimethylsulfoxide and added dropwise under 
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stirring to the polymer solution. The mixture was stirred in the dark for 3 hours 
at room temperature before the labelled polymer was purified by ultrafiltration 
in an Amicon cell (regenerated cellulose membrane, molecular weight cut off 
10,000) and washed with 0.1 M borate / 1.0 M sodium chloride solution pH 7.5. 
The washing procedure was performed until no absorption was detectable at 488 
nm in the cell outflow. As a final step, the buffer was exchanged with distilled 
water.   
Ribozyme and plasmid 
A 5-carboxytetramethylrhodamine labelled 37-mer ribozyme with the sequence 
3´-UCUCUCAAAGCAGGAUUGCCUGAGUAGUCAUAACCUU-5´ was 
purchased from MWG-Biotech. A luciferase plasmid (pGL3-control, Promega) 
was used for transfection experiments. The plasmid was amplified in JM109 
competent cells (Promega) and purified with QIAfilter plasmid Kits (Qiagen) 
according to the manufacturers protocol.  
Complex formation 
All ribozyme/PEI or plasmid/PEI complexes were prepared at a PEI-nitrogen to 
DNA/RNA- phosphate ratio (N/P ratio) of 8. For microscopic experiments 
ribozyme (2 g) and PEI (2.2 g) were each dissolved in 100 L of 0.9 % 
sodium chloride solution pH 7. The two solutions were mixed by gentle 
pipetting. Complexes were allowed to interact for 10 minutes before use. 
Ribozyme/poly(L-lysine) and plasmid/poly(L-lysine) complexes were prepared 
at an N/P ratio of 2. In this case 2 g of ribozyme and 1.6 g poly(L-lysine) 
were dissolved in 100 L 0.9 % sodium chloride solution pH 7. For transfection 
experiments using pGL3-control luciferase plasmid, complexes were prepared in 
a similar manner with 4 g plasmid and 4.4 g PEI or 3.2 g poly(L-lysine) 
dissolved in double the volume of sodium chloride solution 0.9 % pH 7. 
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Cell culture 
All experiments were performed with the SW13 adrenal gland carcinoma cell 
line (ATCC number CCL-105) which was a kind gift from Dr. A. Aigner 
(Philipps University, Marburg, Germany). Cells were cultured in IMDM 
medium (PAA) containing glutamine (584 mg/l) and 25 mM 4-(2-
hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES), supplemented with 
10 % fetal bovine serum (HyClone). For transfection experiments cells were 
grown at 37 °C in a humidified atmosphere containing 10 % CO2 (V/V).  
Confocal laser scanning microscopy with Lyso Tracker Blue 
A Zeiss Axiovert 100 M microscope coupled to a Zeiss LSM 510 scanning 
device was used for all confocal microscopy experiments. 
Cells were seeded at a density of 20,000 cells per well in 8 well chamber slides 
(LabTek, Nunc). After 24 hours, medium was removed and complexes of 
Oregon Green-labelled PEI and non-labelled pGL3-control plasmid were added 
in new medium containing 100 nM Lyso Tracker Blue (Molecular Probes). 
After 1h the incubation medium was aspirated, cells were washed three times 
with phosphate buffered saline (PBS) pH 7, and observed in PBS with the 
confocal microscope. For excitation of the blue Lyso Tracker an Enterprise UV 
laser with an excitation wavelength of 364 nm was used. For excitation of green 
fluorescence (labelled PEI) an argon laser with an excitation wavelength of 488 
nm was used. This experiment was performed using a longpass filter of 385 nm 
for blue fluorescence and a longpass filter of 505 nm for green fluorescence. All 
images were recorded using the Zeiss LSM 510 Multitracking Mode in which 
each fluorescence channel was scanned individually.    
Living cell confocal laser scanning microscopy 
An argon laser was used to excite green fluorescence at 488 nm and a helium-
neon laser was used for red fluorescence at 543 nm. Images were taken using a 
band pass filter of 505-530 nm for green fluorescence and a long pass filter of 
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560 nm for red fluorescence. Detector sensitivity was set relatively high in order 
to be able to visualize faint fluorescence, however was kept constant during 
experiments. Thickness of the optical sections was between 0.5 and 1 µm. 
Stacks of 15-35 images were recorded every 3-9 minutes to obtain information 
over time (setting descriptions for the individual figure are listed below each 
figure). The different layers were overlaid for each time point by Zeiss LSM 510 
software. For creating movies the overlaid images of the single time points were 
animated over time. Total thickness of stacks ranged between 10–20 m. 
Temperature was maintained at 37 °C for the duration of the experiment. A CO2 
atmosphere was not necessary, as the cell culture medium contained 25 mM 
HEPES. For living cell microscopy 30,000 cells were seeded on 2 cm2 self-made 
chamber dishes containing a total of 500 L medium. Bafilomycin A1 was 
added to the media at a concentration of 300 nM, where indicated.  
Transfection experiments with luciferase plasmid 
Transfection experiments with pGL3-control luciferase plasmid were performed 
with poly(l-lysine)/plasmid complexes in addition to PEI/plasmid complexes in 
the presence of, as well as without bafilomycin A1. Cells were seeded in 12 well 
plates at a density of 50,000 cells per well. After 24 hours medium was removed 
and complexes were added to fresh medium containing 300 nM bafilomycin A1, 
when applicable. Media was exchanged again after four hours and cells were 
incubated for 44 hours. Luciferase gene expression was quantified using a 
commercial kit (Promega) and photon counting with a luminometer (Sirius, 
Berthold).  
Results in relative light units per second (RLU/s) were converted into ng 
luciferase by creating a calibration curve with recombinant luciferase 
(Promega). Protein concentration in each sample was determined using a BCA 
assay [10]. All experiments were performed in quintuplet and data were 
expressed in ng luciferase per mg protein. 
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RESULTS 
Confocal laser scanning microscopy using Lyso Tracker Blue 
In Figure 1, colocalization of PEI/DNA complexes (green) and Lyso Tracker 
Blue is shown approximately 1 hour after transfection (turquoise vesicles). 
Several predominantly green vesicles are also present in this image. These could 
either represent PEI in nonacidic prelysosomal compartments or in lysosome 
remnants, suggesting that in this case the lysosomes had already burst. This 
strongly indicates that complexes accumulate in the lysosomal compartment 
after one hour. We obtained similar results with OVCAR-3 (ATCC number 
HTB-161) cells (data not shown).  
 
Figure 1 
PEI/plasmid complexes colocalize with Lyso Tracker Blue ~ 1 hour post incubation 
(turquoise vesicles). In addition, vesicles containing predominantly PEI are visible 
(green vesicles). The image shows an overlay of light microscopic and confocal 
fluorescence image. (Lyso Tracker is blue in this image, PEI is green)  
Living cell confocal laser scanning microscopy 
Five short movies have been chosen to demonstrate the results of living cell 
confocal laser scanning microscopy [see Table 1]. Movies #1 and #2 were 
obtained with PEI/ribozyme complexes. Movie #3 shows PEI/ribozyme 
complexes in the presence of 300 nM bafilomycin A1 and Movie #4 was 
recorded using poly(L-lysine)/ribozyme complexes. Movie #5 shows an 
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overview of approximately 20 cells incubated with PEI/ribozyme complexes, 
whereas only the green fluorescence of PEI is shown. All movies can be 
accessed as supplementary material for this publication on our website 
“http://www.uni-marburg.de/iptb/institut/akkissel/motherpage.htm". Essential 
excerpts from Movies #1 and #2 are shown in Fig. 2 and 3. It should be noted 
that the vesicle sizes in Movies #1-5 do not accurately display actual sizes, due 
to fluorescence outshine, however relative changes in localization and size over 
time can be observed.   
       
  
      
Figure 2a 
Living cell microscopic visualization of swelling and, finally, bursting of a single vesicle 
(yellow arrow). PEI is green and ribozyme is red in this sequence. Before burst, the 
characteristic appearance of the vesicle with a yellow core and green PEI-corona can be 
seen. Afterwards the faint green-yellow fluorescence can be seen evenly distributed 
throughout the entire cell. The remnant of the vesicle is significantly smaller and deeper 
red. Images were recorded 28, 31, 37 and 40 minutes after incubation. They display 
computer overlaid projections of the different confocal slices for each time point. The 
whole movie can be accessed on our website [Movie #1]. The yellow mark displays the 
size of 10 µm.  
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Figure 2b 
The same confocal layer of 1 µm thickness before and after lysosomal burst (37 and 40 
minutes after incubation). It may be observed that fluorescence intensity  increases 
throughout the whole cell after burst whereas there seems to be an area where it is 
slightly weaker. This area might display the nucleus. The right image shows a light 
microscopic image. The complete sectioning of this cell for the 37 and 40 minutes time 
point can be accessed on our website.  
In Fig. 2 and 3 (Movies #1 and #2) it is shown that PEI/ribozyme complexes and 
also some free PEI, resulting from an N/P ratio of 8, adhere to the cellular 
membrane within a few minutes after incubation, possibly due to interactions 
between positively charged complexes and the negative charges of certain 
membrane constituents. Time of uptake into cells is rather heterogeneous. In 
several cells uptake is very rapid, occurring approximately 10-15 minutes after 
incubation [e.g. Fig. 3, Movie #2]. In other cells internalization seems to be 
much slower, e.g. several cells shown in Fig. 2 [Movie #1]. Under the conditions 
used in this experiment (i.e. microscope settings), some PEI containing vesicles 
display a very typical appearance (Fig. 2, Image 1,vesicle marked with yellow 
arrow; Fig. 3, Images #1-7). The inner core of these vesicles is yellow, 
indicating that ribozyme and PEI are colocalized here, whereas a very small 
surrounding ´corona´ is green, which implies that PEI is predominantly located 
in this area. This ´corona´ might represent interactions between PEI and 
components of the lysosomal membrane and/or extensive swelling of the 
polymer matrix in proximity to the vesicular membrane. Separation of PEI and 
ribozyme close to the membrane might be another possible explanation for this 
appearance. The size of the vesicle in Fig. 2, Image 1 (marked with the yellow 
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arrow) seems to increase within the 9 minutes between Images 1 and 3, possibly 
due to osmotic swelling or fusion with other PEI containing vesicles. Finally it 
releases its content into the cytoplasm (Fig. 2a, Image 4). After this event the 
whole cell, including the nuclear compartment, is filled with a faint green-
yellow fluorescence, resulting from the mixture of green fluorescence from PEI 
(predominantly) and the red fluorescence from ribozyme (very faint). This 
fluorescence can be seen only with sensitive instrument settings, but is 
significantly brighter than background fluorescence. If distribution of 
fluorescence in the different confocal layers is regarded before and after 
endosomal/lysosomal burst one finds a significant increase of fluorescence 
throughout the whole cell after burst. In Fig. 2b it can be seen that the 
distribution of fluorescence is not totally homogeneous after burst. These images 
represent the fluorescence in a single confocal layer of 1 µm thickness before 
and after burst. The area exhibiting slightly less intense fluorescence may likely 
display the nuclear compartment.  
However, it should be noted that both green and red fluorescence also increase 
significantly in this area, thus implying that PEI and ribozyme are present in the 
nucleus a maximum of 3 minutes after burst. The complete sectioning of the 
whole cell can be accessed on our supplementary material website. The remnant 
of the burst vesicle is predominantly red and seems to consist of ribozyme and 
PEI whereas relatively more ribozyme seems to be present than before burst. It 
persists in the cytosol and only changes its size and color marginally. The 
further fate of these remnants is unclear and requires a more thorough 
investigation. In most of the cells only a small percentage of vesicles burst. The 
majority of the PEI/ribozyme complexes persists in the endosomal/lysosomal 
compartment for a minimum of several hours or longer [4].   
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Figure 3 
Living cell microscopic images of three cells loaded with enormous amounts of 
PEI/ribozyme complexes. PEI is green and ribozyme is red in this sequence. Vesicles 
start bursting between Images 3 and 4. In the next ~ 20 minutes all vesicles release their 
content. Yellow arrows point out vesicles which have already burst in the next image. 
For example, Image 8 shows the evenly distributed  fluorescence throughout cells # 1 
and # 3. In cell 2, obvious interactions between PEI and ribozyme with nuclear 
constituents occur and in this case a fluorescence remains in the nucleus. Images were 
recorded every 3 minutes starting 15 minutes after incubation. Images 1-15 are duo 
fluorescence images derived from the computer aided overlay of different confocal 
layers for each time point. Image 16 is a light microscopy image to show positions and 
numbers of the cells. The whole movie can be accessed on our website [Movie #2].      
1
2 3
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Movie # Type of Experiment Excerpts in Figure
 
Colors 
1 PEI/ribozyme complexes Figure 2 PEI green, ribozyme red
2 PEI/ribozyme complexes Figure 3 PEI green, ribozyme red
3 PEI/ribozyme complexes   PEI green, ribozyme red
 
with bafilomycin A1     
4 Poly(L-lysine)/ribozyme   Poly(L-lysine) green, 
complexes   ribozyme red 
5 PEI/ribozyme complexes   PEI green 
overview     
Table 1 
Characteristics of movies accessible on our website. Additionally the complete sections 
of Images 3 and 4 from Figure 2 can be regarded. The website is optimized for Microsoft 
Internet Explorer and a resolution of  1024 x 768 pixels.  
In Fig. 3 (Movie #2) three cells can be seen which contain enormous amounts of 
PEI/ribozyme complexes. Although under average conditions vesicle burst 
occurs only once or twice per cell, this example is suitable to demonstrate the 
mechanism of escape. In this case, a clear sequential increase in fluorescence in 
the cells after burst of individual vesicles can be readily observed. Vesicles 
move in a random fashion within the cells and also fuse to create larger vesicles 
(in Fig. 3 Images 1-4). Between Images 3 and 4 some vesicles seem to burst 
(arrow in Image 3), thus initiating a disastrous process for these cells. Within the 
next ~ 20 minutes a chain reaction takes place during which all vesicles in these 
three cells burst and release their contents into the cytosol (yellow arrows in 
images of Fig. 3 mark vesicles which have burst in the next image). A possible 
explanation for this phenomenon could be the destabilizing effect of PEI on the 
lysosomal membrane not only from the inner compartment, but from the 
cytosolic side, as well [5]. Once one lysosome releases its content, PEI is present 
in the cytosol and can destabilize other vesicles that are still intact. The more 
endosomes/lysosomes that rupture, the more PEI is released and the higher is the 
destabilizing potential present in the cytosol. This process may progress until all 
vesicles have burst, as shown in this example. The distribution of fluorescence 
throughout cells after destabilization of vesicles can be observed very well in 
this sequence. Interestingly, there seems to be an accumulation of green and red 
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fluorescence in the nucleus of cell number 2 in Fig. 3. This accumulation might 
display interactions of the high PEI and ribozyme concentrations present in this 
cell with DNA in the nucleus.  
It is important to note that the time scale for uptake and lysosomal release of the 
PEI/ribozyme complexes is very heterogeneous, occurring after 20 minutes in 
some cells, whereas in others the process may take hours for unknown reasons.  
Movie #5 on our supplementary material website shows an overview of 
approximately 20 cells, thus demonstrating that data shown here is 
representative. In this movie the bursting of several endosomes/lysosomes can 
be observed as a sudden increase of green fluorescence (PEI) within cells 
indicated by yellow arrows. Also the sequential increase in fluorescence within 
one particular cell can be observed. 
When the acidification of lysosomes was prevented by using 300 nM 
bafilomycin A1, no bursting of lysosomes could be observed over a period of 4 
hours [data shown in Movie #3 on our supplementary material website]. Cells 
examined under these conditions take up complexes as efficiently as without 
bafilomycin A1. The vesicles move within the cells in a disorganized manner, 
however no escape of PEI or ribozyme can be observed.  
Using poly(L-lysine)/ribozyme complexes under similar experimental 
conditions showed that complexes were taken up into cells efficiently, however, 
there was no bursting of lysosomes or other visible escape route from this 
compartment [Movie #4 on our internet pages].  
Transfection experiments with luciferase plasmid 
Transfection experiments with PEI/luciferase-plasmid complexes at N/P=8 led 
to a high reporter gene expression [Fig. 4]. In the presence of bafilomycin A1, 
however, expression was decreased more than 200-fold. This stresses the great 
importance of endosomal/lysosomal acidification for the release of complexes 
from this compartment. With poly(L-lysine)/plasmid complexes only a very low 
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transfection efficiency could be observed, suggesting that these complexes are 
not as readily able to leave endosomes/lysosomes. These data are in good 
agreement with our microscopic observations.  
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Figure 4 
Luciferase reporter gene expression of PEI in the presence of and without bafilomycin 
A1 and using poly(L-lysine).   
DISCUSSION 
The subcellular trafficking of PEI/ribozyme complexes could be followed using 
living cell confocal microscopy. Especially the escape from the 
endosomal/lysosomal compartment, as well as the distribution of PEI and RNA 
after this event could be visualized for the first time. We also demonstrated that 
acidification is equally essential for the release of PEI/RNA polyplexes, as for 
efficient gene expression after application of PEI/luciferase-plasmid complexes.  
Complexes of PEI and DNA/RNA reach the lysosomal compartment. This may 
be concluded from our microscopic data with the acidotropic Lyso Tracker, 
which is in agreement with the results of subcellular fractionation experiments 
[4]. In contrast, Godbey et al. [2] found PEI located in non-acidic structures 
using confocal laser scanning microscopy. A possible explanation for this 
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discrepancy could be that, in this case, non-intact endosomes or lysosomes were 
observed. Instead, remnants of lysosomes, such as those in the last images of 
Figures 2 and 3 could have been observed. These compartments are no longer 
acidic and, therefore, do not accumulate acidotropic agents, such as Lyso 
Tracker Blue.  
Concerning the escape mechanism of PEI/RNA complexes from 
endosomes/lysosomes, our results demonstrate that release occurs as a sudden 
event, such as the bursting or rupture of endosomes or lysosomes. No release of 
PEI-polyplexes from endosomes/lysosomes was observed, however, when 
acidification of these vesicles was prevented. In addition, there was a dramatic 
reduction of luciferase reporter gene expression in the presence of bafilomycin 
A1, a finding which is consistent with recent results of Kichler et al. [24]. The 
manifest importance of endosomal/lysosomal acidification suggests that the 
buffering capacity of PEI is one of the crucial properties of the polymer for its 
high efficiency in DNA/RNA delivery. There is evidence in the literature that 
this is one of the key features which cationic polymers require to obtain high 
transfection efficiencies. Cationic polymers with strong basic groups (e.g. 
poly(L-lysine) or quaternary amines with poor to no buffering properties possess 
low transfection efficiencies when used without chloroquine [11, 12, 13] or 
other lysosome destabilizing agents [14]. In contrast, polymers with a significant 
buffering capacity in the lysosomal pH range show a much higher transfection 
capability. For example imidazole containing polymers [16] exhibit a high 
reporter gene expression, very likely due to the pKa of imidazole (~ 6). Midoux 
et al. [16] performed transfection experiments in the presence of bafilomycin A1 
and, similar to our results, reporter gene expression was reduced more than 100-
fold compared to experiments without inhibition of endosomal/lysosomal 
acidification. Other examples of polymers supporting these findings include 
polyamidoamine dendrimers [17, 19] or fractured dendrimers [18]. These groups 
of polymers are quite similar to PEI as they also exhibit a large number of 
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terminal amino groups on their surface and higher order amines in their interior, 
whereas not all amino-groups are protonated at physiological pH. Transfection 
efficiencies with these polymers are significantly higher than those obtained, for 
example, with poly(L-lysine) and it is likely that efficient endosomal/lysosomal 
release is at least part of the reason for this. Further examples in literature of 
effective nucleic acid delivery agents with titratable groups between pH 5-7 
include lipospermines [20] and poly[2-(N,N-dimethylamino)ethyl methacrylate] 
[21] which both exhibit good transfection efficiencies.  
These similar findings with structurally unrelated agents suggest that several 
requirements must be fulfilled for an efficient transfection with cationic 
polymers. The polymer must be of low toxicity and, because of its three 
dimensional structure, capable to effectively complex with DNA/RNA at 
physiological pH. It also needs to possess a certain buffering capacity between 
pH 5-7. These factors enable effective uptake and a sufficient release from the 
endosomal/lysosomal compartment, thus leading to the desired gene expression 
or ribozyme action.  
As suggested by Behr [6], the buffering capacity of the polymer could lead to 
lysosomal swelling based on two possible mechanisms: An increased H+/Cl-
/water influx and possible swelling of the polymer network as a result of the 
increasing electrostatic repulsion of charged groups. Both effects eventually lead 
to rupture of vesicles and release of their contents into the cytosol. In our study 
it is remarkable that PEI and ribozyme are distributed throughout the cytoplasm 
and nucleus minutes after endosomal/lysosomal burst, due to the fact that 
PEI/ribozyme complexes are rather stable. The cause of this could be the 
extension of the polymer network during acidification or interactions of PEI 
with the lysosomal membrane or cytoplasm constituents. Both effects could lead 
to destabilization of the complexes and enhanced dissociation after release from 
vesicles. Interactions of cationic polymers and negatively charged lipids have 
been previously demonstrated [22]. Also other pH dependent interactions of 
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polyplexes with the endosomal/lysosomal membrane could play an important 
role for efficient escape from vesicles. 
A very important question that remains to be answered is: At what stage of the 
endosomal/lysosomal pathway does bursting of the vesicles occur? Although 
our data and the findings of Lecocq et al. [4] suggest that the majority of 
complexes accumulate in lysosomes, release could also occur from late 
endosomes. If release takes place from lysosomes the simultaneous release of 
lysosomal content, such as hydrolytic enzymes, might be harmful for cells [25]. 
This could be one mechanism of toxicity of PEI/nucleic acid complexes and 
might be a limiting factor for this branch of nonviral nucleic acid delivery.  
Another intensively discussed point is the mode of entry of PEI and DNA/RNA 
into the nucleus. Our results indicate that no cell division is necessary for the 
entry of PEI and ribozyme, a finding that has also been shown for plasmids by 
Pollard et al. [7]. The entry of PEI and ribozyme into the nucleus in our 
experiments could occur via diffusion, as implied by the high speed of the 
process. This is a reasonable assumption, based upon the fact that ribozyme and 
PEI have molecular weights of ~ 11 kD and ~ 25 kD, respectively, and therefore 
could be small enough to diffuse through the nuclear pore complex. The 
maximum size for this form of nuclear entry has been determined as ~50 kD 
[23]. PEI could promote this process by compacting the ribozyme in such a way 
as to facilitate nuclear entry. In addition, negatively charged phospholipids 
might coat these structures, such as suggested by Godbey et al. [3] to allow for 
an easier nuclear entry. This mechanism, however, is speculative and requires a 
more detailed investigation. For plasmids, on the other hand, the free diffusion 
or coating mechanism is unlikely, due to their large size. In this case, a 
condensation caused by PEI may also play a crucial role, although the nuclear 
transfer is much more inefficient [7]. Interactions between plasmid or 
plasmid/PEI and the nuclear pore complex might be considered. Experiments 
investigating the nuclear entry of plasmids are in progress at this time. 
Intracellular processing of polyethylenimine/ribozyme complexes  123
In summary, CSLM in living cells allows visualization of subcellular trafficking 
of PEI/RNA complexes and sheds some light on the mechanism, as well as 
kinetics of their  endosomal/lysosomal escape. Our data are compatible with the 
‘proton sponge hypothesis´ [6], however other pH dependent membrane 
interactions of the polycation may play a significant role for the escape of 
polyplexes into the cytoplasm as well. CSLM in living cells may be a valuable 
tool for the design of  more efficient non-viral vectors based on polycations in 
gene delivery.   
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SUMMARY 
Specific targeting of ovarian carcinoma cells using pegylated polyethylenimine 
(PEG-PEI) conjugated to the antigen binding fragment (Fab´) of the OV-TL16 
antibody, which is directed to the OA3 surface antigen, was the objective of this 
study. OA3 is expressed by a majority of human ovarian carcinoma cell lines.  
To demonstrate the ability of the PEG-PEI-Fab´ to efficiently complex DNA, an 
ethidium bromide exclusion assay was performed.  Comparison with PEG-PEI 
or PEI 25 kDa showed only minor differences in the ability to condense DNA.  
Since conjugation of Fab´ to PEG-PEI might influence complex stability, this 
issue was addressed by incubating the complexes with increasing amounts of 
heparin.  This assay revealed stability similar to that of unmodified PEG-
PEI/DNA or PEI 25 kDa/DNA complexes.  Complexes displayed a size of 
approximately 150 nm with a zeta potential close to neutral.  The latter property 
is of particular interest for potential in vivo use, since a neutral surface charge 
reduces nonspecific interactions.  Binding studies using flow cytometry and 
fluorescently labeled DNA revealed a more than 6 fold higher degree of binding 
of PEG-PEI-Fab´/DNA complexes to epitope-expressing cell lines compared to 
unmodified PEG-PEI/DNA complexes. In OA3-expressing OVCAR-3 cells, 
luciferase reporter gene expression was elevated up to 80 fold compared to 
PEG-PEI and was even higher than that of PEI 25 kDa.  The advantage of this 
system is its specificity, which was demonstrated by competition experiments 
with free Fab´ in the cell culture media during transfection experiments and by 
using OA3-negative cells.  In the latter case, only a low level of reporter gene 
expression could be achieved with PEG-PEI-Fab´.      
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INTRODUCTION 
The general feasibility of gene delivery using synthetic polymers has been 
demonstrated in numerous studies [1-5].  Cationic polymers, such as linear or 
branched polyethylenimine (PEI) [2,3], starburst dendrimers [4] or imidazole 
containing polymers [5], were found to be suitable for in vitro applications. 
Unmodified cationic polymers lead to complexes with DNA displaying a 
relatively high cationic surface charge. Therefore, unspecific binding, as well as 
a fairly high toxicity due to electrostatic interactions with the negatively charged 
components  of cellular membranes, e.g. sialic acid, remain a serious limitation 
for in vivo gene delivery [3,6].  After intravenous injection of these polyplexes 
serious damage of body tissues [7] and a rather high rate of mortality [8] was 
observed in laboratory animals. 
In order to progress from in vitro gene delivery towards in vivo gene therapy, 
vectors are needed that exhibit high stability in body fluids, minimal nonspecific 
interactions, low toxicity and a targeting moiety that provides selective uptake 
into target cells. Since an excess of cationic polymer is necessary for 
complexation of DNA, the cationic surface charge needs to be shielded to 
reduce nonspecific interactions with blood components in non target tissues. 
A possible strategy towards achieving an optimized polymeric gene delivery 
system is schematically shown in Figure 1.  Polyplexes prepared with 
unmodified cationic polymer yield a rather high level of reporter gene 
expression under in vitro cell culture conditions (Figure 1a).  Yet, due to the 
high cationic surface charge of these vectors, this effect is nonspecific.  
Pegylation [8-10] or attachment of other hydrophilic polymers, such as pHPMA 
[11], to cationic polymers leads to vectors with a surface charge close to 
neutrality (Figure 1b).  Lower levels of nonspecific interactions have been 
demonstrated for these systems and some have been used successfully in vivo.  
These studies have shown that such shielded gene delivery systems offer the 
advantage of lower toxicities and prolonged circulation times in vivo [8,10].  
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However, the resulting complexes with DNA display rather low levels of 
reporter gene expression.  Although this property might be less favorable in 
vitro, it would be valuable for in vivo application because it may minimize gene 
expression in non-target cells.  If a targeting ligand, for example Fab´, is 
conjugated to these polymers, the resulting complexes could then be capable of 
targeting specific cell types with only low levels of reporter gene expression in 
non-target cells (Figure 1c).    
Figure 1  
Rationale behind polymer modifications described in this publication.  Unmodified 
complexes (A) displayed high levels of transfection efficiency, due solely to unspecific 
electrostatic interactions with cellular membranes.  Pegylation of PEI (B) led to 
complexes with an almost neutral zeta-potential, however, reporter gene expression 
remained at a low level.  Yet, when targeting moiety was conjugated to PEG-PEI (C), 
the resulting PEG-PEI-Fab’complexes showed lower levels of unspecific interactions, 
combined with a highly specific uptake and transfection of target cells.  
A variety of targeting moieties, such as transferrin [12], folate [13,14], RGD-
peptides [15,16], different types of saccharides [17,18] antibodies or antibody 
fragments [19,20] have been described for active gene delivery.  Most studies 
used ligands conjugated directly to unmodified cationic polymers, such as PEI 
or poly(L-lysine) resulting in polymer/DNA complexes with a high cationic 
surface charge.  Of the various targeting moieties already under investigation, 
antibodies and their fragments are of particular interest, due to their high 
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specificity for their target epitopes, as well as the wide variety of possible target 
structures.  
In this publication, we describe the use of a pegylated PEI to generate 
polymer/DNA complexes with a nearly neutral surface charge.  We then 
synthesized a conjugate consisting of pegylated PEI and an antigen binding 
antibody fragment (Fab´) that provided specific binding and efficient reporter 
gene expression coupled with a high specificity for target cells. Fab´ was used 
instead of the whole monoclonal antibody due to its lower molecular weight and 
therefore a lower level of steric hindrance during complex formation with DNA. 
As a model, we used OVCAR-3 human ovarian carcinoma cells that express 
high levels of the OA3 surface antigen, a structure that is expressed on most 
human ovarian carcinomas [21,22].  The OV-TL16 antibody specifically binds 
to the OA3 antigen triggering subsequent internalization [22].  Conjugation of 
OV-TL16 Fab´ to PEG-PEI produced conjugates that efficiently complexed 
DNA.  These complexes were stable and showed a very high specificity for 
OVCAR-3 cells as demonstrated by their enhanced binding capabilities and 
strongly elevated levels of reporter gene expression in vitro.  Furthermore, only 
a low level of gene expression occurred in OA3-negative cells.   
MATERIALS AND METHODS 
Chemicals and plasmid   
PEI 25 kDa, hexamethylene diisocyanate (HMDI), PEG monomethylether (2 
kDa), salmon testes DNA and N-succinimidyl 3-(2-pyridyldithio)propionate 
(SPDP) were purchased from Sigma-Aldrich, Taufkirchen, Germany.  
Luciferase plasmid (pCMV-luc) was produced by Plasmid Factory, Bielefeld, 
Germany.      
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Antibody and (Fab´)2 production   
OV-TL16 IgG directed against the surface antigen OA3 [21] was produced by in 
vitro cartridge bioreactor culture of the OV-TL16 hybridoma cell line (Cellco, 
Spectrum Labs, Pancho Dominguez, CA).  IgG purification and pepsin digestion 
to produce (Fab’)2 antibody fragments were performed as previously described 
[23].  
Cell culture   
NIH/3T3 (Swiss mouse embryo) cell line was purchased from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany).  NIH:OVCAR-3 cells were purchased from the American Type 
Culture Collection (ATCC), Teddington, UK.  Cells were cultured according to 
the protocols suggested by the supplier.  
Synthesis of PEG-PEI   
PEI(25k)-g-PEG(2k)10 was synthesized via a strategy which was described 
previously [24]. Briefly, PEG monomethylether (2 kDa) was dissolved in 
anhydrous chloroform (200 g/L) and activated with a 10-fold excess of 
hexamethylene diisocyanate, HMDI (60 °C, 24 h).  Unreacted HMDI was 
carefully removed by repetitive extraction with light petrol.  The reaction of 
activated PEG with the amino groups of PEI was carried out in anhydrous 
chloroform at 60 °C for 24 h.  The reaction solution was precipitated in diethyl 
ether and the product was dried in vacuo.   
Synthesis of PEG-PEI-Fab’ conjugate  
PEG-PEI (5 mg total polymer corresponding to 2,8 mg PEI) was dissolved in a 1 
mL reaction buffer containing 150 mM sodium chloride and 20 mM 4-(2-
hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES) pH 7.5. SPDP (80 µg) 
was added to this solution in 80 µL 100% ethanol while stirring and the reaction 
was allowed to continue for 90 min.  SPDP-activated PEI was then purified by 
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gel filtration on a PD-10 column.  The amount of SPDP coupled to PEI was 
determined by pyridine-2-thione release upon addition of a 20-fold excess of 
dithiothreitol (DTT) and by measuring the absorption at 343 nm against a 
standard curve of pyridine-2-thione.  PEG-PEI content was measured by a 
copper complexation assay [25].  
In the second step, a 1.4 fold molar excess of freshly reduced Fab’ was added in 
the same buffer.  The reaction proceeded for 12 h at room temperature and 
purification was performed by ion exchange chromatography as described 
earlier using 0.9 % NaCl, 10 mM HEPES pH 7.4 as buffer A and 3 M NaCl, 10 
mM HEPES pH 7.4 as buffer B [12].  The solvent was exchanged with 150 mM 
NaCl solution pH 7.4 via a further gel filtration step and the PEI concentration 
was determined by a copper complexation assay [25].  The amount of Fab’ per 
PEG-PEI was determined by UV-absorption at 280 nm with background 
correction using a solution of PEG-PEI with the same concentration.  
Complex formation   
Luciferase plasmid (pCMV-luc) and the appropriate amount of polymer were 
dissolved separately in 0.9 % sodium chloride solution, pH 7.  The two solutions 
were mixed by vigorous pipetting and complexes were allowed to interact for 10 
min before use.  Complexes were prepared for transfection experiments with 
either 0.5 or 4 g plasmid in 45 or 300 µL 0.9 % NaCl and the appropriate 
amount of  polymer or PEG-PEI-Fab´ in 45 or 300 µL 0.9 % sodium chloride 
solution pH 7.  Flow cytometry experiments required 10 µg of plasmid dissolved 
in 300 µL sodium chloride solution, into which the appropriate amount of 
polymer in 300 µL 0.9 % NaCl was added. Complexes for the complex stability 
assay were formed with 1 µg plasmid in 50 µL sodium chloride solution and the 
appropriate amount of polymer in the same volume.  
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Ethidium bromide exclusion assay   
DNA condensation was measured by the decrease in ethidium bromide 
fluorescence, as described earlier [26].  The assay was performed in 96 well 
plates in triplicate.  Eight µg of salmon testes DNA was dissolved in 79 µL 
water and 50 µL of 60 mM Tris buffer pH 7.4 were added to each well. 
Volumes were equalized to 300 µL with water.  Subsequently, appropriate 
volumes of 0.05 mg/mL polymer solutions were added to produce N/P ratios 
between 0.2 and 4.  These were incubated for 10 min and then 20 µL of a 0.1 
mg/mL ethidium bromide solution were added.  Wells were mixed thoroughly 
and the fluorescence was measured using a fluorescence plate reader with 
excitation wavelength at 518 nm and an emission wavelength of 605 nm.  
Photon correlation spectroscopy   
Hydrodynamic diameters of the polymer/DNA complexes were determined by 
photon correlation spectroscopy.  Plasmid (0.5 µg pCMV-Luc) in 25 µL 0.9 % 
NaCl were complexed with the appropriate amount of polymer in 25 µL NaCl 
each, as described above.  Measurements were performed on a Zetasizer 3000 
HS from Malvern Instruments, Herrenberg, Germany (10 mW HeNe laser, 633 
nm).  Scattering light was detected at 90° angle through a 400 µm pin hole.  For 
data analysis, the viscosity (0.88 mPa s) and the refractive index (1.33) of 
distilled water at 25 °C were used.  The instrument was routinely calibrated 
using Standard Reference latex particles (AZ 55 Electrophoresis Standard Kit, 
Malvern Instruments).  Values given are the mean of 5 measurements.   
Measurement of zeta potential 
Zeta-potential measurements were carried out in the standard capillary 
electrophoresis cell of the Zetasizer 3000 HS from Malvern Instruments at 
position 17.0.  Measurements were performed in 0.9 % NaCl and average values 
were calculated with the data obtained from 5 runs.   
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Complex stability against heparin 
Complexes were formed in septuplet, as described above, in a total volume of 
100 µL sodium chloride solution at an N/P ratio of 7.  To these solutions, 0.01, 
0.03, 0.05, 0.1, 0.2, 0.5 and 1 International Units heparin were added in 10 µL 
0.9 % sodium chloride.  These solutions were mixed well and incubated for 10 
min before they were applied to a 1 % agarose gel containing ethidium bromide. 
In the eighth lane of each gel, plasmid was applied as a reference.  Gels were run 
for 50 min at 100 V, and then scanned using a Biometra gel analysing system. 
   
Atomic force microscopy (AFM)   
The polymer-DNA complexes were prepared as described above and diluted in 
milliQ water (pH 5.5, 18.2 M ).  The formulations were directly transferred 
onto a silicon chip by dipping into the polyplex solution for 10 min.  Atomic 
force microscopy was performed on a Digital Nanoscope IV Bioscope (Veeco 
Instruments, Santa Barbara, CA), as described elsewhere [27].  The microscope 
was vibration-damped.  Commercial pyramidal Si3N4 tips (NCH-W, Veeco 
Instruments, Santa Barbara, CA) on a I-type cantilever with a length of 125 µm, 
a resonance frequency of about 220 kHz and a nominal force constant of 36N/m 
were used.  All measurements were performed in Tapping mode to avoid 
damage to the sample surface.  The scan speed was proportional to the scan size.  
The scan frequency was between 0.5 and 1.5 Hz.  Images were obtained by 
displaying the amplitude signal of the cantilever in the trace direction, and the 
height signal in the retrace direction, both signals were simultaneously recorded.  
The results were visualized in amplitude mode.   
Flow cytometry   
Flow cytometry was performed with plasmid DNA labeled with the intercalating 
dye YOYO-1 (Molecular Probes, Leiden, The Netherlands), as described by 
Ogris et al. [28].  Briefly, cells were grown for 24 h in six-well plates at a 
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density of 400,000 cells per well.  Complexes were prepared as described above 
and applied in fresh media with a total volume of 3 mL.  After 10 min, media 
was aspirated and cells were washed two times with cold (4 °C) PBS pH 7.3.  
Cells were suspended in PBS after detachment via trypsin incubation for 1 min. 
Cell suspensions were kept on ice until analysis. Flow cytometry was performed 
using a Becton Dickinson FACS Scan equipped with an argon laser with an 
excitation wavelength of 488 nm. The filter settings for emission was 530/30 nm 
bandpass.   
Transfection experiments   
Transfection experiments with pCMV-Luc luciferase plasmid were performed 
with PEI 25 kDa, PEG-PEI and PEG-PEI-Fab´ at N/P ratios of 2.5, 3.5, 7 and 10 
using 0.5 and 4 µg of plasmid. OVCAR-3 or NIH/3T3 (negative control) cells, 
were seeded in 12 well plates at a density of 50,000 cells per well.  After 24 h, 
the media was removed and the complexes were added in 1.5 mL fresh media 
containing different amounts of free Fab´ (where applicable).  Media was 
exchanged again after four hours and the cells were incubated for an additional 
44 h.  Luciferase gene expression was quantified using a commercial kit 
(Promega) and photon counting on a luminometer (Sirius, Berthold).  Results 
were measured in relative light units per second (RLU/s) which were then 
converted into ng luciferase by creating a calibration curve with recombinant 
luciferase (Promega).  Protein concentration in each sample was determined 
using a BCA assay [29].  All experiments were performed in triplicate and data 
were expressed in ng luciferase per mg protein.     
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RESULTS AND DISCUSSION 
Synthesis of PEG-PEI and PEG-PEI-Fab’ conjugates   
Polymer synthesis resulted in a pegylated polyethylenimine consisting of 10 
PEG chains (2 kDa) grafted to one PEI 25 kDa molecule as determined by 1H-
NMR and FT-IR spectroscopy [24].  Previous investigations suggest that this 
degree of pegylation is suitable for obtaining vectors with a suitable size and 
neutral surface charge [10].   
Using SPDP as a linker for coupling OV-TL16 Fab´ to PEG-PEI led to 
efficient conjugation.  SPDP modification of PEG-PEI produced a polymer 
containing approximately 0.5 PDP linkers per polymer.  In the second step, OV-
TL16 Fab´ was coupled to SPDP-modified PEG-PEI.  The progress and the end 
point of the reaction were followed by measuring pyridine-2-thione release 
using absorption at 343 nm (data not shown).  Purification of PEG-PEI-Fab´ 
conjugate via ion exchange chromatography displayed one peak containing free 
Fab´ shortly after application to the column in buffer A and one peak containing 
PEG-PEI-Fab´ after changing to buffer B.  UV measurement at 280 nm revealed 
that approximately every other polymer molecule carried one OV-TL16 Fab´.  
The overall polymer yield after purification was about 70 %, as determined by 
the copper complexation assay [25].  
Ethidium bromide exclusion assay   
Since ethidium bromide shows fluorescence only when intercalated with DNA, 
the reduction of fluorescence after the addition of polymer to DNA/ethidium 
bromide complexes can be regarded as a measurement for the efficiency of 
complex formation of the polymer.  
Monitoring complex formation via decrease of ethidium bromide 
fluorescence revealed efficient DNA complexation using the PEG-PEI-Fab´ 
conjugate (Figure 2).  The shape and position of the curve were only slightly 
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different when compared to that of PEG-PEI or PEI 25 kDa, suggesting a similar 
DNA condensing ability.   
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Figure 2  
Ethidium bromide exclusion assay using PEI 25 kDa, PEG-PEI and PEG-PEI-Fab’.  
The ability to complex DNA was only marginally hindered by pegylation and Fab´ 
conjugation to PEI 25 kDa.  
Photon correlation spectroscopy  
The sizes of complexes with PEI, PEG-PEI and PEG-PEI-Fab’ at different N/P 
ratios are shown in Figure 3a.  Complexes containing PEG displayed a similar 
size over the N/P ratio of 3.5 to 10.  Unmodified PEI 25 kDa/DNA complexes 
were significantly smaller at higher N/P ratios.  It is very important to note that 
complexes of PEI 25 kDa tend to aggregate especially at low N/P ratios, with 
sizes increasing from about 300 to 900 nm in the first 10 min after formation 
(large error bar).  However, those containing PEG exhibit an increase of size of 
less than 20 nm, probably due to efficient shielding of cationic surface charge, 
hereby abolishing aggregation (data not shown).  This effect has been 
demonstrated for pegylated PEIs in several studies [8,24].   
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Furthermore, it can be summarized that all complex sizes except the one of PEI 
25 kDa at N/P=3.5 are in a range that is suitable for endocytic uptake into cells 
[30].  Remarkably, sizes of DNA complexes with PEG-PEI-Fab’ are only 
marginally different than those of PEG-PEI/DNA complexes.  Obviously, the 
inclusion of Fab´ only slightly influences complex properties.  
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Figure 3  
Comparison of hydrodynamic diameters and zeta potentials of complexes at three 
different N/P ratios 
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Measurement of zeta potential  
Zeta potentials of complexes with PEI, PEG-PEI and PEG-PEI-Fab´ are shown 
in Figure 3b.  Zeta potentials of PEG-PEI/DNA complexes are close to neutral 
throughout the whole N/P range tested and differences are rather small.  This 
data suggests that the shielding effect of PEG is rather efficient, an observation 
that is in good agreement with previous studies [9,24,31].  Conjugation of Fab´ 
to PEG-PEI did not lead to significant changes in surface charge of complexes at 
N/P ratios from 2.5 to 10.  As expected the zeta potentials of complexes with 
unmodified PEI were rather high.  Interestingly, surface charge of these 
complexes decreased for N/P ratios from 3.5 and 10 although the amount of 
cationic polymer increased.  A possible explanation for this property could be 
differences in complex shape and size and therefore a different exposure of 
cationic polymer to the surrounding media. 
A neutral zeta potential is of major importance since it has been demonstrated 
that surface charge plays an important role for the in vivo fate of complexes.  For 
example, Plank et al. found a direct relationship between opsonization of 
complexes via attachment of complement factors and accessible cationic surface 
charge [32].  Furthermore, interactions of cationic polyplexes with albumin may 
result in the formation of large aggregates with a reversed surface charge leading 
to a rapid clearance by the reticulo-endothelial system [33].  For complexes with 
a neutral surface charge reduced interactions with plasma proteins, vessel 
endothelia or cellular blood components have been demonstrated [8,11].   
Complex stability against heparin.   
To evaluate complex stability, we compared levels of DNA release after 
incubation of PEI 25 kDa/DNA, PEG-PEI/DNA and PEG-PEI-Fab’/DNA 
complexes with increasing amounts of heparin (Figure 4).  Heparin, a polyanion 
capable of displacing DNA from polycation/DNA complexes, was chosen as a 
model substance for this assay.  The lowest concentration of heparin where 
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displacement occurs provides an estimation of the complex stability against 
polyanions.  In this case, no striking differences could be detected when PEG-
PEI-Fab’/DNA complexes were compared to native PEG-PEI/DNA or PEI 25 
kDa/DNA complexes.  In all three gels shown in Figure 4, DNA release started 
at the same concentration, suggesting no major influence of Fab´ conjugation on 
complex stability.  This data is in good agreement with the DNA complexing 
profiles obtained in the ethidium bromide exclusion assay.      
 
PEI 25 kDa
PEG-PEI
PEG-PEI-Fab´
Figure 4  
Determination of complex stability using increasing amounts of heparin.  In the first 
seven lanes of each gel increasing amounts of heparin were added in order to determine 
the threshold where DNA release occurs.  This concentration was similar in all gels  
Atomic force microscopy 
Images of complexes recorded under the conditions described above are shown 
in Figure 5.  The polymers and PEG-PEI-Fab´ have been shown to form defined, 
toroidal complexes with plasmid DNA.  The shape and size of complexes 
prepared with PEI, PEG-PEI and PEG-PEI-Fab´ were only slightly different.  
Size measurements from the AFM images were in good agreement with those 
obtained by photon correlation spectroscopy.  The data indicated complex 
diameters around 140 nm. 
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Figure 5  
Atomic force microscopy images from PEI 25 kDa/plasmid, PEG-PEI/plasmid and 
PEG-PEI-Fab’/plasmid complexes  
Flow cytometry   
Flow cytometry data revealed a moderate degree of cell binding of the 
unmodified PEI 25 kDa/DNA complexes (Figure 6).  The binding efficiency of 
complexes prepared with PEG-PEI is only slightly less for both cell types 
investigated in this study.  This is somewhat surprising since surface charges of 
PEI/DNA complexes are about 20 mV higher than that prepared with PEG-PEI.  
Obviously charge is only one factor that influences cell binding. As expected, 
PEG-PEI-Fab´/DNA complexes show an about 6-fold higher degree of binding 
to OVCAR-3 cells compared to those prepared with PEI 25 kDa and PEG-PEI.  
However, using OA3-negative NIH/3T3 cells, PEG-PEI-Fab´/DNA complexes 
displayed least efficient cell binding of all three polymers.  The data strongly 
suggests a specific binding of PEG-PEI-Fab´/DNA complexes to OA3 antigen 
expressing cell lines.  This property is of great importance for the transfection of 
particular cell types in vivo.    
100 nm 
PEI                    PEG-PEI          PEG-PEI-Fab´ 
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(A) 
(B) 
Figure 6  
Investigation of cell binding using flow cytometry. In (A), a strongly enhanced binding 
of PEG-PEI-Fab’/DNA complexes to OA3-expressing OVCAR-3 cells can be observed 
when compared to PEG-PEI/DNA and PEI/DNA complexes at an N/P ratio 3.5.  (B) 
shows binding to NIH/3T3 cells, which do not express OA3 antigen.  PEI/DNA display 
the strongest binding compared to PEG-PEI/DNA and PEG-PEI-Fab’/DNA complexes.  
The latter exhibit the least efficient binding to this non OA3-expressing cell line at an 
N/P ratio of 3.5  
Transfection experiments   
Data from transfection experiments using luciferase as a reporter gene are 
shown in Figure 7.  When experiments were performed using OA3 antigen 
expressing OVCAR-3 cells PEG-PEI-Fab´/plasmid complexes yielded fairly 
high levels of reporter gene expression between N/P 2.5 and 10 using either 0.5 
or 4 µg plasmid per well (Figure 7a and b).  Expression levels were 10 to 80-
Untreated 
cells 
PEG-PEI/DNA 
PEI/DNA
PEG-PEI-
Fab’/DNA 
Untreated 
cells 
PEG-PEI/DNA 
PEI/DNA
PEG-PEI-
Fab’/DNA 
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fold higher than those of complexes prepared with PEG-PEI or unmodified PEI.  
In OA3-negative NIH/3T3 cells, however, reporter gene expression remained at 
a rather low level (Figure 7c), probably due to a lower level of cellular 
association as determined by flow cytometry.   
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Figure 7 (A) and (B) 
Levels of reporter gene expression in OA3-positive OVCAR-3 cells using either 4 µg (A) 
or 0.5 µg (B) of luciferase plasmid per well are shown. Strongly enhanced levels of 
reporter gene expression can be observed compared to PEG-PEI which is especially 
distinct at low N/P ratios.   
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Figure 7 (C) and (D) 
In (C) luciferase expression in OA3-negative NIH/3T3 cells using 4 µg pCMV-Luc per 
well is depicted.  Here PEG-PEI-Fab´/plasmid complexes led to only low levels of 
reporter gene expression, stressing the high specificity of this system.  (D) Shows levels 
of reporter gene expression in OVCAR-3 cells in the presence of different amounts of 
free Fab´ in the incubation media.  The higher the Fab’ concentration, the lower the 
gene expression.  
In both cell lines, PEG-PEI/DNA complexes showed rather low levels of 
luciferase expression and only a moderate increase from N/P 2.5 to 10, probably 
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due to the low surface charge of complexes and, therefore, a reduced uptake.  
Unmodified PEI, however, displayed rather high levels of reporter gene 
expression at all N/P ratios with an increase of more than two orders of 
magnitude.  This effect cannot be attributed to the zeta potential of complexes 
since it decreases with increasing N/P ratio.  Increase in reporter gene 
expression occurs probably due to a more efficient complexation of DNA and a 
reduced size of complexes.  This may lead to a more efficient endocytic cellular 
uptake.  
Competition experiments with increasing amounts of Fab´ in the cell culture 
media showed a constant decrease in reporter gene expression in the case of 
PEG-PEI-Fab´/DNA complexes (Figure 7d).  This together with the low 
transfection efficiency in OA3-negative cell lines (Figure 7c) demonstrated a 
high degree of  specificity for this gene delivery system.  
Cytotoxicity of either PEG-PEI/DNA or PEG-PEI-Fab´/DNA complexes 
remained on a low level.  At N/P=10 using 4 µg of DNA per well, protein 
content was as high as that of an untreated control containing the same amount 
of cells.  The reason for this reduced in vitro toxicity is probably a reduced 
surface charge and hereby a reduced membrane disruptive potential of 
complexes as described earlier in the literature [24,34].  Unmodified PEI, 
however, caused a rather high cytotoxicity, leading to a protein content of as low 
as ~ 50 % at this N/P ratio.  
In summary it can be stated that complexes formed with plasmid DNA and 
PEG-PEI-Fab´ display only minor differences concerning physicochemical 
complex properties compared to PEG-PEI/DNA and PEI/DNA complexes. A 
possible disadvantage of the method we described here may be a reduced ability 
of PEG-PEI-Fab´ or PEG-PEI to complex DNA, or a reduced complex stability 
due to steric hindrance by PEG chains or the targeting moiety.  However, for our 
system, we have been able to demonstrate that neither the grafting of ten 2 kDa 
PEG chains, nor the conjugation of Fab´ leads to significant changes in complex 
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properties.  An explanation could be that in the complex cationic PEI moiety is 
oriented towards the core where it efficiently interacts with DNA, leading to 
similar curves in the ethidium bromide exclusion assay.  Hydrophilic PEG-
chains, as well as Fab´, most likely form a shell around this core, which 
accounts for the efficient shielding properties and proper presentation of the 
targeting ligand.  Consequently, complexes show a neutral zeta potential and a 
high level of reporter gene expression on cells expressing the OA3 antigen. The 
attachment of the targeting ligand to the end of a PEG-spacer like described by 
Woodle et al. for RGD-peptides [35] and Blessing et al. for EGF (epidermal 
growth factor) [36] could lead to further improvements of vector efficiency. This 
work is currently in progress. 
Interestingly, the differences of reporter gene expression obtained with PEG-
PEI-Fab´/DNA complexes were minor in the N/P range from 2.5 to 10.  This 
strongly suggests an internalization or cell binding mechanism that is not related 
to charge.  Flow cytometry data suggest that the increase in reporter gene 
expression with PEG-PEI-Fab´/DNA complexes when compared to PEG-
PEI/DNA complexes is at least partially due to enhanced binding to OA3-
positive cells.  These results are in good agreement with previous studies where 
a variety of PEG-PEI copolymers and PEIs containing a targeting moiety have 
been investigated [16,24].  Advantages of the strategy described here are the 
possibility to produce conjugates in larger quantities and an easy one-step 
complex formation.  Several steps are required in other strategies [8].  
Due to their high specificity and low toxicity targeted vectors with PEG-
shielding are attractive constructs for in vivo use.  Three general approaches 
have been described in the literature.  The first approach is the one we described 
here using conjugates of block polymers and a targeting moiety.  In the second 
strategy pegylation and conjugation of a targeting moiety were performed after 
complex formation with unmodified PEI [36].  This method was developed 
using EGF as a targeting moiety.  Complexes prepared via this strategy showed 
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significantly enhanced levels of reporter gene expression in target cells and 
almost neutral surface charges.  The major disadvantage of this method 
compared to our procedure is that the reaction products or the reaction solvent 
(e.g. DMSO) may remain in the complex solution and, therefore, influence their 
properties.  In addition, the means of characterization the true composition of the 
resulting complexes with regard to the degree of pegylation, for example, are 
limited.  Furthermore, the preparation of targeted vectors via this strategy is 
much more complicated than in the case of simple electrostatic vectors since 
several sequential steps are required. 
The third approach used to obtain a targeted and pegylated vector starts with the 
conjugation of a targeting moiety followed by complexation with DNA.  
Pegylation is carried out as the last step.  This strategy has been performed using 
EGF [36] and transferrin [8], and showed rather high levels of reporter gene 
expression in target cells.  The advantage of this approach is the possibility of 
purification and characterization of the intermediate PEI conjugate and targeting 
moiety.  The disadvantage is the difficulty in characterizing the PEG-content of 
the complex, the high operating expense of the pegylation process and the 
possibility that reaction products may remain in the complex solution.  
In conclusion, the strategy described in this publication represents a 
straightforward and efficient method to achieve active targeting using non-viral 
gene delivery systems with a high specificity and a low cytotoxicity. These 
investigations suggest that the PEG-PEI-Fab´ conjugates might be promising 
candidates for in vivo applications.  
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SUMMARY 
Differences between polyethylenimine (PEI)/plasmid and pegylated 
polyethylenimine (PEG-PEI)/plasmid complexes were investigated especially 
with regard to in vivo application. Size and zetapotential of complexes were 
measured and complex structures were visualized by atomic force microscopy. 
Furthermore, the stability of complexes against anionic exchange reactions was 
investigated, as well as the protection of complexed DNA against digestion by 
DNase I. To obtain an insight into the stability of complexes in blood we 
performed in vitro transfection experiments with polymer/DNA complexes in 
blood and investigated plasmid integrity after incubation with serum. Finally, to 
characterize the in vivo stability of complexes the fate of both types of 
complexes was investigated in vivo in mice after intravenous injection with 
radioactive labels attached to the polymer and incorporated into the DNA. 
Our data indicate that both types of complexes are spherical in shape with a size 
of approximately 100-150 nm. PEI/DNA complexes display a highly positive 
zeta potential, while PEG-PEI/DNA complexes possess a nearly neutral surface 
charge. Complex stability against polyanions does not show striking differences. 
A significant discrepancy was found with respect to the ability of polymers to 
protect against DNase digestion. While PEI offers effective protection against 
degradation, this effect is less pronounced for PEG-PEI. Transfection 
experiments in blood revealed that both types of complexes were at least partly 
stable in blood. In vivo investigations showed similar pharmacokinetic profiles 
and similar levels of organ accumulation for both the polymer and DNA from 
PEI/plasmid complexes indicating a considerable in vivo stability of these 
structures. PEG-PEI/DNA complexes, in contrast, showed obvious differences 
between polymer and DNA profiles. Kinetic curves and organ accumulation of 
DNA applied as PEG-PEI/DNA complexes were similar to those obtained with 
naked DNA. This data provides evidence for a rapid complex separation after 
injection with subsequent DNA degradation by serum nucleases. Our data 
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indicate that simple electrostatic vectors prepared with pegylated PEI and DNA 
are, despite favorable in vitro properties, not suitable for systemic gene delivery, 
at least under the conditions used in this study.   
INTRODUCTION 
Gene delivery has proven its efficiency in numerous in vitro studies [1]. The use 
of genes as therapeutic agents offers a tremendous potential for the causal 
treatment of yet incurable diseases, especially viral infections or cancer [2]. 
However, if this technique is to be applied systemically for the treatment of, e.g. 
malignant metastases, it is necessary to develop a vector system with sufficient 
stability and circulation time in the bloodstream in order to reach remote sites of 
the body. Cationic polymers, such as linear PEI [3,4] or methacrylates [5], have 
been frequently used for in vivo transfection experiments with primarily 
luciferase as a reporter gene. Some pharmacokinetic and organ distribution data 
has been obtained for different vectors [6-8]. In order to extend the circulation 
time of these vectors, hydrophilic polymers, such as PEG or pHPMA have been 
incorporated into the vector structure [9-11] with the intent to obtain a stealth-
like effect. Similar to that described for liposomes [12]. Several of these PEG-
modified cationic polymers display promising in vitro properties, such as a 
neutral zeta potential, very low toxicity and little to no aggregation [9,11,13]. 
Remarkable efforts have gone into the investigation of the in vitro stability of 
polyplexes [11,14], however, it is still unclear which factors are crucial for the in 
vivo stability of these systems. Several promising in vivo results have been 
obtained with local application of PEG-modified polymer/DNA complexes 
[15,16]. In a recent study, for example, it was demonstrated that the repeated 
administration of PEG-PEI/DNA complexes led to a prolonged transgene 
expression in the spinal cord as compared to unmodified PEI/DNA complexes 
[17]. However, little is known about the stability of simple electrostatic 
complexes in the bloodstream after intravenous injection and how the 
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incorporation of hydrophilic polymers, such as PEG, influences this stability. A 
study comparing poly(L-Lysine) and pegylated poly(L-Lysine)/DNA complexes 
revealed less efficient DNA protection in vivo, when using the pegylated 
polymer [7]. Further studies have investigated the pharmakokinetics and organ 
distribution of either DNA or polymer after intravenous injection [9,11], 
however, it still remains unclear if and to what extent complexes stay together in 
the bloodstream.  
The adequate dose for in vivo gene delivery is controversial. Some in vivo 
studies have used enormous amounts of DNA with up to 100 µg of plasmid per 
mouse [18]. However, the high levels of gene expression in lung and liver in 
such studies were also accompanied by a substantial in vivo toxicity leading to a 
high mortality among laboratory animals, due to lung embolism [19], and 
serious tissue damage [20]. If highly efficient plasmids encoding, e.g. suicide 
genes [21], are used for in vivo gene therapy, unspecific gene expression in the 
lung or liver is highly undesirable.  
In the present study complexes were characterized with regard to size, zeta 
potential and complex shape. In vitro stability of complexes was assessed by 
incubation with increasing amounts of anions, such as heparin and dextran 
sulfate. Furthermore we investigated complex stability by performing 
transfection experiments in blood and analyzed plasmid integrity by extracting 
DNA after incubation with serum. In order to assess the in vivo stability of 
PEI/plasmid and PEG-PEI/plasmid complexes after intravenous injection, we 
investigated the fate of polymer and DNA using two different radioactive labels. 
In these experiments, a dose of 2 µg plasmid per mouse were chosen to avoid 
tissue damage, lung embolism or other toxic side effects.     
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MATERIALS AND METHODS 
Materials and animals 
Luciferase plasmid (pCMV-luc) was purchased from Plasmid Factory, Bielefeld, 
Germany. PEI 25 kDa, PEG monomethylether (2 kDa) and hexamethylene 
diisocyanate (HMDI) were purchased from Sigma-Aldrich, Taufkirchen, 
Germany. Male balb/c mice as well as citrate mouse blood were purchased from 
Charles River, Sulzfeld, Germany.   
Polymer synthesis  
PEI(25k)-g-PEG(2k)10 was synthesized as previously described [22]. Briefly, 
PEG monomethylether (2 kDa) was dissolved in anhydrous chloroform and 
activated with hexamethylene diisocyanate (HMDI). Unreacted HMDI was 
carefully removed by extraction with light petrol. The reaction of activated PEG 
with the amino groups of PEI was carried out in anhydrous chloroform. The 
reaction solution was precipitated in diethyl ether and the product was dried in 
vacuo.    
Preparation of complexes 
Polymer solutions for complex formation were prepared in 79 µl of 150 mM 
NaCl with 10 mM Hepes buffer pH 7.4 and 36 µl glucose 5 % pH 7.4. These 
mixtures were added to solutions of plasmid in 115 µl glucose 5 % pH 7.4. 
Complexes were prepared at an N/P ratio of 6.  
Photon correlation spectroscopy 
Hydrodynamic diameters of the polymer/DNA complexes were determined by 
photon correlation spectroscopy.  Plasmid (0.5 µg pCMV-Luc) in 25 µL glucose 
5 % were complexed with the appropriate amount of polymer in 25 µL glucose 
5 % each, as described above.  Measurements were performed on a Zetasizer 
3000 HS from Malvern Instruments, Herrenberg, Germany (10 mW HeNe laser, 
633 nm).  Scattering light was detected at 90° angle through a 400 µm pin hole.  
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For data analysis, the viscosity (0.88 mPa s) and the refractive index (1.33) of 
distilled water at 25 °C were used.  The instrument was routinely calibrated 
using Standard Reference latex particles (AZ 55 Electrophoresis Standard Kit, 
Malvern Instruments).  Values given are the mean of 5 measurements.   
Measurement of zeta potential 
Zeta-potential measurements were carried out in the standard capillary 
electrophoresis cell of the Zetasizer 3000 HS from Malvern Instruments at 
position 17.0.  Measurements were performed in glucose 5 % and average 
values were calculated with the data obtained from 5 runs.  
Complex stability against exchange reactions with albumin and anions 
This assay was performed using a procedure described earlier [23] using a more 
narrow range of concentrations. Briefly: Complexes were prepared from 1 µg of 
pDNA and the corresponding amount of polymer in a total volume of 50 µl 
glucose 5 %. 0.075, 0.1, 0.125, 0.15, 0,175, 0.2 and 0.225 international units of 
heparin were added to these complex solutions in 10 µl glucose 5 %. The 
solutions were mixed well and incubated for 10 min before application to a 1 % 
agarose gel containing ethidium bromide. In the eighth lane of each gel, plasmid 
was applied as a reference. Gels were run for 50 min at 100 V and then scanned 
using a Biometra gel analyzing system.   
Studies with dextran sulfate were performed in the same manner. Increasing 
amounts of dextran sulfate (0.5, 0.75, 1.0, 2.5, 5.0, 7.5 and 10 µg) were 
incubated with the complex solutions in 10 µl glucose 5 %.  
Stability against DNase digestion 
Complex stability was investigated according to a method described earlier [24]. 
Briefly, complexes were prepared at N/P=6 in glucose 5 % using 5 µg of 
pCMV-luc in a total volume of 25 µl. Aliquots of 5 µl corresponding to 1 µg of 
plasmid were incubated with 0.0001, 0.01, 0.1, 1 and 5 international units (I.U.) 
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of DNase I in digestion buffer (0.1 M sodium acetate, 5 mM MgSO4 pH 7.4) for 
15 minutes at 37 °C. Subsequently, 6 µl termination buffer (equal volumes of 
0.5 M EDTA, 2 M NaOH and 0.5 M NaCl)  were added, as well as 2 µl of a 
heparin solution containing 1000 I.U. per ml. A positive control reaction 
containing naked DNA was carried out under the same conditions using 5 I.U. 
DNase I. Resulting mixtures were applied to a 1 % agarose gel and 
electrophoresed at 100 V for 1 hour. The resulting gel was visualized and 
photographed on a BioRad transilluminator. 
      
Atomic force microscopy 
The polymer-DNA complexes were prepared as described above and diluted in 
milliQ water (pH 5.5, 18.2 M ).  The formulations were directly transferred 
onto a silicon chip by dipping the chip into the polyplex solution for 10 min.  
Atomic force microscopy was performed on a Digital Nanoscope IV Bioscope 
(Veeco Instruments, Santa Barbara, CA) as described elsewhere [25].  The 
microscope was vibration-damped.  Commercial pyramidal Si3N4 tips (NCH-
W, Veeco Instruments, Santa Barbara, CA) on a I-type cantilever with a length 
of 125 µm, a resonance frequency of about 220 kHz and a nominal force 
constant of 36N/m were used.  All measurements were performed in Tapping 
mode
 
to avoid damage to the sample surface.  The scan speed was 
proportional to the scan size.  The scan frequency was between 0.5 and 1.5 Hz.  
Images were obtained by displaying the amplitude signal of the cantilever in the 
trace direction, and the height signal in the retrace direction, both signals were 
simultaneously recorded. The results were visualized in amplitude mode.  
Transfection in blood 
NIH/3T3 cells were seeded in 12 well plates at a density of 150,000 cells per 
well and grown for 48 hours. Complexes were prepared as described above 
using 4 µg of DNA in a total volume of 100 µl sodium chloride 150 mM and 
added either to 1000 µl mouse blood or 1000 µl sodium chloride 150 mM, pH 7. 
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These mixtures were shaken for 1 hour at 37 °C. After that media was aspirated, 
complex/blood, as well as complex/sodium chloride solutions, were added 
directly to cells and plates were shaken carefully. After 15 minutes, mixtures 
were removed and cells were washed 5 times very carefully to remove all 
cellular blood components. Cells were incubated for a further 24 hours and 
luciferase expression, as well as protein content were determined as described 
earlier [26].  
Stability of DNA in serum   
Complexes were prepared using PEI and PEG-PEI in glucose 5 % at a N/P ratio 
of 6 in a total volume of 200 µl and a plasmid content of 10 µg. Complexes and 
a control sample containing 10 µg of pCMV-Luc in 200 µl glucose 5 % were 
incubated with 800 µl human serum for 30 minutes at 37 °C. Subsequently, 
pDNA was extracted from samples. This was carried out using a commercial kit 
(DNeasy, Qiagen, Hilden, Germany), whereas, as an additional step, pDNA was 
released from polymers using 60 µl of heparin solution (1000 I.U./ml) after 
inactivation of DNases. The volume of eluted DNA was reduced to 20 µl using 
Microcon 10 ultracentrifugation units (Amicon, Bedford, USA) and applied to a 
1 % agarose gel. Electrophoresis was carried out at 100 V for 50 minutes and the 
resulting gel was visualized and photographed on a BioRad transilluminator.  
     
Radioactive labeling of polymers  
Polymers were labeled employing N-succinimidyl-3-(4-hydroxy-3-[125I]iodo-
phenyl)propionate (Amersham Pharmacia Biotech, Freiburg, Germany) 
according to the method of Bolton and Hunter as described earlier [9,27]. 
Briefly: Polymers were dissolved in 0.1 M borate buffer pH 8.5 and the Bolton 
Hunter reagent was dissolved in DMSO. The polymer solution was added to the 
Bolton Hunter reagent solution and the reaction was carried out for 60 minutes 
at room temperature. Purification was performed on a Sephadex G-25 column 
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(PD10, Pharmacia), using an elution buffer containing 150 mM NaCl and 10 
mM HEPES pH 7.4.  
Radioactive labeling of DNA  
Plasmid (pCMV-Luc) was radioactively labeled by incorporation of 32P-dCTP 
(Readivue, Amersham Pharmacia, Freiburg Germany) using a Nicktranslation 
Kit (Amersham Pharmacia, Freiburg, Germany) following a protocol provided 
by the manufacturer. Unincorporated nucleotides were carefully removed using 
Autoseq spin columns containing Sephadex G50 (Amersham Pharmacia, 
Freiburg, Germany) in two subsequent steps. Plasmid purity was verified via 
size exclusion chromatography using a PD-10 column and via 
ultracentrifugation using Microcon 10 spin columns (Amicon, Beverly, USA). 
No significant amounts of free 32P-dCTP were detected.  
Pharmacokinetic analysis and organ distribution   
All animal experiments followed the “Principles of Laboratory Animal Care” 
(NIH publication #85-23, revised 1985) and were approved by an external 
review committee for laboratory animal care. Male balb/c mice with a body 
weight of 20-25 g were anaesthetized using Ketamine (Ketavet, Pharmacia & 
Upjohn, Erlangen, Germany) and Xylazine (Rompun, Bayer AG, Leverkusen, 
Germany). Complexes of either 125I-poylmer/plasmid or polymer/32P-plasmid 
were injected as a bolus of approximately 100µL through the jugular vein. In the 
case of naked DNA, the appropriate amount of DNA was injected as a bolus of 
100 µl in the same buffer mixture as complex solutions. Blood samples were 
obtained via a catheter in the common carotid artery and urine was sampled by 
flushing the bladder with sodium chloride solution through a 2-way catheter. 
After 120 minutes, mice were sacrificed and organs (cortex, liver, kidneys, 
heart, lungs, spleen, fat tissue) were weighed and assayed for radioactivity. 
Radioactivity of the 125I-polymer was measured on a 1277 Gammamaster 
(Perkin Elmer Wallac, Freiburg, Germany). To assess the radioactivity from 32P-
Chapter 4  162
pCMV-Luc, organs and blood samples were dissolved in 1 ml of Soluene 350 
(Amersham Pharmacia, Freiburg, Germany). Subsequently, 200 µl of 30 % 
sodium peroxide were incubated with the mixture for 30 minutes, and then 
added to 15 ml HionicFluor (Perkin Elmer, Dreieich, Germany). Measurements 
were performed using a TriCarb liquid scintillation counter (Perkin Elmer, 
Dreieich, Germany) with a counting time of 15 minutes and 1 minute precount 
delay. Measurements of complex solutions were used for both tracers to 
determine the injected dose of radioactivity. In the case of PEI/DNA complexes 
concentration time curves from polymer and pDNA were fitted to a two 
compartmental model with the Software Kinetica 1.1 from Simed. The model 
used was tt BeAetC )( and the weighting applied was 2)/(1 calcc . Polymer 
concentrations in the samples were then calculated as percent of injected dose 
(%ID) or %ID/mL, respectively. Unpaired t-test was performed using 
Microcal™ Origin to compare blood levels of different polymers at 
corresponding time points. Differences were considered significant if two-tail P 
= 0.05.   
RESULTS AND DISCUSSION 
Size and zeta potential measurements  
At an N/P ratio of 6, both PEI 25 kDa and PEI(25k)-g-PEG(2k)10 are capable of 
forming complexes with plasmid DNA. Complexes prepared with PEI 25 kDa 
display a size of approximately 100 nm and a zeta potential of about + 25 mV. 
In contrast, PEG-PEI/DNA complexes display a size of approximately 145 nm 
and a neutral zeta potential, indicating an efficient shielding of the cationic 
charge by linear PEG molecules. Compared to measurements obtained in 
sodium chloride 150 mM [23] complexes are significantly smaller when 
prepared in glucose 5 %.  
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Complex stability against exchange reactions with anions  
The gels in Figure 1 were obtained with heparin (A) and dextran sulfate (B). 
Both show a similar stability of PEI/DNA and PEG-PEI/DNA complexes 
against exchange reactions with polyanions. Initial release being at the same 
concentrations, however, in the case of PEG-PEI, total release occurs at higher 
concentrations than that of PEI. This can be observed in lane 6 of the heparin 
gels (0.2 international units added) and lane 4 of the dextran sulfate gels (2.5 µg 
added). The differences in release profiles may reflect a DNA complexing 
ability from PEG as described earlier in the literature [28]. Complex stability 
against serum was investigated as well, however in this case no release of DNA 
could be observed (data not shown).  
 
Figure 1a 
Investigation of complex stability against exchange reactions with anions. Gels were 
obtained by incubating PEI/DNA and PEG-PEI/DNA complexes with increasing 
concentrations of heparin. Obviously release starts at the same concentration, however 
in the case of PEG-PEI total release occurs at higher concentrations as when using PEI.   
Figure 1b 
The same experiment with increasing amount of dextran sulfate     
  0.5       0.75      1.0        2.5        5.0      7.5      10 µg
 dextran sulfate added to complex preparation 
  0.5       0.75      1.0        2.5        5.0      7.5      10 µg
 dextran sulfate added to complex preparation 
PEI PEG-PEI 
PEI PEG-PEI
0.075     0.1     0.125  0.15    0.175    0.2      0.225    free  
International Units Heparin added                           DNA 
 0.075  0.1     0.125     0.15    0.175   0.2        0.225     free  
 International Units Heparin added                             DNA 
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Stability against DNase digestion 
Gels in Figure 2 show that if complexes of PEI/DNA and PEG-PEI/DNA are 
incubated with increasing concentrations of DNase I for 15 minutes, digestion of 
pDNA starts at an enzyme concentration of 1 I.U. DNase I per complex 
preparation. However, the degree of degradation is different. While complete 
degradation can be observed for DNA from PEG-PEI/DNA complexes, 
PEI/DNA shows only partial degradation with the majority of pDNA remaining 
intact. These results suggest a significantly greater ability of PEI 25 kDa to 
protect pDNA as compared to PEG-PEI. An explanation for this finding may be 
the denser complex structure of PEI, which provides a more efficient steric 
hindrance against DNase attack. Similar results have been obtained by Mullen et 
al. in a study where the ability of poly(L-lysine) and pegylated poly(L-lysine) to 
protect plasmid DNA against DNase was compared and the unmodified polymer 
achieved a better protection, as well [7].  
  
 
Figure 2 
Investigation of DNA protection against DNase digestion using PEI (A) and PEG-PEI 
(B). Complexes were incubated with increasing amounts of DNase for 15 minutes and, 
after enzyme inactivation, DNA was released from complexes. Data suggests that PEI 
offers a significantly higher protection against digestion than PEG-PEI, indicating a 
denser complex structure.      
10-4         10-2         0.1           1             5  
International Units DNase I added  
A B 
10-4         10-2         0.1           1             5  
International Units DNase I added  
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Atomic force microscopy (AFM)  
AFM images shown in Figure 3 as three dimensional plots illustrate that PEI and 
PEG-PEI are capable of forming defined, spherical complexes with plasmid 
DNA. Shape and size for both complex types appear similar. However, 
PEI/DNA complexes seem to be rounder, more compact and smoother. PEG-
PEI/DNA complexes lie flatter on the surface of the silicon chip. Furthermore, 
they seem to have a slightly more irregular shape. However, no free or only 
loosely complexed DNA can be observed. We have put a significant effort into 
the confirmation of the absence of free DNA in several AFM preparations. 
However no free DNA could be observed, as described in earlier studies [22].  
Transfection in blood  
A comparison of reporter gene expression in sodium chloride 150 mM and 
mouse blood are shown in Figure 4. Obviously, both PEI/DNA and PEG-
PEI/DNA complexes are capable of mediating gene expression when applied in 
blood. In the mouse blood used for this study, blood clotting was prevented by 
addition of citrate. This multivalent anion complexes not only calcium, but also 
magnesium ions, thus inhibiting serum nucleases. Since nuclease degradation is 
abolished in this experiment we can assume that the reduction of gene 
expression observed in this study is due to interactions with plasma proteins or 
cellular blood components. Probably a variety of serum proteins attach to 
complexes as described earlier [14,19]. If the degree of reduction of gene 
expression between sodium chloride 150 mM and blood are compared, a 
reduction of reporter gene expression of approximately 50 % can be observed 
for PEI/DNA complexes. When regarding PEG-PEI/DNA complexes, on the 
other hand, reduction goes down to less than 20 % when complexes are applied 
in blood, indicating a higher level of interactions with blood components. This is 
surprising, because one would expect less interactions with blood components as 
a result of the stealth-like effect and the neutral zeta potential.  
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Figure 3 
Complexes of PEI/DNA and PEG-PEI/DNA visualized by atomic force microscopy at 
N/P=6 in glucose 5 %. Images display a similar appearance of complexes, however 
PEI/DNA complexes seem to be more uniform and show a more regular structure than 
that prepared with PEG-PEI.  
(A) PEI/DNA 
(B) PEG-PEI/DNA 
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Our data does provide evidence of a certain degree of complex stability after 
incubation with blood for one hour, since the transfection levels of PEG-
PEI/DNA are about one order of magnitude higher than that of naked DNA.  
PE
I 2
5 k
Da
PE
I 2
5 k
Da
 
blo
od
PE
G-
PE
I
PE
G-
PE
I b
loo
d
pla
in 
DN
A
pla
in 
DN
A b
loo
d
1E-3
0,01
0,1
1
n
g 
lu
ci
fe
ra
se
 
/ m
g 
pr
o
te
in
 
Figure 4 
Comparison of luciferase reporter gene expression when complexes are applied to cells 
in in sodium chloride 150 mM and in blood.  
Stability of DNA in serum  
Results from plasmid extraction after incubation of complexes and naked DNA 
with human serum are shown in Figure 5. While naked DNA is almost totally 
degraded after 30 minutes of incubation, PEG-PEI does offer a certain 
protection against degradation by serum nucleases. However this effect is less 
pronounced than in the case of PEI 25 kDa. These results are in good agreement 
with data from Figure 2 and similar results have been published using poly(L-
lysine) [7].      
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Figure 5 
Investigation of plasmid integrity after incubation with human serum for 30 minutes. 
This assay reveals that PEG-PEI does protect plasmid DNA from degradation in  serum, 
however this effect is less pronounced than when using PEI 25 kDa. Naked DNA is 
almost totally degraded after 30 minutes.   
Pharmakokinetic analysis and organ distribution 
Pharmacokinetic profiles of polymers and DNA are depicted in Figures 6-8. 
None of the animals used in this study died during the experiments and no signs 
of acute toxicity were observed.  The stability of the label attached to the 
polymer has been proven by previous studies [9]. 32P labeled plasmid DNA is 
subject to degradation when injected intravenously [7,29,30] and, as a result, 
organ distributions detected after 2 hours do not contain the entire amount of 
intact plasmid. However, despite the evidence of a certain degree of degradation 
our data does show differences between PEI and PEG-PEI that allows valuable 
conclusions about protection against degradation. 
PEI/plasmid complexes (Figure 6). Pharmacokinetic profiles obtained with 
labeled PEI and plasmid DNA display a very rapid clearance from the 
bloodstream. Curves fitted to a biexponential disposition equation by non-linear 
curve fitting (Figure 6) exhibit very steep alpha phases followed by very flat 
beta elimination phases for both, the polymer and pDNA. After 30 minutes, less 
than 3 % of the injected dose (polymer, as well as pDNA) per milliliter blood is 
still circulating in the bloodstream, approaching levels of approximately 1 % 
PEI/         PEG-PEI/     Naked        untreated  
plasmid   plasmid        plasmi      pCMV-Luc     
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ID/ml blood after 2 hours. Differences between the curves, especially in the first 
30 minutes are only marginal. These similarities suggest that PEI/DNA 
complexes remain stable to a substantial degree in the bloodstream. 
The organ distribution of both PEI and pDNA after two hours reveals similar 
levels of radioactivity in important organs, such as liver, kidney and lung. This 
great similarity provides additional evidence for a certain degree of complex 
stability in the bloodstream with joint uptake into tissues. Uptake into the liver 
probably occurs due to opsonization of complexes as demonstrated by Planck et 
al. [31] with a subsequent rapid capture by mononuclear phagocytic cells. A 
remarkable difference in organ deposition can be observed in the spleen, 
displaying an approximately threefold higher accumulation of 125I compared to 
32P.  This fairly high accumulation in the spleen has been reported earlier for PEI 
25 kDa [9] and probably occurs due to free polymer present at the N/P ratio used 
or a minor degree of complex separation in the bloodstream. A significantly 
higher amount of radioactivity from 32P was detected in the urine, as compared 
to 125I from the polymer. This difference most likely occurs as a result of a 
minor degree of complex separation within 2 hours accompanied by a rapid 
degradation by serum nucleases as described earlier [29].  
Remarkably, the uptake into the lung is fairly low in this study, despite the fact 
that the lung is the main organ of gene expression after systemic administration 
of PEI/DNA complexes [3,4,32]. The reason for this is very likely a result of the 
low dose of only 2 µg pDNA used for the present investigation. At higher doses 
of PEI/DNA complexes a substantial accumulation is detectable in the lung even 
after 2 hours following injection (data not shown). Furthermore, deposition of 
pDNA and gene expression do not necessarily correlate as described ealier by 
Liu et al. [33]. Other tissues investigated in this study, such as heart, cortex, 
fatty tissue or the injection site in the jugular vein, did not exhibit significant 
levels of radioactivity from either polymer or pDNA after application of both 
PEI/DNA and PEG-PEI/DNA complexes. 
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Figure 6 
Pharmacokinetic profile and organ distribution after 2 hours of PEI 25 kDa / pCMV-
Luc complexes. A very rapid clearance from the bloodstream of both, DNA and polymer 
can be observed as well as a similar organ distribution.   
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PEG-PEI/plasmid complexes (Figure 7). Pharmacokinetic data from PEG-
PEI/DNA complexes reveals major differences between polymer and plasmid 
DNA. Similar to PEI 25 kDa, PEG-PEI displays a rapid initial elimination 
phase, however, after approx. 5 minutes a plateau can be observed at ~25 % of 
the injected dose per milliliter blood. The blood level decreases only marginally 
over the following two hours. A plausible reason for this long circulation of the 
polymer could be an efficient steric barrier created by PEG chains against 
opsonization and thus less uptake into the reticuloendothelial system of the liver. 
Another explanation could be the attachment of the polymer to e.g. cellular 
blood components. While the pharmacokinetic profile of the polymer seems 
very promising at the outset, it soon becomes clear that the polymer rapidly 
loses its cargo. The kinetic profile from 32P labeled pCMV-Luc complexed with 
PEG-PEI displays an initial decrease over the first two minutes with a 
subsequent maximum at 5 minutes of approximately 25 % of the injected dose 
per milliliter blood. The reason for this maximum could be an initial entrapment 
of DNA or PEG-PEI/DNA complexes in the lung microvaculature with a 
subsequent time-delayed redistribution into the bloodstream as described earlier 
[34]. After crossing of this maximum, however, the blood level of DNA 
decreases rapidly reaching levels of less than two percent after 120 minutes. The 
organ distribution after 2 hours shows great differences between the polymer 
and DNA, as well. While radioactivity from the polymer accumulates 
predominantly in the liver, reaching approximately 40 % of injected dose, 
radioactivity from the DNA appears in the liver at a lower level, remarkably 
even significantly lower than that of naked DNA (Figure 8). Furthermore, a high 
level of radioactivity from 32P was found in the urine after two hours, most 
likely present as pDNA degradation products.   
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Figure 7 
Pharmacokinetic profile and organ distribution (after 2 h) of PEI(25k)-g-PEG(2k)10 / 
pCMV-Luc complexes. Blood levels as well as organ distribution show great differences 
between polymer and DNA.   
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From pharmacokinetic profiles and organ accumulation data it can be concluded 
that PEG-PEI/DNA complexes very likely undergo a rapid separation of 
polymer and DNA after injection into the bloodstream. After separation, the 
PEG-PEI is taken up by the liver and a substantial amount of the injected dose 
circulates in the blood, possibly attached to cellular blood components. Plasmid 
DNA, however, is probably degraded by serum nucleases rapidly after 
separation leading to a high renal excretion of degradation products. Similar 
findings have been obtained by Mullen et al. [7]. They reported that pegylated 
poly(L-lysine)/plasmid complexes very likely separate rapidly after intravenous 
injection.   
Naked DNA (Fig. 8). The pharmacokinetic profile and organ distribution of 
naked pCMV-Luc was investigated under our experimental conditions and used 
as a reference. Interestingly, a maximum was obtained with naked DNA after 15 
minutes, as well, probably again due to accumulation in the lung with 
subsequent release. The curve progression following this maximum shows a 
rapid clearance from the bloodstream. The organ distribution after 2 h shows a 
substantial accumulation in the liver and excretion via the urine. The high renal 
excretion is probably a result of degradation of unprotected pDNA by serum 
nucleases [7,29].  
When the pharmacokinetic profile and organ distribution of DNA complexed to 
PEI is compared to that of naked pDNA, the impact of the polymer becomes 
obvious. The blood level curve for PEI/pDNA is similar to that obtained for the 
labeled polymer alone, while naked DNA shows a different behavior. This 
finding indicates that the polymer dictates the fate of the DNA and this 
observation can be explained by the assumption that the complexes remain 
stable in the bloodstream. Organ distributions of PEI complexed pDNA 
compared to naked pDNA shows great differences as well. In the case of 
PEI/pDNA, a much higher DNA accumulation in the liver and a lower excretion 
via the urine were measured. The threefold decrease in urine excretion is  
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Comparison of pharmacokinetics and organ distribution of 32P labeled pCMV-Luc 
complexed to PEI 25 kDa, PEG-PEI and plain DNA. Complexation with PEI 25 kDa 
leads to significant changes in organ distribution and blood levels over time, whereas 
remarkable similarities can be observed for free DNA and PEI(25k)-g-PEG(2k)10 / DNA 
complexes.  
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evidence that efficient protection of pDNA from degradation in the bloodstream 
is provided by PEI 25 kDa.  
Comparison of pDNA profiles from PEG-PEI/DNA complexes, however, shows 
similarities to that of naked DNA. While blood concentration levels are different 
at early time points, they become very similar after 15 minutes. Furthermore, 
organ distributions after 2 hours are similar, as well. Both show a moderate 
accumulation in the liver and a substantial renal excretion. These similarities 
support the assumption that PEG-PEI/DNA complexes separate rapidly after 
injection and that DNA is subject to degradation.  
In conclusion, we can summarize that under the conditions described in this 
study, complexes of unmodified PEI 25 kDa and pCMV-Luc exhibit a certain 
stability in the bloodstream. Complexes prepared with PEI(25k)-g-PEG(2k)10 
and pCMV-luc, however, very likely separate rapidly after injection. The reason 
for this rapid in vivo separation of PEG-PEI/DNA complexes is not yet clear, 
especially since in vitro studies revealed a similar capability of both polymers to 
condense DNA [23]. Furthermore, complex stability against heparin and dextran 
sulfate were very similar, as well. A possible explanation for this reduced 
stability in blood could be the higher susceptibility of PEG-PEI/DNA complexes 
to enzymatic degradation via  DNase I and serum nucleases as described in this 
study. This may lead to degradation of DNA in the complexes and thus 
destabilization. Similar findings are described for pegylated poly(L-
lysine)/plasmid complexes [7]. Furthermore, AFM images showed flatter and 
more irregular structures indicating less stable complexes. Transfection data in 
nuclease inactivated blood revealed a lower stability of PEG-PEI/DNA 
complexes in vitro. This lower stability together with a degradation of 
complexed DNA by serum nucleases may lead to separation of complexes. 
Especially in fine capillary beds of the lung complexes are exposed to vigorous 
shear stress. Furthermore negatively charged endothelia or blood components, as 
suggested in the literature [14] may contribute to complex destabilization. The 
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sum of these factors may lead to penetration of proteins or polyelectrolytes into 
the core of complexes [18]. This process could be facilitated by the hydrophilic 
PEG-chains incorporated into the inner layers of the complexes. A more detailed 
investigation concerning this issue is currently underway.  
It is yet unclear if complex separation of PEG-PEI/DNA complexes occurs to 
the same extent at higher doses as well. In this study only approximately 2 µg of 
plasmid DNA per mouse were used and it is conceivable that there is a saturable 
mechanism of complex destabilization that can be overcome or at least delayed 
with higher doses. Furthermore it is unclear if and to what extent the size of the 
complexed DNA influences complex stability. It is conceivable that complexes 
formed with small nucleic acids, such as antisense oligonucleotides or 
ribozymes, show a higher stability. Currently PEG-PEIs with different polymer 
structures complexed with nucleic acids of various sizes are under investigation 
concerning their in vivo properties. If a rapid destabilization occurs with other 
PEG-PEIs or at higher doses, it will be necessary to create new methods to 
stabilize the electrostatic complexes. For example, lateral stabilization using 
bioreversible disulfide bonds has shown promising properties [18].    
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SUMMARY 
Major problems using cationic polymers for nonviral gene delivery stem from 
fairly high positive surface charges of the resulting polyplexes with DNA and 
consequently high toxicity under in vitro and in vivo conditions. Attachment of 
hydrophilic polymers such as polyethylenglycol (PEG) has reduced toxicity of 
formulations. However most of these systems are not biodegradable at all. We 
therefore developed a biodegradable gene delivery system showing high 
transfection efficiency while displaying a low toxicity.  
A new type of copolymer was synthesized by grafting a diblock copolymer 
consisting of PEG and polycaprolactone (PCL) onto hyperbranched 
polyethylenimine (hy-PEI). Since the solubility of these compounds is only very 
poor, we formed supramolecular inclusion complexes by threading a-
cyclodextrin (a-CD) over PEG and PCL chains. The successful threading of a-
CD onto PCL blocks was investigated by FTIR and UV spectroscopy as well as 
1H NMR. Furthermore we investigated the ability of the resulting compounds to 
complex DNA by ethidium bromide fluorescence quenching. Hydrodynamic 
diameters of complexes and zeta potentials were assessed using a Zetasizer.  
Furthermore, cellular uptake was evaluated by confocal laser scanning 
microscopy and flow cytometry. Transfection efficiencies were evaluated 
employing a luciferase reporter gene assay and toxicity was estimated by 
determination of protein content. 
Characteristic shifts of PCL in FTIR, 1H NMR and UV spectra strongly suggest 
that -CD is threaded over PEG and PCL. Due to the reduced hydrophobic 
interaction between PCL blocks the resulting supramolecular complexes 
displayed a dramatically increased solubility. Their ability to complex DNA 
was almost as efficient as that of PEI 25 kDa. Resulting complexes show a size 
of approximately 200 nm and a neutral surface charge. Cellular uptake was 
increased as well when the inclusion complex is compared to the -CD-free 
triblock copolymer. Subcellular localization suggests an uptake in distinct 
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structures, probably by endocytosis with subsequent trafficking to lysosomes. 
Transfection efficiencies of inclusion complexes were in the same order of 
magnitude as PEI, however, a significantly lower toxicity was observed 
allowing the administration of nitrogen to phosphate ratios of up to 20. 
The supramolecular vesicles combine a very low toxicity with high levels of 
reporter gene expression, which is comparable to that of unmodified PEI 25 
kDa. Due to its adequate biocompatibility this system is especially promising 
for in vivo use.  
INTRODUCTION 
A host of nonviral gene delivery systems consisting of DNA complexes with 
various polycations has been investigated [1-3]. Among synthetic cationic 
polymers, polyethylenimine (PEI) is known to offer the highest positive charge 
density leading to strong DNA binding. Another positive feature of PEI is the 
“proton-sponge effect” over a broad pH range, which allows endosomal/ 
lysosomal escape without the use of disruptive agents [4]. Only high molecular 
weight PEIs have been reported to be very effective for gene delivery [5-7]. 
However, high molecular weight PEI was found to be cytotoxic due to its 
interaction with negatively charged cell membranes.  
Therefore, the use of PEI-based copolymers, instead of PEIs, to form DNA 
polyplexes has been extensively investigated recently [8-12]. Most studies 
utilize nonionic hydrophilic polyethers, e.g. polyethylenglycol (PEG), as a 
building block to obtain block or graft copolymers with linear or hyperbranched 
PEIs. When these copolymers were mixed with pDNA in aqueous solution, the 
cationic PEI segments of the copolymers were first bound to DNA via 
electrostatic interactions and then the neutralized polyions aggregated to form 
an insoluble core, while the nonionic water-soluble PEG chains served as a 
hydrophilic shell stabilizing the resultant nanoscale particles [8]. Complexes 
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thus prepared show a lower positive surface charge compared to polyplexes 
from homo PEIs, and are therefore less cytotoxic. 
A drawback for the in vivo application of these copolymers is their lack of 
biodegradability, since PEI and PEG were linked by chemical bonds stable 
under physiological conditions.  Therefore, very recently we synthesized a new 
type of biodegradable copolymers by grafting diblock copolymers of PEG and 
PCL onto hyperbranched polyethylenimines (hy-PEIs). Strong hydrogen 
bonding between PCL and PEI blocks was observed in the bulk materials, and 
the solubility of these copolymers were strongly dependent on their 
compositions, i.e. block length and graft density. Further, DNA polyplexes 
formed with soluble copolymers or copolymers possessing high critical micelle 
concentration (cmc) showed considerably increased gene transfection 
efficiency. By contrast, those copolymers having high graft density and long 
PCL blocks showed very poor transgene expression. In the latter case, the 
access and binding of DNA to the PEI block were seriously hindered by the 
dense hydrophobic PCL chains surrounding the hydrophilic PEI head. 
Hydrogen bonding between PCL and PEI blocks is also believed to be an 
impediment for the DNA complexation with PEI [13]. Therefore, breaking of 
hydrogen bonding between PCL and PEI as well as the dissolution of PCL 
block in aqueous media seem to be key factors for improving gene transfection 
efficiency of these copolymers. 
In this paper, we present an unusual way to dissolve the PCL blocks of hy-PEI-
g-PCL-b-lPEGs in aqueous solution by including them inside the -
cyclodextrin ( -CD) cavities. -CD is a cyclic oligosaccharide consisting of 6 
glucose units [15]. One of its distinctive properties is the amphiphathy, i.e. it 
possesses a hydrophobic cavity of 4.5 Å in diameter with a hydrophilic outer 
layer carrying many hydroxyl groups [15-16]. Supramolecular inclusion 
complexes (ICs), organized by noncovalent interactions, can be formed by 
threading -CD molecules onto various polymer chains [17-23]. The driving 
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force for the threading process is probably due to intermolecular hydrogen 
bonding between neighboring CDs, as well as steric compatibility and 
hydrophobic interactions between host and guest molecules. Thus far, it has 
been demonstrated that -CD may form inclusion complexes with both 
polyethylenglycol (PEG) [17-18] and PCL [24-28] chains. In most cases, a full 
coverage of individual polymer chains with -CD bracelets leads to a 
crystalline water-insoluble inclusion complex. However, if insufficient -CD 
was used and the polymer solution is dilute, a partial coverage of polymer chain 
with -CD can also be achieved. In this case, the resultant inclusion complexes 
are completely soluble in water. For instance, selective inclusion of the octane-
1,8-dicarboxylate segment of a PEG octane-1,8-dicarboxylate  polyester with - 
or -CD showed significantly improved water solubility [29].   
MATERIALS AND METHODS 
Materials  
Synthesis and physicochemical properties of graft copolymers, hy-PEI-g-PCL-
b-PEGs, were reported recently [13]. To prepare the inclusion complexes, a 
predetermined amount of -CD aqueous solution (e.g. 5 mg/mL, 20mL) was 
added stepwise to the copolymer micelle solution (e.g. 4.2 mg/mL, 15mL) in a 
glass vial immersed in an ultrasonic water bath at room temperature. Ultrasonic 
agitation was applied for 30 minutes during and after the addition of the -CD 
solution. The mixed solution was then stirred magnetically overnight at room 
temperature, frozen at -40 C, and then freeze-dried to obtain a powder sample 
[30]. 
As a reference polymer for all studies we used PEI 25 kDa (hy-PEI) from 
Sigma-Aldrich, Taufkirchen, Germany. 
pCMV-Luc encoding for luciferase as a reporter gene was purchased from 
Plasmid Factory, Bielefeld, Germany.  NIH/3T3 (Swiss mouse embryo) cell line 
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was purchased from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). Cells were cultured according to 
the protocols suggested by the supplier. Polyplex formation at N/P 3, 7 and 20 
were carried out as described previously [13].  
Ethidium bromide exclusion assay  
DNA condensation was measured by the decrease in ethidium bromide 
fluorescence, as described earlier [31-32]. The assay was performed in 96 well 
plates in triplicate. Eight µg of salmon testes DNA were dissolved in 79 µL 
water and 50 µL of 60 mM Tris buffer pH 7.4 were added to each well. 
Volumes were equalized to 300 µL with water.  Subsequently, appropriate 
volumes of 0.05 mg/mL polymer solutions were added to produce N/P ratios 
between 0.2 and 4.  These were incubated for 10 min and then 20 µL of a 0.1 
mg/mL ethidium bromide solution were added.  Wells were mixed thoroughly 
and the fluorescence was measured using a fluorescence plate reader with 
excitation wavelength at 518 nm and an emission wavelength of 605 nm.  
Characterization of inclusion complexes and polyplex nanoparticles  
FTIR, 1H NMR and DSC measurements of inclusion complexes were 
performed as reported earlier [13]. UV spectra were recorded on a Shimadzu 
UV-160 UV-visible recording spectrophotometer.  
Photon correlation spectroscopy   
Hydrodynamic diameters of the polymer/DNA complexes were determined by 
photon correlation spectroscopy.  Plasmid (0.5 µg pCMV-Luc) in 25 µL 0.9 % 
NaCl were complexed with the appropriate amount of polymer in 25 µL NaCl 
each, as described above.  Measurements were performed on a Zetasizer 3000 
HS from Malvern Instruments, Herrenberg, Germany (10 mW HeNe laser, 633 
nm).  Scattering light was detected at 90° angle through a 400 µm pin hole.  For 
data analysis, the viscosity (0.88 mPa s) and the refractive index (1.33) of 
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distilled water at 25 °C were used.  The instrument was routinely calibrated 
using Standard Reference latex particles (AZ 55 Electrophoresis Standard Kit, 
Malvern Instruments).  Values given are the mean of 5 measurements.   
Measurement of zeta potential  
Zeta-potential measurements were carried out in the standard capillary 
electrophoresis cell of the Zetasizer 3000 HS from Malvern Instruments at 
position 17.0.  Measurements were performed in 0.9 % NaCl and average 
values were calculated with the data obtained from 5 runs.   
Transfection experiments   
Transfection experiments were performed at N/P ratios of 3, 7 and 20. NIH/3T3 
cells were seeded in 12 well plates at a density of 50,000 cells per well. After 24 
h, the media was removed and the complexes were added in 2 ml fresh media. 
Media was exchanged again after four hours and the cells were incubated for an 
additional 44 h. Luciferase gene expression was quantified using a commercial 
kit (Promega, Mannheim, Germany) and photon counting on a luminometer 
(Sirius, Berthold, Bundoora, Australia).  Results were measured in relative light 
units per second (RLU/s) which were then converted into ng luciferase by 
creating a calibration curve with recombinant luciferase (Promega, Mannheim, 
Germany). Protein concentration in each sample was determined. All 
experiments were performed in triplicate and data were expressed in ng 
luciferase per mg protein.  
Fluorescent Labeling of PEI and DNA for Confocal Laser Scanning 
Microscopy Experiments  
Polymer (20 mg) was dissolved in 2 mL 0.1 M sodium bicarbonate solution at 
pH 9. Oregon Green 488 carboxylic acid succinimidyl ester (1 mg, Molecular 
Probes, Leiden, The Netherlands) was dissolved in 200 L dimethylsulfoxide 
and added dropwise under stirring to the polymer solution. The mixture was 
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stirred in the dark for 3 hours at room temperature before the labelled polymer 
was purified by ultrafiltration in an Amicon cell (regenerated cellulose 
membrane, molecular weight cut off 10,000) and washed with 0.1 M borate / 
1.0 M sodium chloride solution pH 7.5. The washing procedure was performed 
until no absorption was detectable at 488 nm in the cell outflow. As a final step, 
the buffer was exchanged with distilled water. Plasmid (pCMV-Luc) was 
labeled with Cy-3 using a commercial kit (Mirrus Label It, Mobitec, 
Goettingen, Germany). Procedure was performed according to the 
manufacturer’s manual.  
Confocal Laser Scanning Microscopy Experiments  
A Zeiss Axiovert 100M microscope coupled to a Zeiss LSM 510 scan module 
was used. NIH/3T3 cells were seeded at a density of 50,000 cells per well in 8 
well chamber slides (Lab Tek, Nunc, Wiesbaden, Germany). After 24 h the 
media was removed and complexes of 0.5 mg Oregon Green-labeled PEI and 
0.5 mg Cy3 labeled plasmid were added in new media. After an additional 4 h 
media was removed again and cells were washed 4 times with phosphorus 
buffered saline (PBS). Fixation of cells was done by incubation with 400 mL 
paraformaldehyde solution 3 % in PBS for 20 min. Cells were washed again for 
4 times and incubated for an additional 20 min with a 0,1 mg/mL DAPI (4’,6-
diamidino-2-phenylindole, dihydrochloride) (Molecular Probes, Leiden, The 
Netherlands) solution in PBS. For excitation of DAPI fluorescence, an 
Enterprise UV laser with an excitation wavelength 364 nm was used. Excitation 
of Oregon Green was performed using an argon laser with an excitation 
wavelength of 488 nm and for excitation of Cy3 a Helium-Neon laser with an 
excitation wavelength of 543 nm was used. Images were recorded in the 
multitracking mode using a longpass filter of 385 nm for DAPI, a longpass filter 
of 505 nm for Oregon Green and a longpass filter of 560 nm for rhodamine.  
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Flow cytometry   
Flow cytometry was performed with plasmid DNA labelled with the 
intercalating dye YOYO-1 (Molecular Probes, Leiden, The Netherlands), as 
described by Ogris et al [33]. Briefly, cells were grown for 24 h in six-well 
plates at a density of 400,000 cells per well. Complexes were prepared as 
described above and applied in fresh media with a total volume of 3 ml.  After 
30 min, media was aspirated and cells were washed twice with cold (4 °C) PBS 
pH 7.3 and once with 1 M NaCl to remove complexes attached to the cell 
membrane as described earlier [34]. Cells were suspended in PBS after 
detachment via trypsin incubation for 1 min. Cell suspensions were kept on ice 
until analysis. Flow cytometry was performed using a Becton Dickinson FACS 
Scan equipped with an argon laser with an excitation wavelength of 488 nm. 
The filter setting for emission was 530/30 nm bandpass.   
RESULTS AND DISCUSSION 
Formation of soluble inclusion complexes  
Except for hy-PEI-g-PCL-b-PEG copolymers with very short PCL block length 
and low graft density which are completely soluble in a wide concentration 
range, most copolymers showed a distinct critical micellization concentration 
(cmc) in water [13]. To form inclusion complexes, the -CD solution of 
predetermined concentration was added stepwise to the dilute micellar solution 
of the ternary block copolymer under ultrasonic agitation.  During this process, 
dynamic light scattering (DLS) measurements were employed to monitor the 
micelle collapse upon dilution and addition of -CD. When the turbid solution 
became transparent upon addition of an aqueous -CD solution, nanoparticles 
were no longer detectable by DLS measurement, suggesting the dissolution of 
micelles. The copolymer concentration calculated at this point was much higher 
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than its initial cmc, suggesting solubilization of the hydrophobic blocks upon 
threading by -CD.   
It is worth noting that copolymer solutions must be dilute in order to obtain 
soluble inclusion complexes. Otherwise, precipitation from the solutions of 
copolymers of low graft density (< 3) or gelation for the solutions of highly 
grafted copolymers will occur, indicating the formation of insoluble crystals of 
inclusion complexes. In solutions of highly grafted copolymers, the graft 
copolymer was physically crosslinked by the insoluble crystals of inclusion 
complex formed between -CD and the copolymer side chain [35]. Our 
objective was to dissolve PCL blocks while avoiding the occurrence of either 
precipitation or gelation of copolymer solution. Therefore, the control of 
copolymer concentration is very crucial.  
It was found that the effect of adding -CD on the solubility of the copolymers 
depends much on the copolymer compositions. For instance, we failed to 
dissolve the copolymers containing long PCL block (e.g. 3800) [13] and 
PEG5000 regardless of varying the graft density from 1.4 to 4.5.  When 
attempting to dissolve these copolymers upon addition of -CD solutions, clear 
solutions were not obtained, and eventually hy-PEI25K-g-(PCL3800-b-
PEG5000)1.4 solution formed a precipitate while gelation occurred in hy-
PEI25K-g-(PCL3800-b-PEG5000)2.6 and hy-PEI25K-g-(PCL3800-b-
PEG5000)4.5 solutions. For other copolymers, we successfully obtained soluble 
inclusion complexes. Table 1 (page 197) summarizes four typical soluble 
inclusion complexes selected for the gene delivery experiments. 
It is well known that the cavity depth of -CD molecules is 7 Å, which is equal 
to the length of approximately 0.86 repeat units of PCL. Presuming that only 
PCL block of copolymer had been fully and selectively covered by -CD 
molecules, the PEI contents in hy-PEI25k-g-(PCL580-b-PEG5k)2.9, hy-PEI25k-
g-(PCL1.2k-b-PEG2k)5.1 and hy-PEI25k-g-(PCL2k-b-PEG2k)2.8 should be 
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approximately 43%, 24% and 27% respectively. The actual PEI content of 
complexes shown in Table 1 is close to or higher than that of the complex 
compositions described above (40% vs 43%, 34% vs 24%, and 26% vs 27%). 
Since PEG can also form an inclusion complex with -CD, apparently the 
copolymer side chains (PCL-b-PEGs) were only partially covered by -CD in 
these soluble inclusion complexes. 
The threading of -CD molecules onto the copolymer PCL blocks was 
demonstrated spectroscopically.  Figure 1 shows an expansion of FTIR spectra 
covering the carbonyl bands of a diblock prepolymer MPEG-b-PCL, its 
corresponding ternary copolymer hy-PEI-g-PCL-b-PEG and a typical inclusion 
complex with -CD.   
168017301780 
Figure 1 
FTIR spectra of HO-terminated PCL2k-b-MPEG2k (a), hy-PEI25k-g-(PCL2k-b-
PEG2k)2.8 (b), inclusion complex of -CD and hy-PEI25k-g-(PCL2k-b-PEG2k)2.8 (c)   
The complexed powder sample was obtained by freeze-drying of an aqueous 
sample solution and was allowed to crystallize at room temperature for one 
month before FTIR measurements. It is known that the expanded c=o 
Wave number (cm-1) 
[a] 
[b]
 
[c] 
 Chapter 5   192
absorption band of the semicrystalline PCL is very indicative of the PCL phase 
structure in FTIR measurements [27,28]. In agreement with these reports, the 
PCL carbonyl absorption band (s, C=O) of PCL-b-MPEG can be well resolved 
into a peak at 1726cm-1 and a prominent shoulder at 1736cm-1, corresponding to 
the carbonyl absorption of the crystalline and the amorphous PCL phases, 
respectively. The carbonyl absorption of the crystalline phase (1726cm-1) is 
much stronger than that of the amorphous one, suggesting high PCL 
crystallinity in the diblock prepolymer. Upon grafting onto hy-PEIs, the 
absorption of crystalline PCL at 1725 cm-1 becomes weak, while the absorption 
of the amorphous PCL at 1736 cm-1 appears as the main peak, as shown in 
spectrum (b).  These results indicate that the crystallization of PCL blocks has 
been suppressed but not completely eliminated in the hy-PEI-g-PCL-b-PEG 
copolymers. By contrast, as shown in spectrum (c), the C=O absorption of 
crystalline PCL regions completely disappears, and only the C=O absorption of 
noncrystalline PCL blocks is detected in the spectrum of the ICs. These results 
suggest that PCL chains are individually inserted in -CD channels and hence 
were not able to fold and aggregate to form any PCL crystalline domains. 
1H NMR measurements further demonstrated the preferential complexation of 
PCL block with -CD. 1H NMR spectra of copolymer micelles in D2O do not 
show detectable resonance signals of PCL blocks due to suppressed chain 
mobility (data not shown). When the micelles were dissociated upon addition of 
-CD, clear PCL resonance signals (see ref [13] for detailed peak assignments) 
were observed in the 1H NMR measurements. Moreover, as shown in Figure 2, 
the 1H NMR resonance signals of PCL blocks show significant down-field shift 
upon forming the inclusion complex with -CD.  These results are consistent 
with previous reports in which similar down-field shifts were observed when 
polymer chains were included inside CD cavities [29,36].  
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It was reported that protonated polyiminooligomethylenes may form soluble 
inclusion complexes with -CD and result in the similar down-field chemical 
shift of oligomethylene signals. However the threading process was very slow 
at room temperature. In our work, the PEI block signal did not show down-field 
shifts upon mixing with -CD even after several days at room temperature. A 
model study with homo-PEI showed the same results. Thus apparently, PEI 
does not form an inclusion complex with -CD at room temperature. The 
different behavior of PEI and polyiminooligomethylenes may be due to the fact 
that the reported polyiminooligomethylenes contain long oligomethylene chains 
which are known to form an inclusion complex with -CD. The PEI we used, 
however, is branched and therefore probably the formation of inclusion 
complexes is abolished.  
Indeed, polyethylene is known to form an inclusion complex with -CD [37]. It 
is well known that PEG, similar to PCL, can form inclusion complexes with -
CD. However, 1H NMR signals of the PEG blocks of the copolymer complexes 
listed in Table 1 did not show any significant down-field shifts. These results 
suggest that the -CD molecules have preferably formed an inclusion complex 
with the PCL block in these complexes, in case that the -CD molar amount 
was stochiometrically insufficient for the whole side chain (MPEG-b-PCL-) 
inclusion. It is noteworthy that a precipitate or a gel was usually formed if a 
large amount of -CD was used, indicating that whole side chains including the 
PEG blocks were included inside -CD and new insoluble IC crystals were 
formed.  
Based on these results, we concluded that there are two preconditions for 
copolymer solubilization resulting from complexation with -CD. First, the 
amount of -CD should be stochiometrically insufficient to include both side 
chain blocks.  
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Second, copolymer PCL blocks need to be sufficiently isolated by the other two 
soluble components, i.e. the long PEG and bulky hy-PEI blocks. Under these 
two conditions, the newly formed complexes between PCL blocks and -CD 
are not able to aggregate and form insoluble inclusion complex crystals. This is 
probably the reason, why we were not able to dissolve the copolymers 
containing PCL3800.      
Formation of inclusion complex between -CD and PCL block was also 
confirmed by UV measurements. As shown in Figure 3, upon adding -CD, the 
UV absorption peak of the PCL carbonyl showed a clear red-shift from 216 nm 
to 226 nm due to the interaction between -CD and the included PCL chain.   
Figure 2 
1H NMR spectra of hy-PEI25k-g-(PCL580-b-PEG5k)2.9 (a),  inclusion complex of -CD 
and hy-PEI25k-g-(PCL2k-b-PEG2k)2.8, in D2O prepared under its cmc (b).     
(a)
(b)PCL
PEI 
PCL
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Figure 3 
UV spectra of hy-PEI25k-g-(PCL580-b-PEG5k)2.9 (a), and its inclusion complex (b), in 
water.   
Ethidium bromide (EtBr) exclusion assay  
Fluorescence of ethidium bromide added to polyplex solutions was determined 
to monitor DNA condensation. While free ethidium bromide in solution only 
shows weak fluorescence, fluorescence intensity strongly increases when it 
intercalates with DNA. If the DNA is condensed by a polycation, EtBr cannot 
intercalate with DNA. Therefore, condensation of DNA by polycations can be 
monitored by the decrease of EtBr fluorescence. As shown in Figure 4, 
increasing amount of PEI 25 kDa and inclusion complex both led to a 
significant decrease in relative fluorescence intensity from 100% to 26% until 
N/P ratio reached 2. By contrast, the relative fluorescence intensity was only 
slightly decreased to 90% at this N/P scale when DNA was condensed with hy-
PEI25k-g-(PCL1.2k-b-PEG2k)5.1. Apparently, PEI 25kDa and the inclusion 
complexes are much more efficient for DNA condensation, in comparison with 
the non- -CD-complexed copolymers.  
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Figure 4  
Condensation potential of hy-PEI 25kDa, hy-PEI25k-g-(PCL1.2k-b-PEG2k)5.1 and its 
inclusion complex with -CD (Inclusion 34), as determined by EtBr assay   
Size, zeta-potential and biocompatibility of polyplex polyplexes 
The particle size and -potential of various pDNA/copolymer complexes 
formed at an N/P ratio of 7 are summarized in Table 1. Homo PEI 25kDa 
formed the smallest polyplexes of approximately 160 nm in diameter indicating 
the best compaction and condensation of DNA molecules with the high 
molecular weight PEI. For our polymers it is noteworthy that threading of -CD 
does not increase the particle size of polyplexes, i.e. polyplex sizes detected are 
all around 200 nm no matter whether -CD was incorporated or not. Since all 
polyplexes were prepared by controlling the copolymer concentration below its 
critical micellization concentration, the particle size should be mainly affected 
by complexation of DNA and copolymer. This means that the particle size is 
affected not only by the DNA loading but also by the particle density. The 
insoluble micelle core rather than the soluble micelle shell should contribute to 
the micelle size.   
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Copolymer  
 
Inclusion complex 
Zeta Zeta PEI Size 
potential
PEI Size 
potential
Composition (%) (nm) (  SD) (mV)   (%) (nm) (  SD) (mV)  
PEI25k 100 164.6  5.4 20.9  2.7  ncb ncb ncb 
PEI25k-g-
(PCL580PEG5k)2.9
61 
 207.8  6.2 -0.4  1.9  40 208.5  7.2 0.3  1.8 
PEI25k-g-
(PCL2kPEG2k)2.8 
69 234.4 9.8 -3.5  0.3  26 217.5  9.6 -1.5  1.9 
PEI25k-g-
(PCL1.2kPEG2k)5.1
61 208.4  8.6 -3.0  0.9  34 222.5  12.7 1.4  1.4 
Table 1 
DNA complexes formed respectively with net copolymers and copolymer/ -CD 
complexes at N/P 7a 
aDetected with dynamic light scattering. bNo detectable inclusion with -CD.   
As expected, the –potential of the polyplex with hy-PEI 25kDa is relatively 
high (+ 21mV) suggesting high positive charge on the particle surface. In 
contrast, polyplexes based on both copolymer and inclusion complexes 
apparently possess approximately neutral surfaces (-3.5 to +1.4 mV –
potential). Since it is well known that low –potential usually correlates with 
low cytotoxicity, polyplexes based on copolymer and their inclusion complexes 
with -CD should be much more biocompatible than polyplexes with high 
molecular weight PEI alone. This notion was also supported by the viability of  
NIH/3T3 cells observed during the transfection experiments, as shown in Table 
2. At N/P ratios of 3 and 7, cells remained viable when transfected with 
complexes based on the copolymers and their inclusion complexes. By contrast, 
cell viability dropped to 80 % and 69 % respectively when transfected with the 
PEI 25kDa-based polyplexes. As the N/P ratio reached 20, all cells were killed. 
However, cells retained about 50% of their viability when transfected with 
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copolymer-based polyplexes. Furthermore, cell viability is even higher (> 80%) 
when cells were transfected with inclusion complex-based polyplexes at N/P 20, 
suggesting that incorporation of -CD can further improve the biocompatibility 
of these gene delivery systems.   
Gene transfection efficiency of polyplexes 
The transfection efficiencies in NIH/3T3 cells with polyplexes based on three 
copolymers and their inclusion complexes are shown in Figure 5. All inclusion 
complexes showed a significant increase in transfection efficiency compared to 
their copolymer counterparts. Although hy-PEI25k-g-(PCL580-b-PEG5000)2.9 
was soluble in a wide concentration range and showed quite good performance 
in DNA condensation and transgene expression [13], threading of -CD onto 
the PCL blocks may further enhance the gene transfection of this copolymer-
based polyplex by further reducing the hydrophobic hindrance of DNA binding 
to PEI. Effect of incorporating -CD on the transgene transfection of 
polyplexes of the two other copolymers is even much more significant. 
Surprisingly, at N/P 3 and 7, although hy-PEI25k-g-(PCL1200-b-PEG2000)5.1 
did not transfect the cells at all presumably due to its insufficient loading of 
DNA [13], the polyplex based on the inclusion complex of this copolymer 
exhibited excellent transfection efficiency. In Figure 4, it is especially 
noteworthy that biocompatible inclusion complexes formed polyplexes showing 
a transfection efficiency in the same range than that of more cytotoxic PEI 25 
kDa when N/P ratios of 7 and 20 are regarded. 
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Figure 5 
Transfection efficiency of polyplexes based on: (1) hy-PEI 25kDa, (2) hy-PEI25k-g-
(PCL580-b-PEG5k)2.9, (3) inclusion complex of PEI25k-g-(PCL580-b-PEG5k)2.9, (4) hy-
PEI25k-g-(PCL2k-b-PEG2k)2.8 , (5) inclusion complex of hy-PEI25k-g-(PCL2k-b-
PEG2k)2.8, (6) hy-PEI25k-g-(PCL1.2k-b-PEG2k)5.1, and (7) inclusion complex of hy-
PEI25k-g-(PCL1.2k-b-PEG2k)5..1   
Cell viability*  (%) 
N/P = 3 N/P = 7 N/P = 20 POLYMER 
Polymer ICb Polymer IC Polymer IC 
PEI25kDa 80  69  0  
PEI25k-g-(PCL580PEG5000)2.9 99 100 94 91 46 83 
PEI25k-g-(PCL1200PEG2000)5.1 100 100 95 100 45 97 
PEI25k-g-(PCL2000PEG2000)2.8 91 100 90 88 41 84 
*calculated based on the protein level detected. bDNA complexes prepared with inclusion complexes.  
Table 2 
Cell viability in transfection experiments with polymers and inclusion complexes  
Intracellular uptake of polyplexes 
To study the intracellular uptake and distribution of DNA incorporated into 
polyplexes, DNA was labeled with YOYO-1 and Cy3, respectively, for flow 
cytometry analysis and confocal laser scanning microscopy observation. 
Fluorescence of cells treated for 30 min with copolymer- and its inclusion 
complex-based polyplexes was analyzed by flow cytometry and compared with 
that of the untreated cells. As shown in Figure 6, incorporation of -CD to the 
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polyplex led to a approximately 10-fold enhancement of cellular fluorescence 
compared with cells identically treated with the -CD-free polyplex. As it is 
well known that particle size is a critical factor affecting cellular uptake, and 
DLS measurements have already demonstrated the sizes of -CD-containing 
and free polyplexes are almost the same. The enhanced intracellular uptake with 
the inclusion complex-based polyplexes should be mainly due to the enhanced 
DNA condensation, as already revealed by the EtBr exclusion assay. Further 
investigations are carried out to determine whether the incorporated -CD itself 
has any positive effects on the cellular uptake of polyplexes. We are especially 
interested whether the incorporated -CD molecules are helpful for cell 
targeting, cell membrane binding and permeation of gene delivery vectors. 
Similar differences for cellular association were obtained for the the other 
inclusion complexes and their a-CD-free counterparts (data not shown).   
After incubating NIH/3T3 fibroblasts for 3 h, a typical confocal laser scanning 
microscope image of a polyplex is shown in Figure 7. The microscopic image 
demonstrates the efficient internalization of polyplexes, in spite of their neutral 
surface charge. Both DNA and hy-PEI-g-PCL-b-PEG colocalize in punctuate 
vesicles, probably in the lysosomal compartment. The mechanism by which the 
polyplexes escape from the endo/lysosome is presently under investigation. 
Most likely, the hy-PEI component of the copolymer acts as proton sponge, 
while inclusion complex formation modulates complex solubility and 
cytotoxicity.  
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Figure 6 
Flow cytometry of untreated cells (a), cells treated for 30 min with the YOYO-1-labeled 
pDNA/hy-PEI25k-g-(PCL1.2k-b-PEG2k)5.1 (b) and the corresponding inclusion complex 
with -CD (c)  
Figure 7 
CLSM micrographs of internalization of fluorescently-labeled polyplex based on 
inclusion complex of hy-PEI25k-g-(PCL2k-b-PEG5k)2.8 into 3T3 fibroblasts after 3 h of 
incubation. Images assignment: Red: DNA, green: inclusion complex, and blue: nucleus 
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CONCLUSIONS 
The transfection efficiency of polyplexes based on hy-PEI25k-g-PCL-b-PEGs 
depends on composition, i.e. graft density and block length, of the copolymers. 
The PCL chains connected to the PEI blocks of hy-PEI25k-g-PCL-b-PEGs may 
impede the access and binding of hydrophilic DNA to PEI. Consequently, DNA 
compaction and condensation are poor. In addition, polyplexes based on 
copolymers were probably loaded with very low content of DNA because the 
copolymers possess low values for cmc that tends to further decrease upon 
complexation of DNA. Therefore, polyplexes based on hy-PEI25k-g-PCL-b-
PEGs showed very poor gene transfection efficiency, especially when the PCL 
blocks are long and/or the graft density is high. Upon formation of inclusion 
complexes between -CD and preferably the PCL blocks of hy-PEI25k-g-PCL-
b-PEGs, the copolymers lost their amphiphathy and became more hydrophilic. 
This change on one hand favored the DNA access and binding to PEI. On 
another hand, when the solubility of a copolymer increased, it probably tended 
to complex more DNA molecules until a new critical micellization 
concentration is reached due to the electrostatic neutralization of the PEI head 
and DNA. Both effects led to the enhancement of DNA complexation and 
condensation resulting in very high gene transfection efficiency.  
To further evaluate the high gene transfection efficiency of these novel delivery 
systems, we are carrying out in vivo gene transfection studies.     
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SUMMARY 
We investigated several properties of electrostatic complexes prepared with 
plasmid DNA and novel hy-PEI-g-PCL-b-PEG polymers with -cyclodextrin 
threaded over PEG and PCL chains.  
The ability of these polymers to complex DNA was investigated by an ethidium 
bromide exclusion assay and atomic force microscopy was performed to obtain 
insights into complex size and shape. Complex stability against heparin was 
investigated, as well as protection of complexed plasmid DNA against 
degradation by DNase I. Furthermore, we investigated the pharmacokinetic 
profile of plasmid DNA complexed to these polymers. This data was compared 
to profiles gathered from PEI 25 kDa after intravenous injection in mice. Organ 
accumulation of both types of complexes was assessed after 30 minutes. 
Our data reveal an efficient complexation of DNA by inclusion compounds 
resulting in the formation of defined, spherical particles. DNA release after 
incubation with polyanions was less efficient and commenced at higher anion 
concentrations than in the case of PEI 25 kDa indicating a greater stability 
against exchange reactions with anions. Protection of plasmid DNA against 
degradation by DNase I is as efficient as that of PEI 25 kDa for one inclusion 
compound tested in this study. Pharmacokinetic profiles of DNA complexed 
with either PEI or Inclusion compounds reveal an elevated area under the curve 
for the latter compared to PEI 25 kDa. Organ distribution after 30 minutes 
revealed a negligible accumulation in the lung, when inclusion complexes were 
used together with a very low in vivo toxicity. PEI, in contrast, was 
characterized by a high level of lung accumulation as well as a high rate of 
mortality among laboratory animals.  
In conclusion this study provides evidence for high stability of inclusion 
compound/DNA complexes combined with elevated in vivo circulation times 
and an improved biocompatibility.  
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INTRODUCTION 
Gene therapy is an evolving field with a tremendous potential for the causal 
treatment of yet incurable diseases, especially cancer or viral infections [1]. A 
variety of functional gene constructs have been designed which pursue different 
therapeutic strategies, e.g. cancer vaccination [2], suicide gene therapy [3] or 
downregulation of gene expression via ribozyme or siRNA constructs [4-6]. 
However, before the full potential of these techniques can be exploited, a safe 
and efficient delivery system must be developed. Viruses exhibit a very high 
efficiency, however their major disadvantage is an oncogenic and especially an 
immunogenic potential after repeated administration, as has been demonstrated 
by several lethal incidents in gene therapy clinical trials [7]. To circumvent this 
problem, alternatives must be found which also possess the capability to deliver 
DNA across systemic and cellular barriers. Cationic polymers, such as PEI [8], 
poly(L-lysine) [9] or starburst dendrimers [10], have been frequently used to 
deliver DNA, as well as RNA into cells. Among these polymers, different 
polyethylenimines have attracted particular attention, due to their enhanced 
ability to complex DNA and protect it from degradation [11] as well as their 
built-in endosomolytic activity [12] both of which lead to high levels of reporter 
gene expression in vitro. One major problem of these systems, however, is a 
limited in vivo applicability resulting from the highly cationic surface charge. 
The charge of complexes leads to incalculable interactions with vessel 
endothelia, plasma proteins and cellular blood components when injected 
intraveneously [13,14]. Furthermore, the circulation time of these vector 
systems are fairly short [15] and, therefore, are not suitable for a therapeutic 
systemic application. Several strategies have been developed to shield the 
cationic surface charge of the complexes using hydrophilic polymers, such as 
PEG or pHPMA [13,15-17], which aim to achieve a similar stealth-like effect as 
has been described for liposomes [18]. Complexes with these modified 
polymers exhibited favorable in vitro properties, such as a neutral surface 
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charge, lower toxicity and less interactions with blood components 
[13,15,17,19]. In vivo evaluations displayed elevated circulation time for these 
systems in some cases [13,15,20]. However, a delivery system that combines a 
high transfection efficiency with a high stability, as well as long circulation 
times and a high level of biocompatibility, is still not available. 
Recently, we described the synthesis and in vitro evaluation of novel, 
biodegradable hy-PEI-g-PCL-b-PEG polymers with -cyclodextrin inclusion 
[21,22]. A scheme of the formation of inclusion polymers is depicted in Figure 
1. The -cyclodextrin is threaded over PEG and PCL chains in these polymers 
by applying ultrasonic agitation. Since the inner part of cyclodextrin is 
hydrophobic, cyclodextrin molecules slide over the PEG chains and attach to 
polycaprolactone via hydrophobic interactions. Successful threading and 
attachment of cyclodextrin predominantly to polycaprolactone was verified by 
1H NMR, UV and FTIR spectroscopy [22,23].   
COMPOSITION OF BASIS POLYMER Name PEI content [%] 
PEI25k-g-(PCL580PEG5k)2.9  "Inclusion 40" 40 
PEI25k-g-(PCL2kPEG2k)2.8 "Inclusion 26" 26 
PEI25k-g-(PCL1.2kPEG2k)5.1 "Inclusion 34" 34 
Table 1 
Composition of polymers investigated in this study.  
The resulting hypermolecular inclusion polymers are capable of forming 
micellar complexes with plamid DNA. When complexed, the micellar structures 
displayed high levels of reporter gene expression combined with a neutral 
surface charge and low toxicities. In the present publication, we aimed to gain 
insight into the stability of this novel type of complexes species and to estimate 
if these systems possess potential for in vivo application. We investigated these 
novel vector systems with regard to their ability to complex DNA in 
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comparison to PEI 25 kDa. We also characterized complex size and shape using 
atomic force microscopy. Furthermore, we assessed complex stability against 
polyanions and determined whether inclusion polymers are able to protect 
pDNA against DNase I degradation. Finally, we performed in vivo studies 
investigating pharmacokinetic profiles and organ distribution after 30 minutes. 
A list of polymers used in this study and their structures is given in Table 1.  
Figure 1 
Scheme of inclusion compound formation: a-cyclodextrin threads over linear PEG and 
locates predominantly on PCL chains due to hydrophobic interactions. Primary 
localization on PCl chains was demonstrated by spectroscopic methods as described in 
chapter 5 of this dissertation.    
MATERIALS AND METHODS 
Polymer synthesis and threading of -cyclodextrin 
hy-PEI-g-PCL-b-PEG polymers were synthesized as described previously [21]. 
Subsequently, Inclusion compounds were prepared by stepwise addition of a-
cyclodextrin and ultrasonic agitation [22]. Successful a-cyclodextrin threading 
was verified by FTIR, UV, and 1H-NMR spectroscopy as described earlier 
[22,23].  
Complex formation 
All complexes were prepared in glucose 5 % pH 7.3. For the determination of 
complex stability against heparin 1 µg pCMV-Luc was diluted in 50 µl glucose 
5 % and added to the corresponding amount of polymer in the same volume. 
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For atomic force microscopy, complexes were prepared using 2 µg of pCMV-
Luc in 50 µl glucose 5 % and the corresponding amount of polymer in the same 
volume. For animal experiments, complexes were prepared using 50 µg of 
pCMV-Luc in 125 µl and the corresponding amount of polymer in 125 µl 
glucose 5 %, as well. From this solution 120-130 µl were injected into mice 
corresponding to approximately 25 µg of pDNA per mouse.   
Fluorescence quenching assay 
DNA condensation was measured by the decrease in ethidium bromide 
fluorescence, as described earlier [24]. The assay was performed in 96 well 
plates in triplicate. Eight µg of salmon testes DNA was dissolved in 79 µL 
water and added to 50 µL of 60 mM Tris buffer pH 7.4. Volumes were 
equalized to 300 µL with water.  Subsequently, appropriate volumes of 
0.05 mg/mL polymer solutions were added to each well to produce N/P ratios 
between 0.2 and 8.  These were incubated for 10 min and then 20 µL of a 0.1 
mg/mL ethidium bromide solution were added.  Wells were mixed thoroughly 
and the fluorescence was measured using a fluorescence plate reader with 
excitation wavelength of 518 nm and an emission wavelength of 605 nm.  
Atomic force microscopy 
A Multimode™ AFM (Veeco Instruments ™, Santa Barbara, USA) operating 
with a NanoScope IIIa™ controller and a size E scanner was used throughout 
this study. Silicon nitride, oxide sharpened, triangular cantilevers (Veeco 
Instruments™) were selected, operating at resonant frequencies of 
approximately 8 kHz.  All experiments were conducted in tapping mode, with 
either 256 x 256 or 512 x 512 pixel resolution. Scan speeds varied between 
applications. To reduce sample distortion, all data were acquired using optimum 
set-points and drive amplitudes aimed at minimising tip-sample interaction. 
Gains and scan-rate were adjusted to optimize the images obtained.  Post-
imaging analysis was carried out on NanoScope IIIa™ software, version 
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5.12b48. The background slope was removed using a first or second order 
polynomial function.  
Complex stability against exchange reactions with anions 
Complexes were formed in septuplet, as described above, in a total volume of 
100 µL sodium chloride solution at an N/P ratio of 7.  To these solutions, 0.01, 
0.03, 0.05, 0.1, 0.2, 0.5 and 1 International Units of heparin were added in 10 
µL 0.9 % sodium chloride. These solutions were mixed well and incubated for 
10 min before approximately 45 µl were applied to a 1 % agarose gel containing 
ethidium bromide. In the eighth lane of each gel, plasmid was applied as a 
reference. Gels were run for 50 min at 100 V and then scanned using a 
Biometra gel analyzing system.    
Stability against DNase digestion 
Complex stability was investigated according to a method described earlier 
[11]. Briefly, complexes were prepared at N/P=7 in glucose 5 % using 5 µg of 
pCMV-luc in a total volume of 25 µl. Aliquots of 5 µl corresponding to 1 µg of 
plasmid were incubated with 0.0001, 0.01, 0.1, 1 and 5 international units (I.U.) 
of DNase I in digestion buffer (0.1 M sodium acetate, 5 mM MgSO4 pH 7.4) for 
15 minutes at 37 °C. Subsequently, 6 µl termination buffer (equal volumes of 
0.5 M EDTA, 2 M NaOH and 0.5 M NaCl)  were added, as well as 2 µl of a 
heparin solution containing 1000 I.U. per ml. A positive control reaction 
containing naked DNA was carried out under the same conditions using 5 I.U. 
DNase I. Resulting mixtures were applied to a 1 % agarose gel and 
electrophoresed at 100 V for 1 hour. The resulting gel was imaged on a BioRad 
transilluminator.       
Radioactive labeling of plasmid  
pCMV-Luc was radioactively labeled by incorporation of 32P-dCTP (Redivue, 
Amersham Pharmacia, Freiburg, Germany) using a Nicktranslation Kit 
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(Amersham Pharmacia, Freiburg, Germany) following a protocol provided by 
the manufacturer. Unincorporated nucleotides were carefully removed using 
Autoseq spin columns (Amersham Pharmacia, Freiburg, Germany) in two 
subsequent steps. Plasmid purity was verified via size exclusion 
chromatography using PD-10 columns and via ultracentrifugation using 
Microcon 10 spin columns (Amicon, Beverly, USA). No significant amounts of 
free 32P-dCTP were detected.  
Investigation of pharmakokinetics and organ distribution in mice 
All animal experiments followed the “Principles of Laboratory Animal Care” 
(NIH publication #85-23, revised 1985) and were approved by external review 
committee for laboratory animal care. Male balb/c mice with a body weight of 
approximately 25 g were anaesthetized by injection of ketamine (Ketavet, 
Pharmacia & Upjohn, Erlangen, Germany) and xylazine (Rompun, Bayer AG, 
Leverkusen, Germany). Complexes were injected as a bolus of approximately 
120 µL through the jugular vein. Blood samples were obtained through a 
catheter in the common carotid artery and urine was sampled by flushing the 
bladder with sodium chloride solution through a 2-way catheter. After 120 
minutes mice were sacrificed by decapitation and organs (liver, kidneys, heart, 
lungs, spleen, fatty tissue and vena jugularis) were weighted and sampled. 
Radioactivity of all samples was measured on a 1277 Gammamaster (Perkin 
Elmer Wallac, Freiburg, Germany). Measurements of complex solutions were 
used to determine the injected dose of radioactivity. DNA concentrations in the 
samples were then calculated as the percent of injected dose (%ID), %ID/mL or 
%ID/g, respectively. An unpaired t-test  was performed using Microcal Origin 
Version 6.0 to compare blood levels of different copolymers at corresponding 
time points. Differences were considered significant if two-tail P = 0.05. 
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Non-linear curve fitting 
Concentration time curves were fitted to a two compartmental model with the 
Software Kinetica 1.1 from Simed. The model used was tt BeAetC )( and 
the weighting applied was 2)/(1 calcc . Each concentration time curve was fitted 
individually for all samples, as well as the mean of the concentrations for each 
time point. Pharmacokinetic parameters provided are composed of the mean of 
the parameters calculated from individual fits. a and ß values were transformed 
to half-life periods. Plots shown in the results and discussion section are fits for 
the mean concentrations with the standard deviation for each time point shown.  
RESULTS AND DISCUSSION 
Fluorescence quenching assay 
Ethidium bromide exhibits fluorescence only when intercalated with DNA. 
When polymer is added to DNA/ethidium bromide it excludes ethidium 
bromide from DNA thus reducing the fluorescence signal. The degree of 
reduction of fluorescence can be regarded as a measure for the ardency with 
which the polymer complexes DNA. Fluorescence exclusion curves obtained 
with the three inclusion compounds and PEI 25 kDa are depicted in Figure 2. 
This assay revealed a very efficient complexation of DNA by inclusion 34 
which was almost similar to that of PEI 25 kDa. Inclusion 26 and Inclusion 40 
display a less efficient DNA condensation. It seems that this implies that a 
higher number of short PCL-PEG chains with a-cyclodextrin threading, as in 
the case of Inclusion 34, leads to more efficient interactions with DNA than a 
smaller number of long chains. It is astonishing that Inclusion 26 is more 
efficient in DNA complexation than Inclusion 40, although the latter has a 
higher PEI content. The reason for this finding is probably the smaller size of 
linear PEG chains of Inclusion 26 and therefore less steric hindrance.  
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Figure 2 
Ethidium bromide exclusion assay of inclusion compounds and PEI 25 kDa as a 
reference.      
Atomic force microscopy 
Images of complexes between inclusion compounds and DNA, as well as 
PEI/DNA complexes, are shown in Figure 3. All polymers formed defined, 
spherical complexes with plasmid DNA. The shape and size of complexes 
prepared with PEI 25 kDa and inclusion compounds were only slightly 
different. Sizes ranged from about 80 to 120 nm, which is suitable for endocytic 
cellular uptake. Sizes determined via AFM are significantly smaller than those 
measured via photon correlation spectroscopy [22]. A likely explanation for this 
finding is that complexes were prepared in glucose in this study, whereas they 
were prepared in sodium chloride 150 mM in the previous study. A size 
reduction of complexes prepared in glucose 5 % as compared to sodium 
chloride 150 mM has been observed earlier ([25] and own unpublished data).   
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Figure 3 
Atomic force microscopy images of inclusion compound/DNA complexes and PEI/DNA at N/P 
ratio 7. All polymers are capable of forming defined, spherical particles.  
Complex stability against polyanions 
Complex stability was determined by adding increasing amounts heparin. 
Heparin is a highly polyanionic polymer capable of displacing DNA from 
polymer/DNA complexes at a certain concentration. In the case of PEI/DNA 
complexes, total DNA release occurred at a defined concentration. Inclusion 
compound/DNA complexes, however, showed an incomplete release at all 
concentrations tested and smeared bands can be observed. Remarkably, DNA 
100 nm
PEI 25 kDa 
Inclusion 26 Inclusion 34 
Inclusion 40 
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release from the inclusion compound 34 starts at a twofold higher concentration 
than PEI 25 kDa, indicating  a substantially higher stability of these complexes 
compared to PEI/DNA. The reason for this higher stability is presumably a 
hindered penetration of the highly anionic and thus highly hydrophilic heparin 
molecules through the PEG-PCL/cyclodextrin layer surrounding the core of 
complexes. Since Inclusion 34 is the polymer with the highest graft density, it 
can be assumed that a higher amount of PCL-PEG chains leads to enhanced 
stability of complexes.    
 
Figure 4 
Investigation of complex stability against polyanionic exchange reactions. Complexes 
prepared in an identical way were incubated with increasing amounts of heparin. 
Obviously Inclusion 34 forms the most stable complexes with DNA, since release in this 
case takes place at a higher concentration compared to all other polymers investigated. 
All gels with inclusion polymers suggest that release of DNA is less complete than when 
regarding PEI 25 kDa.        
DNA protection against DNase I digestion 
Gels containing DNA from complexes incubated with increasing amounts of 
DNase I are shown in Figure 5. Digestion of pDNA starts at the same DNase I 
concentration of one international unit in all gels. However, analysis of the 
degree of digestion shows that complete degradation can be only observed with 
Inclusion 26 and Inclusion 40. Inclusion 34 and PEI 25 kDa, in contrast, exhibit 
PEI 25 kDa 
Inclusion 26 
Inclusion 34 
Inclusion 40 
0.01     0.03    0.05      0.1      0.2       0.5         1        free  
International Units Heparin added                           DNA 
0.01     0.03    0,05     0.1      0.2       0.5         1        free  
International Units Heparin added                           DNA 
0,01    0.03   0.05      0.1      0.2       0.5         1         free  
International Units Heparin added                           DNA 
0.01   0.03    0.05       0.1      0.2       0.5        1         free  
International Units Heparin added                           DNA 
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very little degradation with a substantial amount of pCMV-Luc remaining 
intact. This data suggests that, depending on the polymer architecture, inclusion 
compounds can provide very efficient protection of complexed DNA against 
DNase attack. It is probable that the PCL-PEG chains with cyclodextrin 
threading erect an effective steric barrier against enzymatic degradation, 
especially when polymers feature a higher graft density, as with inclusion 34.     
  
Figure 5 
Investigation of DNA protection against DNase digestion using PEI 25 kDa (A) and 
inclusion polymers (B-D). Complexes were incubated with increasing amounts of DNase 
for 15 minutes and, after enzyme inactivation, DNA was released from complexes. Data 
suggests that Inclusion 34 offers a similar protection against DNase digestion than PEI 
25 kDa. Inclusion 26 and 40 are less efficient and here no intact plasmid is existent any 
more at high enzyme concentrations.  
Pharmacokinetic profiles over 30 minutes 
Pharmacokinetic profiles from 32P-labeled pDNA complexed with PEI 25 kDa 
and inclusion compounds are shown in Figure 6. Pharmacokinetic parameters 
for all polymers investigated are shown in Table 2. All graphs could be fitted to 
Inclusion 26  
Inclusion 34  
Inclusion 40  
     5          1            0.1       10-2      10-4    plasmid   plain
International Units DNase I added      + DNA  plasmid
     5          1            0.1       10-2      10-4    plasmid   plain
International Units DNase I added      + DNA  plasmid
     5          1            0.1       10-2      10-4    plasmid   plain
International Units DNase I added      + DNA  plasmid
     5          1            0.1       10-2      10-4    plasmid   plain
International Units DNase I added      + DNA  plasmid
PEI 25 kDa  
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a biexponential disposition equation by non linear curve fitting using Simed 
Kinetica. A very steep a-phase and a rather slow ß-elimination could be 
observed for all inclusion compounds and for PEI. Compared to PEI 25 kDa, all 
inclusion compound/DNA complexes show elevated AUCs, mainly arrising 
from a slower ß-elimination compared to PEI 25 kDa. Especially Inclusion 34 
exhibits an area under the curve that is more than twofold higher than that of 
PEI 25 kDa. After 30 minutes approximately 10 % of the injected dose is still in 
circulation compared to approximately 4 % for PEI 25 kDa (if the total blood 
volume is assumed to be 1.7 ml). After 5 minutes Inclusion 34 and after 15 
minutes Inclusion 26 and 40 show significantly enhanced blood levels. The 
reason for the prolonged circulation of these vector systems is probably their 
neutral zeta potential as described in an earlier publication [22]. The efficient 
shielding of the positive charge from polyethylenimine is provided by PCL-
PEG chains with cyclodextrin inclusion. This presumably reduces opsonization 
of complexes and leads to a less pronounced uptake into the reticuloendothelial 
system (RES) of the liver, as described earlier [15].   
Organ distribution after 30 minutes 
Results from organ distribution assessed after 30 minutes are shown in Figure 6. 
Other tissues and organs investigated like heart, fatty tissue and the vena 
jugularis (site of injection) did not accumulate weighty amounts of radioactivity 
neither for PEI nor for any of the inclusion compounds. Data from PEI 25 kDa 
revealed a rather high and variable uptake into the lung. This accumulation in 
the lung is very likely caused by aggregate formation of the highly cationic 
PEI/DNA complexes with erythrocytes or plasma proteins and subsequent 
filtration of these associates in fine lung capillaries. This phenomenon is 
probably responsible for the high mortality of laboratory animals when using 
PEI 25 kDa as described earlier in the literature [13]. In the present study, about 
25 % of laboratory animals died within 30 minutes after injection of PEI/DNA  
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Figure 6 
(A) Pharmacokinetic profile of 32P labelled pDNA complexed to PEI 25 kDa and 
inclusion compounds. All inclusion compounds exhibit a significantly elevated AUC. 
(B) Organ distribution of 32P labelled pDNA complexed to PEI 25 kDa and inclusion 
compounds 30 minutes after injection. Most remarkable is the high and variable 
accumulation of 32P labelled DNA complexed with PEI 25 kDa in the lung, something 
that could not be observed with inclusion compounds.      
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AUC A t1/2,alpha B t1/2,beta Polymer 
[%ID*mL-1*min] [%ID/mL] [min-1] [%ID/mL] [min-1] 
PEI 25 kDa  300 ± 84 29.8 ± 2.3 1.8 ± 0.1 4.7 ± 1.7 38.2 ± 21 
Inclusion 26 564 ± 122 20.1 ± 3.5 1.8 ± 0.4 7.5 ± 1.7 50.8 ± 20 
Inclusion 34 699 ± 188 29.5 ± 4.1 1.4 ± 0.5 9.1 ± 1.8 53 ± 24 
Inclusion 40 594 ± 72.9 27.4 ± 4.1 1.5 ± 0.4 7.1 ± 1.1 53 ± 9 
Table 2 
Pharmacokinetic parameters of 32P labelled DNA complexed with inclusion compounds 
and PEI 25 kDa. Values were obtained by fitting concentration time curves to a 
biexponential disposition model using Simed Kinetika version 1.1. Figures shown were 
calculated from the pharmacokinetic data obtained from four animals.    
complexes. An assessment of organ accumulation revealed very high 32P values 
in the lung. This finding indicates that lung embolism may be the likely cause of 
death, as has been described earlier [13]. Lung accumulation of inclusion 
compound/DNA complexes on the other hand, was very low and none of the 
animals died during experiments. This difference is probably due to the neutral 
surface charge of inclusion complexes and, therefore, a reduced aggregate 
formation with cellular blood components or plasma proteins, preventing 
entrapment in fine lung capillaries. The negligible accumulation of complexes 
in the lung is a key advantage of such inclusion compounds. The largest fraction 
of radioactivity is found in the liver. PEI exhibits the highest hepatic values, 
whereas those of the inclusion compounds are slightly lower. The discovery of 
the liver as the main organ of complex deposition is not surprising and this 
finding is in good agreement with various studies using cationic polymers 
published earlier [15]. A fairly high amount of radioactivity from PEI 
complexes is found in the spleen. The reason for a higher deposition of 
PEI/DNA complexes in organs of the reticuloendothelial system is probably the 
result of a higher degree of opsonization of these highly cationic structures.  
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Several strategies have been pursued in order to obtain a better shielding of 
cationic surface charges and an extended circulation in the bloodstream. One 
frequently applied strategy is the attachment of hydrophilic polymers, such as 
polyethylenglycol or pHPMA, to polyethylenimine via different strategies 
[13,15-17]. The attachment of PEG to preformed PEI/DNA complexes led to 
increased circulation times and to reduced interactions with plasma proteins 
[13,17]. The major disadvantage of this system is a rather high operating 
expense for complex preparation and a fairly difficult characterization of the 
resulting structures. When PEI or poly(L-lysine) were pegylated prior to 
complex formation, neutral surface charges and enhanced circulation times were 
obtained as well [15]. However, these systems exhibited a reduced stability and 
evidence exists that suggests that complexes of this type separate shortly after 
injection into the bloodstream [26,27]. Another very promising group of vectors 
consists of electrostatic complexes stabilized via bioreversible crosslinking 
agents. The most frequently used system is that of disulfide bridges which are 
stable in the bloodstream [20,28]. On the subcellular level, however, the DNA 
can be released due to the reductive environment created by e.g. glutathion. 
Several of these vectors have shown greatly enhanced circulation times and a 
high degree of stability in the bloodstream. The major problem of these systems 
is the rather time consuming preparation of complexes on the one hand and a 
rather low or even entirely abolished reporter gene expression on the other [29]. 
When using this approach, a compromise between the degree of crosslinking 
required for stabilization in the bloodstream and that which is required for 
possible release at the subcellular level has to be found.  
The system we describe in this publication can be used to prepare complexes 
with plasmid DNA in a simple one step procedure and polymers can be 
produced in bulk. As described above these new vectors are more stable against 
exchange reactions than those prepared with PEI 25 kDa and exhibit an 
excellent stability against DNase I digestion. The reason for this enhanced 
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stability, despite a rather low PEI content of 34 %, is probably due to a micellar 
assembly of the complexes with pDNA. A micellar complex structure has been 
suggested previously for PEG-PEI/oligonucleotide complexes, whereas in these 
structures PEI is believed to neutralize the anionic charge of DNA forming an 
insoluble complex core with PEG chains directed to the surface of the 
complexes [30]. This hydrophilic PEG corona leads to an efficient charge 
shielding and, thus, to reduced charge interactions and toxicity [19]. 
Furthermore, complexes are stabilized, due to a reduction in complex 
aggregation [19]. In the system described in this publication, a further 
stabilizing factor has been incorporated into the complex architecture, PCL-
PEG. The hydrophobic polycaprolactone  becomes partially hydrophilic when 
-cyclodextrin is threaded over its linear chains. However, because these chains 
are not totally covered with -cyclodextrin [22], hydrophobic regions still exist, 
which can interact with each other via hydrophobic interactions and, thus, 
provide a certain lateral stabilization of the micellar structure of complexes.   
From our data, we can state that a higher number of shorter PCL-PEG chains 
leads to more highly stable vector systems. Furthermore, the shielding effect of 
these shorter chains is more effective than the longer chains, which is 
demonstrated by an increased circulation time of Inclusion 34, presumably due 
to reduced opsonization.  
In conclusion, we can state that the approach described in this and in the 
previous chapter represents an easy, efficient method to obtain fairly stable 
vector systems. Furthermore they exhibit a high in vitro and in vivo 
biocompatibility, a high transfection efficiency, and elevated blood levels after 
intravenous injection. These properties make the hy-PEI-g-PCL-b-
PEG/cyclodextrin vectors very attractive for further investigations. We are 
currently conducting more comprehensive studies with these vectors with the 
aim to optimize polymer properties, especially with regard to graft density and 
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chain length of PEG and PCL, as well as the amount of -cyclodextrin 
threading.  
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SUMMARY 
In this dissertation several aspects of polymer based gene delivery were 
investigated. First, key issues in subcellular processing of electrostatic 
polymer/nucleic acid complexes were investigated and new insights into 
mechanisms involved in these processes were gained.  
Secondly, a targeted gene delivery system was developed for the specific 
transfection of ovarian carcinoma cells. The resulting vector exhibited a high 
specificity for target cells combined with low unspecific transfection and 
toxicity. Furthermore, a novel type of gene delivery system was synthesized. 
This vector exhibited a high in vitro transfection efficiency and a very low in 
vitro toxicity as well as favourable in vivo properties, such as reduced toxicities. 
Another aspect that was studied in depth was the investigation of the stability of 
several electrostatic vectors in vitro and when applied intravenously. 
Chapter 1 gives a detailed overview of cationic polymers as delivery systems 
for nucleic acid therapeutics against cancer. The current status quo concerning 
polymeric gene delivery is presented. Systemic and subcellular hurdles, as well 
as the most important strategies for cancer gene therapy, are described in depth.  
In Chapter 2, key steps of the subcellular trafficking of PEI/nucleic acid 
complexes were investigated by confocal laser scanning microscopy and 
inhibitor experiments. Microscopic studies suggest that complexes are taken up 
into cells via adsorptive endocytosis. The major site of complex accumulation 
was identified as the lysosomal compartment by using an acidotropic dye. For 
the first time it was possible to monitor the release of PEI/nucleic acid 
complexes from vesicular compartments by using living cell microscopy. 
Obviously, only a very small fraction of the complex population is able to leave 
the endosomal or lysosomal compartment, whereas the vast majority remains 
within the vesicles for days at least. The application of an endosomal 
acidification inhibitor demonstrated the importance of vesicle acidification for 
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release. These findings were confirmed by performing transfection experiments 
in the presence of and without the acidification inhibitor. Results from these 
experiments demonstrated that pH decrease within the vesicle is essential for 
obtaining efficient reporter gene expression with PEI as a gene delivery agent.  
In Chapter 3, the development of a highly efficient gene delivery system for the 
specific targeting of ovarian carcinoma cells expressing a particular epitope is 
described. An antibody with a high specificity for the target epitope was chosen 
as a targeting moiety. In order to reduce the size of the targeting moiety, antigen 
binding fragments (Fab´) were produced by digestion of the crystallizable 
fragment of the antibody. Conjugates of pegylated polyethylenimine and Fab´ 
were synthesized. It was postulated that the linear polyethylenglycol chains 
could be able to shield the cationic charge of polyethylenimine, thus decreasing 
the degree of unspecific interactions. The conjugate was capable of complexing 
DNA as efficiently as unmodified PEI. Complex stability against the polyanion 
heparin was similar, as well. Cell binding studies using flow cytometry revealed 
a high affinity binding of conjugate/DNA complexes to epitope expressing cell 
lines and a significantly lower degree of binding to a reference cell line. 
Transfection experiments in epitope expressing cell lines exhibited up to 
approximately 100fold higher gene expression compared to PEI or pegylated 
PEI. In non epitope expressing cell lines, however, gene expression obtained 
with conjugate/DNA complexes remained low. In order to further confirm the 
specificity of conjugate/DNA complexes transfection experiments were 
performed with free antigen binding fragments in the cell culture media. A 
concentration dependent decrease in reporter gene expression could be observed 
indicating that the specificity of conjugate/DNA complexes is due to Fab´-
epitope interactions.   
In Chapter 4, the in vitro and in vivo stability as well as the organ deposition of 
PEI/plasmid and PEG-PEI/plasmid complexes were investigated. While the 
stability of both types of complexes against polyanions was similar, striking 
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differences were found when the protective properties of complexed DNA 
against DNase digestion was investigated. Unmodified PEI 25 kDa was more 
effective in protecting DNA from degradation than PEG-PEI. Atomic force 
microscopy revealed a slightly different shape of complexes; PEG-PEI/DNA 
complexes exhibited a slightly irregular and rougher structure. However, no 
uncomplexed DNA was observed after complexation with both polymers. In 
vitro transfection experiments in blood revealed significant stability for 
complexes prepared with both polymers. However, the stability of pegylated 
polyethylenimine/DNA complexes was lower indicated by a more pronounced 
decrease of reporter gene expression when transfection efficiencies in blood 
were compared to that in sodium chloride solution. When the in vivo fate of 
complexes was investigated with different radioactive labels attached to 
polymer, as well as incorporated into DNA, significant differences were 
observed between PEI/DNA and PEG-PEI/DNA complexes. In the case of 
PEI/DNA, a similar pharmacokinetic profile was obtained for both polymer and 
DNA with a similar organ distribution after 2 h. Data for PEG-PEI/DNA, in 
contrast, revealed differences in blood levels and a different organ accumulation. 
In this case, the pharmacokinetic and organ distribution data of the complexed 
DNA was similar to that obtained with naked DNA, thus indicating a rapid 
separation of complexes. This study provided valuable information for the 
further development of polymeric vectors for in vivo use. 
In Chapter 5, the development of a novel class of gene delivery systems is 
described. These vector systems are composed of triblock polymers containing 
hyperbranched PEI 25 kDa, polycaprolactone and polyethylenglycol. Due to the 
poor solubility of these compounds, supramolecular inclusion complexes were 
formed by threading a-cyclodextrin over the polyethylenglycol and 
polycaprolactone chains. Since the inner region of cyclodextrin is hydrophobic, 
it is a reasonable assumption that the cyclodextrin molecules were able to slide 
over the PEG chains and attach themselves to the polycaprolactone via 
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hydrophobic interactions. Successful threading and attachment of the 
cyclodextrin to the polycaprolactone was verified by 1H NMR, UV and FTIR 
spectroscopy. The resulting inclusion polymers were capable of efficient DNA 
complexation. Complexes displayed a neutral zeta potential as well as a size 
suitable for endocytic uptake into cells. Cellular uptake was monitored by 
confocal laser scanning microscopy, in which images showing a rapid 
trafficking to vesicular organelles, such as endosomes or lysosomes, could be 
gathered. Transfection efficiencies were in the same order of magnitude as PEI 
25 kDa, however, toxicities were very low, even at high nitrogen to phosphate 
ratios. These unique efficiency-toxicity properties made this system very 
attractive for further investigations.    
In Chapter 6, several triblock polymers with cyclodextrin inclusions, such as 
those described in Chapter 5, were investigated with regard to properties crucial 
for an in vivo application. Complex stability against polyanions was found to be 
higher than that of PEI 25 kDa. Protection of DNA against DNase digestion was 
efficient as well. Visualization of the complex structure via AFM revealed a 
spherical morphology with a size similar to that of PEI 25 kDa. The in vivo 
evaluation of polymer/DNA complexes exhibited a slightly enhanced circulation 
time of complexes with cyclodextrin inclusion, as compared to PEI 25 kDa. The 
major advantage of the inclusion compounds, however, was a negligible 
accumulation in the lung and a reduced in vivo toxicity compared to PEI 25 kDa.    
OUTLOOK 
The ultimate goal of polymeric gene delivery is the development of a safe vector 
system with low in vitro and in vivo toxicity exhibiting a high stability in the 
bloodstream, efficient and exclusive uptake into target cells and high levels of 
gene expression. However, at this time we are far away from such a system.  
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Mechanistic knowledge about the subcellular trafficking of PEI/nucleic acid 
complexes is of major importance for further advances in this field. Although 
insight into this topic is deepening, numerous unanswered questions remain, 
especially concerning how exactly release from the endosome or lysosome 
occurs and which polymer properties are crucial for efficient release. Further, 
more knowledge is required concerning the mode by which plasmid DNA 
crosses the cytoplasm and enters the nucleus, as well as how the efficiency of 
this process can be improved.  
The reduction of in vitro and in vivo toxicity of polymer based gene delivery 
systems is of crucial importance for further advances in this field. Important 
progress has been made, for example, by coupling hydrophilic polymers, such as 
PEG or pHPMA, via different strategies to polymeric gene carriers. These 
modifications have led to a dramatic decrease in toxicity. However a deeper 
insight into the behavior of polymer/nucleic acid complexes in the bloodstream 
is necessary for the rational development of in vivo gene delivery systems. 
Initial studies of the in vivo stability of such vector systems, as described in this 
dissertation, have demonstrated a rapid separation of PEG-PEI/DNA complexes 
at low doses. However, in order to make conclusive statements about the 
applicability of these vector systems, a systematic evaluation of different 
polymers, varying complex doses, and alternative modes of application is 
required. The new generation of triblock polymers with cyclodextrin threading 
described in Chapter 5 and 6 have shown several advantageous properties, such 
as high levels of reporter gene expression, low in vitro and in vivo toxicities, and 
a low accumulation in the lung. Furthermore, circulation times were slightly 
enhanced compared to PEI 25 kDa. However the effects are not very 
pronounced and therefore, further studies are required to be able to fully 
evaluate the potential of this approach.  
The use of reversibly crosslinked complexes may show favourable properties 
and stimulate progress in this field. This approach involves the formation of 
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complexes following the regular protocol, followed by subsequent lateral 
stabilization using bifunctional linkers containing e.g. disulfide bonds. Such 
systems are potentially more stable in the bloodstream, yet when internalized 
into cells, the DNA can be released as a result of the reductive environment 
created by a high concentration of e.g. glutathion. Of course, the degree of 
crosslinking needs to manipulated in such a way that sufficient stability in the 
bloodstream is, on the one hand, guaranteed and on the other an efficient release 
of DNA at the subcellular level is possible.  Currently, optimization of this type 
of system is under intensive investigation.   
This dissertation and numerous other publications have described gene delivery 
systems containing targeting vectors with a high specificity for particular target 
cells in vitro. The challenge, however, is to develop vector systems that work in 
vivo, although the results in this field are still discouraging. Most of the systems 
that are in use display a low specificity and only a marginal gene expression in 
target tissues in vivo. Currently, the antibody fragment targeted vector system 
described in this dissertation are being tested in vivo in a nude mice tumor model 
and preliminary results look promising. 
Generally, it can be stated that significant progress has been made during the last 
years and that polymer based gene delivery is a promising approach for future 
advances in gene therapy.         
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ZUSAMMENFASSUNG 
In der vorliegenden Dissertation wurden verschiedene Aspekte des 
polymerbasierten Gentransfers eingehend untersucht. Zunächst wurden 
Schlüsselereignisse der subzellulären Prozessierung von elektrostatischen 
Polymer/Nukleinsäure-Komplexen erforscht und neue Erkenntnisse über 
Mechanismen, insbesondere von zellulärer Aufnahme und subzellulärer 
Freisetzung aufgedeckt. Ein weiterer Schwerpunkt lag auf der Entwicklung 
eines zielgerichteten Gentransfersystems für die selektive Transfektion von 
Ovarialkarzinomzellen. Das resultierende Vektorkonstrukt zeigte bei sehr 
geringer unspezifischer Transfektion und Toxizität eine sehr hohe Spezifität für 
Zielzellen. Da eine intravenöse Anwendbarkeit von Gentransfersystemen von 
großer Wichtigkeit ist, wurde die Stabilität elektrostatischer Vektoren in vitro 
und in vivo untersucht. Weiterhin war die Entwicklung einer neuen Klasse von 
Transfektionsagentien Gegenstand dieser Arbeit. Diese Systeme weisen eine 
hohe in vitro Transfektionseffizienz kombiniert mit einer sehr niedrigen 
Toxizität auf. Außerdem zeigten sie nach intravenöser Gabe eine verlängerte 
Zirkulationszeit im Blut.  
Kapitel 1 gibt als Einleitung einen detaillierten Überblick über kationische 
Polymere als Transportsysteme für Nukleinsäuren gegen verschiedene 
Krebsarten. Der aktuelle Stand der Wissenschaft bezüglich kationischer 
Polymere als Genfähren wird dargestellt. Hierbei wird insbesondere auf 
systemische und subzelluläre Hindernisse sowie Strategien zur Überwindung 
derselben abgehoben. Weiterhin wird eine Einführung in die wichtigsten 
gentherapeutischen Strategien gegen Krebs gegeben. 
In Kapitel 2 wurden Schlüsselereignisse der subzellulären Prozessierung von 
Polyethylenimin/Nukleinsäure-Komplexen mittels konfokaler Laser Scanning 
Mikroskopie und Inhibitorexperimenten untersucht. Wie mikroskopische 
Untersuchungen zeigten, findet die zelluläre Aufnahme höchstwahrscheinlich 
via adsorptiver Endozytose statt. Als Hauptort der Komplexakkumulation auf 
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subzellulärer Ebene wurde das lysosomale Kompartiment mittels eines 
Markerfarbstoffes identifiziert. Desweiteren konnte, zum ersten Mal überhaupt, 
die Freisetzung von PEI/Nukleinsäure-Komplexen aus einem vesikulären 
Kompartiment, wahrscheinlich Endosom oder Lysosom, mittels konfokaler 
Lebendzellmikroskopie visualisiert werden. Diese Freisetzung findet 
offensichtlich nur zu einem sehr geringen Teil statt, wobei der bei weitem größte 
Teil der Komplexe in vesikulären Strukturen verbleibt. Unter Verwendung eines 
Inhibitors der endosomalen Azidifizierung konnte die Wichtigkeit dieses 
Vorganges für die Freisetzung gezeigt werden. Diese Erkenntnisse wurden 
durch Transfektionsexperimente in Gegenwart und in Abwesenheit des 
Inhibitors untermauert. Auch diese Experimente zeigten, dass Azidifizierung 
notwendig ist, um eine hohe Reportergenexpression mit PEI als 
Transfektionsagens  zu erhalten. 
In Kapitel 3 ist die Entwicklung eines zielgerichteten Gentransfersystems für 
die spezifische Transfektion von Ovarialkarzinomzellen beschrieben. Als 
Targeting-Struktur wurde ein Antikörper ausgewählt, der eine hohe Spezifität 
für ein Epitop aufweist, das von den meisten Ovarialkarzinomzellinien 
exprimiert wird. Um die Größe der Targeting-Einheit zu reduzieren, wurden 
Antikörperfragmente (Fab´), welche die Antigenbindungsstellen beinhalten, 
durch Verdau des kristallisierbaren Teils des Antikörpers hergestellt. 
Anschließend wurden Konjugate aus einem pegylierten Polyethylenimin und 
Fab´ synthetisiert und sowohl physikochemisch als auch biologisch untersucht. 
Die linearen Polyethylenglykol-Ketten sollten die positive Ladung des 
Polyethylenimins abschirmen, um so die Spezifität des Konjugates zu erhöhen. 
Das PEG-PEI-Fab´-Konjugat war in der Lage, DNA genauso effektiv zu 
kondensieren wie unmodifiziertes PEI, außerdem war die Komplexstabilität 
gegenüber dem Polyanion Heparin sehr ähnlich. Zellassoziationsstudien wurden 
mittels Flow Cytometry durchgeführt und zeigten eine sehr effektive Bindung 
von Konjugat/DNA-Komplexen an Epitop-exprimierende Zellinien, jedoch eine 
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wesentlich niedrigere Bindung an Epitop-negative Referenzzellen. 
Transfektionsexperimente offenbarten eine bis zu etwa 100fach höhere 
Reportergenexpression in Epitop-exprimierenden Zellen verglichen mit PEI 
oder PEG-PEI. In Epitop-negativen Referenzzellen jedoch befanden sich die 
Transfektionsraten mit Konjugat/DNA-Komplexen auf sehr niedrigen Niveau. 
Um die Spezifität von Konjugat/DNA-Komplexen weiter zu verifizieren, 
wurden kompetitive Transfektionsexperimente mit verschiedenen 
Konzentrationen an freiem Fab´ im Zellkulturmedium durchgeführt. Hierbei 
konnte eine Reduzierung der Reportergenexpression mit steigender 
Konzentration an freiem Fab´ beobachtet werden. Die so erhaltenen Daten legen 
nahe, dass die hohe Spezifität der Konjugat/DNA-Komplexe auf spezifische 
Wechselwirkungen zwischen dem zellständigen Epitop und den 
antigenbindenden Fragmenten auf den Konjugat/DNA-Komplexen 
zurückzuführen sind.
In Kapitel 4 wurde die in vitro und in vivo Stabilität sowie die Organdeposition 
von PEI/Plasmid und PEG-PEI/Plasmid-Komplexen untersucht. Während die 
Stabilität beider Komplexarten bei Verdrängungsexperimenten gegenüber 
Polyanionen sehr ähnlich war, wurden signifikante Unterschiede beim Schutz 
der DNA vor Abbau durch DNase I gefunden. PEI 25 kDa war hier effektiver 
als pegyliertes PEI. Rasterkraftmikroskopie zeigte eine leicht unterschiedliche 
Komplex-Form, wobei die PEG-PEI/DNA-Komplexe etwas gedrungener und 
unregelmäßiger wirkten. In keinem Fall jedoch konnte freie DNA beobachtet 
werden. Bei der Untersuchung der Transfektionseffizienz in Blut zeigte sich, 
dass beide Komplexarten in Blut eine gewisse Stabilität aufweisen. Betrachtet 
man jedoch den Grad der Reduzierung der Transfektionseffizienz in Blut, zeigt 
sich, dass PEG-PEI/DNA-Komplexe weniger stabil sind. Bei der in vivo 
Untersuchung von Pharmakokinetik und Organdeposition mit zwei 
verschiedenen radioaktiven Markern an Polymer bzw. inkorporiert in Plasmid-
DNA zeigten sich signifikante Unterschiede zwischen PEI/DNA und PEG-
Summary and Outlook   239
 
PEI/DNA-Komplexen. Während im Fall von PEI/DNA-Komplexen ein 
ähnliches pharmakokinetisches Profil für Polymer und DNA sowie eine ähnliche 
Organverteilung nach 2 Stunden beobachtet wurde, zeigten PEG-PEI/DNA- 
Komplexe starke Unterschiede zwischen Polymer und DNA. In diesem Fall 
waren Pharmakokinetik und Organverteilung ähnlich der von nackter DNA. 
Diese Daten legen nahe, dass sich elektrostatische PEG-PEI/DNA-Komplexe 
bereits kurz nach intravenöser Injektion trennen, während PEI/DNA-Komplexe 
zumindest eine gewisse Stabilität aufweisen.  
Kapitel 5 beschreibt die Entwicklung einer neuen Klasse von nichtviralen 
Transfektionsagentien. Diese Vektoren sind Triblock-Polymere bestehend aus 
PEI 25 kDa, Polycaprolacton (PCL) und Polyethylenglykol (PEG). Da die 
Wasserlöslichkeit solcher Strukturen sehr begrenzt ist, wurde diese durch 
Überfädeln von Cyclodextrin über PEG- und PCL-Ketten erhöht. Da das Innere 
des Cyclodextrins hydrophob ist,  liegt die Vermutung nahe, dass die 
Cyclodextrin-Ringe über das hydrophile PEG hinweggleiten und schließlich 
durch hydrophobe Wechselwirkungen auf dem PCL-Bereich des Blockpolymers 
haften bleiben. Der Beweis für das erfolgreiche Einfädeln von Cyclodextrin und 
die vornehmliche Arretierung auf den PCL-Ketten wurde mittels 1H-NMR, UV- 
und FTIR-Spektroskopie erbracht. Die resultierenden Cyclodextrin-Inklusions-
Polymere waren in der Lage, DNA effektiv zu kondensieren. Die resultierenden 
elektrostatischen Komplexe hatten ein neutrales Zetapotential und eine Größe, 
die eine endozytotische Aufnahme in Zellen erlaubt. Zelluläre Aufnahme konnte 
mit Hilfe der konfokalen Laser Scanning Mikroskopie gezeigt werden, wobei 
die Bilder eine schnelle Aufnahme in vesikuläre Organellen wie Endosomen 
oder Lysosomen zeigten. Transfektionsexperimente ergaben eine 
Reportergenexpression in der selben Größenordung wie die von PEI 25 kDa. Ein 
Vergleich der Proteinkonzentrationen im Zell-Lysat zeigte jedoch, dass die 
Toxizität der Inklusionskomplexe sehr gering war im Vergleich zu PEI. Sogar 
bei sehr hohem Stickstoff/Phosphat-Verhältnis konnte keine signifikante 
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Toxizität nachgewiesen werden. Diese einzigartigen Eigenschaften machten das 
Vektorsystem interessant für weitere Untersuchungen. 
In Kapitel 6 wurden ausgewählte Triblock-Polymere mit Cyclodextrin- 
Inklusion aus Kapitel 5 eingehender bezüglich der Eigenschaften untersucht, die 
für eine in vivo Anwendung entscheidend sind. Die Komplexstabilität aller 
Polymer/DNA-Komplexe gegen Polyanionen war höher als die von PEI 25 kDa. 
Außerdem waren die Polymere in der Lage, komplexierte DNA effektiv gegen 
enzymatischen Abbau durch DNase I zu schützen. Die Untersuchung der 
Komplexstruktur mittels Rasterkraftmikroskopie zeigte eine sphärische Struktur 
der Komplexe mit einer Größe ähnlich der von PEI/DNA. Eine in vivo 
Untersuchung von Polymer/DNA-Komplexen mit radioaktiv markierter DNA 
ergab eine leicht verlängerte Zirkulationszeit für DNA, die mit Inklusions-
Polymeren komplexiert war. Der große Vorteil der Inklusionskomplexe jedoch 
war die vernachlässigbare Akkumulation in der Lunge und daraus resultierend 
eine sehr geringe in vivo Toxizität verglichen mit PEI 25 kDa und PEG-PEI.    
AUSBLICK 
Ziel des nichtviralen Gentransfers ist die Entwicklung eines Vektorsystems, das 
eine niedrige in vitro und in vivo Toxizität, eine hohe Stabilität im Blutstrom, 
eine effiziente und exklusive Aufnahme in Zielzellen und eine hohe 
Genexpression in sich vereint. Zur Zeit jedoch sind wir weit entfernt von einem 
solchen System. 
Mechanistisches Wissen über den subzellulären Transport von 
PEI/Nukleinsäure-Komplexen ist von größter Wichtigkeit für den weiteren 
Fortschritt auf diesem Gebiet. Obwohl es in den letzten Jahren einige 
wegweisende Erkenntnisse gab, sind immer noch viele Fragen unbeantwortet.  
So ist zum Beispiel der genaue Mechanismus der Freisetzung aus Endosom oder 
Lysosom noch nicht vollständig geklärt. Außerdem ist weiterhin unklar, welche 
Vektoreigenschaften genau entscheidend sind für ein forciertes Ablaufen dieses 
Summary and Outlook   241
 
Vorganges. Der weitere Weg der Nukleinsäuren auf dem Weg zum Zellkern 
liegt ebenfalls noch weitgehend im Dunkeln. Mechanistisches Wissen auf 
diesem Gebiet würde eine effektiveres Vektordesign erlauben. 
Die Reduzierung der in vitro und in vivo Toxizität von Polymeren als 
Gentransferagentien ist ebenfalls von großer Wichtigkeit für weitere Fortschritte 
auf diesem Gebiet. Hier konnten durch verschiedene Polymermodifikationen, 
zum Beispiel durch die Kopplung der hydrophilen Polymere PEG oder pHPMA 
Fortschritte erzielt werden. Die Inkorporierung dieser Strukturen führte zu einer 
stark verminderten Toxizität der entsprechenden Polymer/DNA-Komplexe. 
Erste Untersuchungen der in vivo Stabilität dieser Systeme im Rahmen dieser 
Arbeit zeigten eine schnelle Trennung der Komplexe im Blutstrom bei den für 
diese Studie gewählten niedrigen Dosierungen. Jedoch ist eine genaue 
Untersuchung des in vivo Verhaltens dieser Vektoren bei unterschiedlichen 
Applikationsarten und Dosierungen unerlässlich für die abschließende 
Beurteilung dieser Systeme. Die beschriebenen Triblockpolymere mit 
Cyclodextrin-Inklusion zeigten exzellente in vitro Eigenschaften wie hohe 
Transfektionseffizienz und sehr niedrige in vitro und in vivo Toxizität verbunden 
mit niedrigen Akkumulationsraten in der Lunge. Außerdem war die 
Zirkulationszeit im Vergleich zu unmodifiziertem PEI 25 kDa etwas erhöht. Ob 
hier noch Potential für Verbesserungen liegt, müssen weitere Untersuchungen 
zeigen. Ein sehr vielversprechender Ansatz für das Erzielen von Fortschritten in 
der in vivo Gentherapie ist der, elektrostatische Komplexe aus PEI und 
Nukleinsäuren zunächst nach standardisiertem Protokoll herzustellen und 
anschließend über bioreversible Bindungen wie z.B. Disulfidbrücken mittels 
bifunktioneller Linker zu stabilisieren. Die Idee hinter dieser Strategie ist eine 
hohe Stabilität der resultierenden lateral stabilisierten Komplexe im Blutstrom. 
Auf subzellulärer Ebene jedoch sorgt das reduzierende Milieu für eine Spaltung 
der Disulfidbindungen und damit für die Möglichkeit der DNA-Freisetzung. Bei 
diesen Systemen muß selbstverständlich der Grad der Quervernetzung so 
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gewählt werden, dass auf der einen Seite die Komplexstabilität ausreichend ist, 
auf der anderen Seite aber auf zellulärer Ebene eine Freisetzung in ausreichend 
schneller Zeit stattfinden kann. An der Optimierung dieser Systeme wird zur 
Zeit intensiv geforscht.  
Bezüglich des zielgerichteten Gentransfers in bestimmte Zell- und Gewebetypen 
zeigten die Resultate dieser Dissertation sowie einige andere Veröffentlichungen 
eine hohe Spezifität der Vektorkonstrukte in der Zellkultur. Die große 
Herausforderung jedoch besteht in der Entwicklung eines zielgerichteten 
Vektorsystems, das auch in vivo selektiv Zielzellen bzw. Zielgewebe transfiziert.  
Die Ergebnisse auf diesem Gebiet sind zur Zeit noch sehr unbefriedigend. Die 
meisten zielgerichteten Systeme zeigen nur eine niedrige Genexpression im 
Zielgewebe in vivo. Zur Zeit wird das PEG-PEI-Fab´-Konjugat, welches in 
dieser Dissertation beschrieben wurde, in einem Nacktmaus-Tumormodell 
untersucht und erste Resultate sehen vielversprechend aus. 
Abschließend kann man sagen, dass in den letzten Jahren beachtliche 
Fortschritte auf dem Gebiet des polymerbasierten Gentransfers gemacht wurden. 
Dieses Feld stellt daher einen vielversprechenden Ansatz für die Zukunft der 
Gentherapie dar.   
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ABBREVIATIONS  
AUC   area under the curve 
CD   alpha-cyclodextrin 
CLSM  confocal laser scanning microscopy 
DAPI   4’,6-diamidino-2-phenylindole, dihydrochloride 
EGF   epidermal growth factor 
EtBr   ethidium bromide 
Fab´   antibody fragment (antigen binding part) 
Fc   crystallizable part of antibody 
FACS   fluorescence assisted cell sorting 
HBS   HEPES buffered saline 
HEPES  2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid 
hy-PEI  hyperbranched PEI (PEI 25 kDa, Sigma-Aldrich) 
kb   kilobase 
Mab   monoclonal antibody 
Mw   molecular weight 
N/P   nitrogen to phosphate ratio 
NHS   N-hydroxysuccinimide 
OG   Oregon Green 
PBS   phosphate buffered saline 
PCL   polycaprolactone 
pDNA  plasmid DNA 
PEG   polyethylenglycol 
PEG-PEI  pegylated polyethylenimine 
PEG-PEI-Fab´ conjugate of pegylated polyethylenimine and Fab´ 
PEI   polyethylenimine 
pHPMA  poly(N-(2-hydroxypropyl)methacrylamide)   
PLL   poly(L-lysine) 
RGD   arginine-glycine-aspartic acid 
Rh   rhodamine 
SEC   size exclusion chromatography 
SPDP   N-succinimidyl 3-(2-pyridyldithio)propinate   
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